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Abstract 
Asthma is a chronic airway disease driven by inflammation, and thus corticosteroids are the 
mainstay of anti-inflammatory therapy to combat the disease. Typically asthma management 
involves long term use of corticosteroids, which often leads to severe side effects. Besides, 
though corticosteroids have a proven clinical efficacy in asthma, many asthmatic inflammatory 
conditions (e.g. infection, exacerbation) are not responsive to them. Therefore, alternative anti-
inflammatory strategies are urgently needed and enhancing the function of endogenous 
phosphatases, especially protein phosphatase 2A (PP2A), offer great promise. PP2A is a master 
controller of multiple inflammatory signalling pathways driven by mitogen activated protein 
kinases (MAPKs) and is a target in asthma. Therefore in our present studies we aim to explore 
the role of PP2A in the context of asthmatic inflammation. 
Inflammation is the key player in asthma pathogenesis, exacerbation and, most importantly, 
airway remodelling. Multiple inflammatory mediators are involved in this phenomenon and 
Sphingosine-1-phosphate (S1P) is one of them. S1P is found in increased amounts in asthmatics’ 
airways and can regulate airway smooth muscle functions associated with asthmatic 
inflammation and remodelling, including cytokine secretion. To date, however, whether S1P 
induces secretion of an important chemokine responsible for neutrophilia in airway inflammation 
– interleukin 8 (IL-8) – was unexplored. In chapter 3, we therefore aim to investigate whether 
S1P induces IL-8 gene expression and secretion to enhance neutrophil chemotaxis in vitro, as 
well as examine the molecular mechanisms responsible for repression by the corticosteroid 
dexamethasone. Our studies show that S1P upregulates IL-8 secretion and enhances neutrophil 
chemotaxis in vitro. The corticosteroid dexamethasone significantly represses IL-8 mRNA 
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expression and protein secretion in a concentration and time-dependent manner. Additionally, we 
reveal that S1P-induced IL-8 secretion is p38 MAPK- and extracellular signal-regulated kinase 
(ERK)-dependent and that these key phosphoproteins act on the downstream effector mitogen- 
and stress-activated kinase 1 (MSK1) to control secretion of the neutrophil chemoattractant 
cytokine IL-8. The functional relevance of this in vitro data is demonstrated by neutrophil 
chemotaxis assays where S1P-induced effects can be significantly attenuated by pre-treatment 
with dexamethasone, pharmacological inhibition of p38 MAPK- or ERK-mediated pathways, or 
by knocking down MSK-1 with small interfering RNA (siRNA).  
As such PP2A controls multiple signalling pathways driven by MAPKs and dephosphorylate a 
critical anti-inflammatory protein; tristetraprolin (TTP). Hence in chapter 4, we aim to explore 
the role of basal protein PP2A in retaining MAPKs and the involvement of TTP. Both in A549 
and BEAS-2B lung epithelial cells, we show that inhibition of basal PP2A activity by okadaic 
acid (OA) releases restraint on MAPKs and thereby increase MAPK-mediated pro-asthmatic 
cytokines, including interleukin 6 (IL-6) and IL-8. Notably, PP2A inhibition also impacts on the 
anti-inflammatory protein – TTP, a destabilizing RNA binding protein regulated at multiple 
levels by p38 MAPK. Although PP2A inhibition increases TTP mRNA expression, resultant 
TTP protein builds up in the hyperphosphorylated inactive form. Thus, when PP2A activity is 
repressed, pro-inflammatory cytokines increase and anti-inflammatory proteins are rendered 
inactive. Importantly, these effects can be reversed by the PP2A activators 2-amino-2-[2-(4-
octylphenyl)]-1,3-propanediol hydrochloride (FTY720) and 2-amino-4-(4-heptyloxyphenyl)-2-
methylbutanol (AAL(S)), or more specifically by overexpression of the PP2A catalytic subunit 
(PP2A-C). Moreover, PP2A plays an important role in cytokine expression in cells stimulated 
with tumour necrosis factor α (TNF); as inhibition of PP2A with OA or PP2A-C siRNA results 
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in significant increases in cytokine production. These data reveal the molecular mechanisms of 
PP2A regulation and highlight the potential of boosting the power of endogenous phosphatases 
as novel anti-inflammatory strategies to combat asthmatic inflammation. 
It is well studied that TTP is regulated by phosphorylation and that PP2A is responsible for 
dephosphorylating (and hence activating) TTP, amongst other targets. However, their 
relationship and underlying molecular mechanisms are not yet clear. Therefore in chapter 5, we 
aim to explore the dynamic relationship between PP2A and TTP. In this study we demonstrate 
that PP2A activators such as FTY720 and AAL(S) significantly increase TNF-induced PP2A 
activity and inhibit mRNA expression and protein secretion of IL-8 and IL-6; two key pro-
inflammatory cytokines implicated in respiratory disease and TTP targets. The effect of PP2A 
activators is not via an increase in TNF-induced TTP mRNA expression. Instead we propose 
here that PP2A activators affect the dynamic equilibrium of TTP; shifting the equilibrium from 
phosphorylated (inactive) towards unphosphorylated (active) TTP. We reveal a link between 
PP2A activation and TTP anti-inflammatory function by showing that specific knockdown of 
TTP with siRNA reversed repression of TNF-induced IL-8 and IL-6 mRNA expression and 
protein secretion by the PP2A activator FTY720. 
Corticosteroids have proven efficacy in chronic respiratory diseases, though these medicines can 
lose their efficacy during respiratory infection resulting in disease exacerbation. In our study it 
appears that PP2A has great promise as an alternative anti-inflammatory strategy in asthmatic 
inflammation. We therefore aim to check whether PP2A is capable of acting as an alternative 
anti-inflammatory molecule during corticosteroid insensitive condition. In line with our aim, in 
Chapter 6, we explore the role of PP2A activators in corticosteroid insensitivity using respiratory 
epithelial cells. To demonstrate the impact of PP2A activators in corticosteroid insensitive 
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conditions, we pre-treated cells with the synthetic bacterial lipoprotein N-Palmitoyl-S-[2,3-
bis(palmitoyloxy)-(2R,S)-propyl]-(R)-cysteinyl-seryl-(lysyl)3-lysine (Pam3CSK4 - a TLR2 
ligand) to mimic bacterial (both +ve and –ve) infection  and TNFα to simulate inflammation. 
Under these conditions, Pam3CSK4 induces corticosteroid insensitivity; demonstrated by 
substantially reduced ability of the corticosteroid dexamethasone to repress TNF-induced IL-6 
secretion. We then explored the molecular mechanism responsible and found that corticosteroid 
insensitivity induced by bacterial mimics was not due to altered translocation of the 
glucocorticoid receptor alpha (GRα) into the nucleus. Moreover, Pam3CSK4 did not affect 
corticosteroid-induced upregulation of anti-inflammatory MAPK deactivating phosphatase - 
MKP-1. However, Pam3CSK4 can induce oxidative stress and we show that a proportion of the 
MKP-1 produced in response to corticosteroid in the context of TLR2 ligation was rendered 
inactive by oxidation. Thus to combat inflammation in the context of bacterial exacerbation we 
sought to discover effective strategies that bypassed this road-block. We show for the first time 
that a known (FTY720) and novel (theophylline) activators of the phosphatase PP2A can serve 
as non-steroidal anti-inflammatory alternatives and/or corticosteroid-sparing approaches in 
respiratory inflammation where corticosteroid insensitivity exists. 
To get further confirmation for our above studies (mostly performed in immortalized cancer cell 
line, A549), in Chapter 7 we aimed to perform some key experiments using another 
immortalized normal cell (BEAS-2B) and primary airway smooth muscle (ASM) cell. However 
due to individual cell type variability, we fail to demonstrate a clear picture. Nonetheless, these 
experiments will certainly improve our knowledge and will lead to future investigations. 
In conclusion, studies performed in this thesis provide a greater understanding of the role of 
some widely used inflammatory mediators such as TNFα, S1P and Pam3CSK in asthmatic 
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inflammation and most importantly the anti-inflammatory impact of one important endogenous 
protein phosphatase, PP2A. Our studies partly revealed the underlying molecular mechanisms 
o f  endogenous PP2A and its relationship with the critical anti-inflammatory protein, TTP in 
the context of asthmatic inflammation in respiratory epithelial cells. Besides, these studies 
clearly demonstrate that PP2A activators can enhance the anti-inflammatory function of TTP and 
work even in corticosteroid insensitive conditions. Hence we presume that PP2A activators may 
have implications as alternative anti-inflammatory strategies to combat inflammation in 
respiratory disease.  
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Chapter 1 
General Introduction 
 
1.1 Asthma 
Asthma is a common chronic disease of the airway characterized by variable and recurring 
symptoms, reversible airflow obstruction, bronchial hyperresponsiveness, and an underlying 
inflammation. The prevalence of asthma has risen drastically in the last two decades, with a 
worldwide impact on health care systems. Asthma is the 14th most important disorder in the 
world in terms of the extent and duration of disability. According to the World Health 
Organization (WHO) asthma is one of the major public health concerns as it occurs in people of 
all ages and is an increasingly prevalent chronic disease in all parts of the world. It is a cause of 
substantial burden and often associated with a reduced quality of life. The burden of asthma is 
greatest for children aged 10-14 and the elderly aged 75-79. The number of people suffering 
from asthma in the world is as high as  334 million worldwide (Asher and Pearce, 2014), with 
250,000 annual deaths attributed to this disease (Masoli et al., 2004). Hence its social and 
economic impacts are very significant. Historically, most people affected by asthma are in low 
and middle-income countries, and its prevalence is estimated to be increasing fastest in those 
countries. However, the increase in asthma prevalence in developed countries seen at the end of 
the last century has raised concern for the considerable burden of this disease on society as well 
as individuals.  
Asthma research has received much attention in the last couple of decades; hence our 
understanding of the processes regarding this disease is in progress. In addition, many issues 
concerning the fundamental molecular mechanisms of airway diseases including asthma and 
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other inflammatory airway diseases are also evolving. However, we have much to do to discover 
effective therapeutic approaches to control the process causing this disease. Therefore for better 
control and management, asthma research still warrants rigorous investigation. 
 
1.1.1 Characteristics of asthma 
Asthma is a chronic inflammatory disease that affects people of all ages. Overactive 
inflammatory signalling pathways are often associated with asthmatic conditions. Hence 
inflammation plays the most critical role in the pathophysiology of asthma that triggers airway 
muscles tightening, swelling and production of high amounts of sticky mucous. These changes 
are ultimately responsible for narrowing the airway causing difficulty in breathing. Moreover, 
severity of asthma is characterized by airway inflammation, airway hyper-responsiveness (AHR) 
and airway remodeling.  
Asthma symptoms commonly consist of coughing, wheezing, chest tightness and shortness of 
breath. These symptoms are usually worse at night and in the early morning or in response to 
exercise or cold air. Most importantly, all asthmatics are not equally responsive to asthma 
triggers. Some patients may hardly experience asthma symptoms in response to asthma triggers, 
whereas others may experience distinct and continual symptoms.  
 
1.1.2 Asthma phenotype 
Although asthma has been considered as a single disease for many years, recent studies reveal its 
heterogeneity (Wenzel, 2012). Exploring this heterogeneity has improved our understanding and 
we now know that asthma comprises of several phenotypes. Hence asthma can be considered as 
a heterogeneous syndrome made up of a number of disease phenotypes characterized by their 
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underlying pathophysiology into “asthma endotypes” (Anderson, 2008; Lötvall et al., 2011). 
Asthma phenotypes (as shown in Table 1.1) allow us to address its complexities; however to date 
very little has been known about the onset as well as the stability of asthma phenotypes. 
Therefore exploring asthma phenotypes demands further study to combat it effectively.  
 
Table 1.1 Asthma phenotypes and their clinical features 
Asthma Phenotype Clinical characteristics 
Early-onset allergic Allergic symptoms and other diseases 
Late-onset eosinophilic Sinusitis; less allergic 
Exercise-induced Mild; intermittent with exercise 
Obesity-related Women are primarily affected; very symptomatic; 
airway hyperresponsiveness less clear 
Neutrophilic Low FEV1; more air trapping 
Aspirin-sensitive Nasal polyposis, aspirin sensitivity 
API-positive preschool 
wheezer* 
Family history of asthma 
*API, asthma predictive indices 
 
1.2 Pathophysiology of asthma 
Asthma pathophysiology is complex and characterised by intermittent airflow obstruction, 
airway hyperresponsiveness and inflammation (Adcock and Lane, 2003). The most common 
signs and symptoms of asthma include intermittent dyspnoea, breathlessness, cough (typically in 
the early morning or at night) and wheezing (especially expiratory wheezing). Asthma syndrome 
is recognized by recurrent airflow limitation, which is caused by a variety of changes in the 
airway, including bronchoconstriction, airway hyperresponsiveness, swelling and airway 
remodelling, as shown in Figure 1.1 and described below-  
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a) Bronchoconstriction: Bronchoconstriction is the leading physiological event that 
triggers clinical symptoms leading to narrowing of the airway and ultimately limiting 
airflow. In severe asthma exacerbation, bronchial smooth muscle contraction 
(bronchoconstriction) occurs quickly to narrow the airways in response to a range of 
stimuli exposure including allergens or irritants. 
 
b) Airway hyperresponsiveness: Airway hyperresponsiveness is an important feature of 
asthma which is exaggerated by bronchoconstriction caused by a wide range of stimuli; 
including allergic and nonallergic stimuli (Skloot et al., 1995). The extent of clinical 
severity of asthma depends on airway hyperresponsiveness. Several mechanisms 
influence airway hyperresponsiveness including inflammation, dysfunctional neuro-
regulation and structural changes. However, inflammation is considered the major factor 
in determining the extent of airway hyperresponsiveness in asthma. 
 
c) Airway swelling: Due to progressive inflammation and persistent disease conditions 
other factors (such as edema, inflammation, mucus hypersecretion and mucus plugs 
formation) further interfere in airflow. These factors cause airway structural changes and 
remodelling, which are not responsive to usual treatment options. 
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Figure 1.1 Pathophysiology of healthy and asthmatic airway 
(http://www.drugs.com/health-guide/asthma.html) 
 
 
 
d) Airway remodelling: Airway remodelling is characterised by a gradual loss of lung 
functions and most importantly this codition cannot be prevented by or be fully reversed 
using existing asthma therapies. In addition, airway remodelling causes activation of a 
wide range of structural cells (Elias et al., 1999) with subsequent permanent changes in 
the airway, which ultimately leads to airflow limitation and airway sensitivity and, most 
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importantly, patients become less responsive to therapy. Asthma severity depends on the 
structural changes of the airway, which includes airway wall thickening, subepithelial 
fibrosis, increases in myocite muscle mass, airway smooth muscle hypertrophy and 
hyperplasia, blood vessel proliferation and dilation, mucus hypersecretion, epithelial 
hypertrophy and mucus metaplasia (Elias et al., 1999). 
 
1.3 Causative factors of asthma pathogenesis 
Asthma pathogenesis is a complex process and a wide range of factors may lead to its 
development. These include host factors such as innate immunity, genetics, age and sex, and 
environmental factors (including allergens exposure), respiratory infections, pollutions, smoke 
(especially tobacco smoke) and stress (Moffatt et al., 2007; Postma et al., 2011; Olin and 
Wechsler, 2014). Key factors associated with asthma pathogenesis (as shown in Figure 1.2) are 
as follows: 
Genetics: Although the link between inheritable components and asthma expression is well-
studied, genetic involvement in asthma development is as yet unclear (Holgate, 1999; Ober, 
2005). Studies revealed that a number of genes are responsible (either directly involved or 
linked) for asthma pathogenesis; however the complexity of their involvement in asthma 
pathogenesis demands more research. Hence, recently much attention has focused on the 
identification of the role of genetics in IgE production, airway hyperresponsiveness, regulation of 
inflammatory mediators (cytokines, chemokines, and growth factors) and how genetic variations 
regulate the response to therapy.  
  Chapter 1 
 
8 
 
 
Figure 1.2 Factors involved in asthma pathogenesis (Adcock and Lane, 2003) 
 
Allergens: Allergens are among the most important environmental factors responsible for the 
development of persistent symptoms and possibly the severity of asthma. However, their role in 
the development of asthma pathogenesis is yet to be explored. Though studies have revealed that 
animal (such as dog and cat) danders are associated with asthma development, under certain 
conditions exposure to animals in early life may boost the immune system to protect against the 
development of asthma. However, the reasons behind these diverse outcomes warrant more 
research.  
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Respiratory infection: Respiratory infection is another important environmental factor which 
has major influences in asthma pathogenesis. Infection is closely associated with airway 
hyperreactivity and asthma exacerbation both in children and adults (Busse, 1990). Respiratory 
syncytial virus (RSV), rhinovirus (RV), influenza and parainfluenza viruses, coronavirus, 
enterovirus, and adenovirus are most commonly involved in asthma pathogenesis and 
exacerbation (Tan, 2005; Pelaia et al., 2006). Currently it is also believed that some atypical 
bacteria such as chlamydia pneumonia and mycoplasma pneumonia are involved in the 
pathogenesis of asthma (Blasi et al., 2001; Pelaia et al., 2006). 
Other factors: Other factors associated with the increased risk of asthma pathogenesis include 
smoke (especially from tobacco), occupation, diet and air pollution. To date the association 
between allergens/respiratory infections and asthma onset are clearly established and it is evident 
that gene-by-environmental interactions play a crutial role in the development of airway 
inflammation and eventual development of asthma characteristics. (Malo et al., 2004). However, 
the link between other factors and asthma pathogenesis is still unclear. 
 
1.4 Airway structural cells in asthma pathogenesis 
Airway structural cells such as airway smooth muscle, epithelial cells, myofibroblasts and 
fibroblasts play a significant role in asthma pathogenesis (Erle and Sheppard, 2014). Among all 
these structural cells airway smooth muscle and epithelial cells are critical for asthma 
pathogenesis. Structural cells are not only important to maintain the integrity of the bronchial 
wall but also they significantly contribute inflammatory responses mediated by various 
inflammatory stimuli including cytokines, chemokines, growth factors and inflammatory 
mediators. Interestingly, structural cells are also sources of these inflammatory molecules 
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(Levine, 1995; Boxall et al., 2006). Further, the most common asthma characteristics such as 
airway remodelling and hyperresponsiveness are driven by these structural cells. Hence in our 
study we focused on two important structural cells (ASM and epithelial cells) for better 
understanding the molecular mechanism of asthmatic inflammation and eventually to find 
effective therapeutic targets.  
 
1.4.1 Airway smooth muscle cells 
Asthma is a heterogeneous multicellular disease associated with airway hyperresponsiveness, 
inflammation and remodelling (Busse and Lemanske, 2001; Denis et al., 2001; Girodet et al., 
2010). Structural cells play the key role in the development of asthma characteristics. Among all 
the structural cells, airway smooth muscle cells play the most crucial role in asthma 
pathophysiology(Zuyderduyn et al., 2008; Black and Roth, 2009), as shown in Figure 1.3. 
Airway smooth muscle cells are considered to be the key effectors. They cause excessive 
narrowing of the airway during severe asthmatic conditions that may lead to excessive shortness 
of breath, respiratory failure, and eventually even death (Erle and Sheppard, 2014). Increased 
ASM mass (Lambert et al., 1993) and surrounding tissue mediated altered load on ASM cells are 
also considered as important causes of airway narrowing (Brown et al., 1995). Previously it was 
thought that airway contraction is the major role of ASM and hence research focused mainly on 
its contractile properties. However, mounting evidence clearly demonstrates that ASM cells have 
proinflammatory and immunomodulatory functions (Hirst, 2003; Damera et al., 2009). ASM 
cells synthesize and express a wide range of cell surface molecules, integrins, costimulatory 
molecules, and Toll-like receptors; thereby ASM cells play an active role in asthmatic 
inflammation (Ozier et al., 2011) as shown in Figure 1.3.  
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The most common feature of asthmatic inflammation is nonspecific airway hyperresponsiveness, 
which is mediated via a number of direct (histamine, methacholine) or indirect (allergen, 
chemical) stimuli. Several studies demonstrate that direct stimuli activate ASM cell membrane 
receptors, whereas indirect mediators stimulate ASM cells via one or more intermediate cells and 
thereby cause airway hyperresponsiveness and ultimately airway contraction (O'Byrne and 
Inman, 2003; Anderson, 2010). ASM cell remodeling represents the airway remodeling, which is 
the key feature of asthma (Bara et al., 2010). A growing body of evidence demonstrates that 
ASM cells are also involved in promoting other bronchial remodeling including alteration of 
other structural cells including epithelial cells (Coutts et al., 2001). Most importantly, current 
asthma medications are insensitive to ASM remodeling, though they are effective in treating 
acute airway narrowing and inflammation (Girodet et al., 2011). Recent studies suggest that 
bronchial smooth muscle is infiltrated by inflammatory cells including mast cells, which may 
contribute to airway remodelling (Begueret et al., 2007). Further, several studies have shown that 
ASM cells amplify inflammatory responses and subsequently express a wide range of cytokines 
including IL-6 (Hollins et al., 2008) and IL-8 (Fong et al., 2000), which are known to be 
implicated in asthmatic inflammation. ASM cells play multifaceted roles in asthma pathogenesis 
and hence targeting these diverse functions is a major challenge for future asthma control and 
management.  
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Figure 1.3 Contribution of airway smooth muscle cells in asthma pathogenesis (Chung, 
2013) 
 
1.4.2 Epithelial cells 
Airway epithelial cells form the first line barrier against mechanical stress, oxidant stress, 
allergens, pollutants, infectious agents, and leakage of endogenous solutes. They also play 
important roles in mucociliary clearance and signaling. Epithelial cells express various types of 
pattern recognition receptors, including Toll-like receptor 4 (TLR4), thereby enabling responses 
to allergic and infectious stimuli (Salazar and Ghaemmaghami, 2013). In asthmatic conditions, 
epithelial cells derive cytokines and chemokines (Lambrecht and Hammad, 2012). The key 
function of the airway epithelial cells was thought to be the formation of a physical barrier. 
However, with the advantages of research it is known that it constitutes the interface between the 
internal milieu and the external environment as well as a primary target for inhaled respiratory 
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drugs. By secreting enormous numbers of molecules and mediators it responds to the changes in 
the external environment. Therefore, the epithelium has a unique role to translate gene–
environment interactions (Knight and Holgate, 2003). Mounting evidence supports that the 
respiratory epithelium of asthmatics is abnormal and very susceptible to injury compared to 
normal epithelium. Furthermore, being more susceptible to damage, normal repair processes are 
compromised. Persistent mucosal injury can also occur due to failure of proper growth and 
differentiation of airway epithelial cells (Polito and Proud, 1998; Knight and Holgate, 2003). 
 
1.5 Asthma management 
Inflammation plays the key role in asthma pathogenesis; hence anti-inflammatory strategy is still 
one of the most important treatment options in asthma. Inflammation is responsible for airway 
swelling and mucus production and thereby it makes the airway more sensitive to asthma 
triggers. Anti-inflammatory medicines are the first line medicines, which help to stop this 
process and prevent asthma attacks. 
The key treatment option (details are shown in Figure 1.4) for asthma is steroid or corticosteroid 
and other anti-inflammatory drugs (leukotriene modifiers and immunomodulators). Both of these 
drugs work by reducing inflammation, swelling, and mucus production in the airways and help to 
control asthma and prevent asthma attack.  
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Figure 1.4 Treatment options for asthma 
 
Asthma is a chronic disease and most importantly to date there is no drug to cure asthma, hence 
asthma patients have no choice other than long term use of corticosteroids, which often leads to 
unwanted side effects including skin and muscle atrophy, disturbed wound healing, osteoporosis, 
growth failure and delayed puberty (children), glaucoma and cataract, steroid psychoses, 
depression, adrenal insufficiency; and hypogonadism, hyperglycaemia, hypertension, 
Asthma 
Treatment options 
Preventive or stoping the 
inflammation 
Avoid or minimize exposure to 
triggers such as- 
-Smoke  
-Pollutants 
-Strong chemicals 
-Allergens 
-pollens 
-Cold air 
-Anticipated future attacks 
Treatment with drugs 
A. Prevent or stoping 
inflammation using anti-
inflammatory medications, which 
includes inhaled-corticosteroids 
(ICS), systemic corticosteroids (oral 
or intravenous), mast cell 
stabilizers, leukotriene modifiers 
B. Relaxing airway muscle using 
bronchodilators. 
C. Immunotherapy via injecting 
increasing amounts of allergens to 
desensitize the person’s immune 
system against allergens. 
D. Plan for asthma management- 
especially for chronic asthma 
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dyslipidaemia, peptic ulcers, upper gastrointestinal bleeding, pancreatitis and severe 
immunosuppression effects (Schäcke et al., 2002).  
Moreover, a small number of asthmatics (<5 %) are not responsive to existing corticosteroid 
therapy (Adcock and Lane, 2003), which is a major drawback of anti-inflammatory strategy. 
Several studies clearly demonstrate that corticosteroid insensitivity can range from relative 
corticosteroid insensitivity to steroid resistance, as seen in severe asthma (reviewed in (Ammit, 
2013; Chung, 2013)).  
Despite, remarkable progress in anti-inflammatory strategies, severe side effects and 
corticosteroid insensitivity are the major challenges in this field. To meet these challenges, we 
urgently require alternative anti-inflammatory strategy with less or minimal side effects and are 
capable to work even corticosteroid insensitivity exist. Enhancing the function of endogenous 
phosphatases, especially PP2A, offer great promise.  
 
1.6 Asthma exacerbation 
Asthma is a highly prevalent chronic disease, which affects millions of people around the globe. 
Asthma exacerbation, an acute or subacute episode of progressive worsening of symptoms 
further worsens the situation and increases the social burden. In addition, asthma exacerbation is 
one of the significant causes of morbidity and drives the majority of the asthma care cost 
(Dougherty and Fahy, 2009). Asthma exacerbation is usually associated with the release of pro-
inflammatory cytokines, chemokines and recruitment of inflammatory cells driven by a number 
of factors; particularly viral infection. Respiratory viral (especially rhinoviruses) infections cause 
most of the asthma exacerbations both in children and adults. Other factors involved in asthma 
exacerbation are bacterial infection, allergens, cigarette smoke, environmental pollutants, 
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occupational irritants, medication, and intrinsic factors such as deficient epithelial cell 
production of the anti-viral type I interferons (IFN-α and IFN-β) (Wark and Gibson, 2006). 
During asthma exacerbation lung functions sharply decline and elicit asthma symptoms 
including shortness of breath, coughing, wheezing, and chest tightness. Severe asthma 
exacerbation is one of the major causes of death from asthma and this number increases during 
winter, when the chance of viral infection is very high. In addition, the frequency of asthma 
exacerbation is also triggered by respiratory viral infections. Though the frequency of asthma 
exacerbation can be reduced by a proper action plan, infection associated exacerbations are very 
difficult to control (Wilson and Silverman, 1990; Doull et al., 1997; Harrison et al., 2004). 
Therefore more research is warranted in the context of asthma exacerbation for better 
understanding and management of this disease.  
 
1.7 Inflammation and asthma exacerbation 
A number of factors are responsible for the development of asthma. Inflammation appears to be a 
common factor that drives to the most severe asthmatic responses. Hence, inflammation is 
considered as a dominant feature in the pathophysiology of asthma (Adcock and Lane, 2003). 
Interactions of various cell types and inflammatory mediators with the airways is the major cause 
of airway inflammation, which eventually results in the pathophysiological features of asthma 
including bronchial inflammation, airflow limitation and subsequent recurrent episodes of 
coughing, wheezeing and shortness of breath (shown in Figure 1.5). The underlying molecular 
mechanisms by which these interactive events take place and direct clinical asthma features are 
yet to be uncovered. However, studies reveal that airway inflammation is a consistent and 
common feature of all asthma phenotypes. More importantly, the extent of airway inflammation 
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is independent of asthma severity, persistence and duration. Notably, the inflammation does not 
alter the cellular profile and response of the structural cells in asthmatics.  
 
 
 
Figure 1.5 The interaction between airway inflammation and the clinical symptoms of 
asthma (Guidelines for the Diagnosis and Management of Asthma. Bethesda (MD): National 
Heart, Lung, and Blood Institute (US); 2007 Aug. Section 3) 
 
Airways inflammation involves activated mast cells, eosinophils, neutrophils, T lymphocytes and 
macrophages, which is an established feature of asthma, and the key target for treatment (Louis 
et al., 2000). Though it is known that many inflammatory cells are involved in asthma (shown in 
Table 1.2), precise role of each cell is not certain yet. However it is evident that multiple 
inflammatory cells are liable for the complexity of asthma pathophysiology and some cells are 
predominant in asthmatic inflammation (Busse and Lemanske, 2001).  
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Table 1.2 Inflammatory cells and their role in asthmatic inflammation 
 
Inflammatory cells Role in asthma 
Mast cells 
 
-Mucosal mast cells activation releases bronchoconstrictor mediators, 
such as histamine, cysteinyl-leukotrienes, prostaglandin D2 (Boyce, 
2003). 
-Airway hyperresponsiveness may be linked with the increased 
number of mast cells in airway smooth muscle (Liesker et al., 2007). 
-Mast cells regulate the airway environment and promote 
inflammation even though limited exposure to allergens via releasing 
huge number of cytokines (Amin, 2012). 
Eosinophils 
 
-Most asthmatic patient’s airway contains increased numbers of 
eosinophils (Chu and Martin). 
-Greater the number of eosinophils greater the severity of asthma 
(Walford and Doherty, 2014). 
-Eosinophils contain inflammatory enzymes, generate leukotrienes, 
and express a wide variety of pro-inflammatory cytokines (Walford 
and Doherty, 2014). 
Neutrophils 
 
-Airways and sputum of severe asthmatic patient contain increased 
number of neutrophils (Fahy, 2009). 
-Neutrophils may be the determinant factor of activation and alteration 
of lung function and response to corticosteroid (Fahy et al., 1995). 
Dendritic cells or 
Antigen presenting 
cells. 
-Stimulate TH2 cells production via increasing interaction with 
allergen (Kuipers and Lambrecht, 2004). 
Macrophages 
 
-Activated by allergen and release inflammatory mediators, cytokines 
and amplify inflammatory responses (Peters-Golden, 2004). 
TH2-lymphocytes -Modulate airway inflammation and control asthma by producing a 
number of cytokines, such as L-4, IL-5, IL-9 and IL-13 (Barnes, 2001) 
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1.8 Inflammatory mediators and MAPKs 
Asthma is a complex chronic inflammatory disease of the airway involving activation of a 
number of inflammatory cells such as mast cells, dendritic cells or antigen-presenting cells, 
eosinophils, neutrophils, macrophages, and TH2-lymphocytes as well as structural cells. These 
inflammatory cells produce a wide range of inflammatory mediators and cytokines that 
exacerbate typical asthma symptoms such as bronchoconstriction, mucosal edema, mucus 
secretion and bronchial hyperresponsiveness (Barnes, 1996). 
Numerous mediators provoke inflammatory response from respiratory structural cells. The cross-
talk between the cells and the mediators are the principle driving force for the inflammatory 
response observed in respiratory diseases like asthma. In the following sections we will overview 
some key inflammatory mediators and stimuli we have used in this study and then we will 
discuss briefly their signalling molecules involved in asthmatic inflammation 
 
1.8.1 Inflammatory mediators 
There are a wide range of inflammatory mediators responsible for initiating/accelerating 
inflammation via triggering inflammation associated signaling pathways. Some important 
inflammatory mediators are described below: 
 
1.8.1.1 Cytokines 
There are significant number of pro-inflammatory cytokines (such as eotaxin, GM-CSF, IFNγ, 
IL-4, IL-5, IL-8, IL-6, IL-10, IL-12, IL-13, IL-17A, IL-17F, IL-18 and TNFα), which direct and 
modify the inflammatory response and determine the severity of asthma. They also play roles in 
eosinophil infiltration, mast cell activation, mucosal hypersecretion, epithelial shedding, 
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allergen-specific IgE production and bronchial muscle contraction. Among all these cytokines 
IL-6 and IL-8 are the two important cytokines which are largely implicated in asthmatic 
inflammation and are regulated by MAPKs family members such as p38 MAPK, ERK and JNK 
(Amrani et al., 2001; Henness et al., 2006; Quante et al., 2008; Moutzouris et al., 2010). 
 
1.8.1.1.1 IL-6 
IL-6 is one of the major cytokines implicated in asthmatic inflammation. It is a small 
glycoprotein produced by numerous cells including mast cells, macrophages, dendritic cells, 
neutrophils, B cells and a small amount by some cluster of differentiation 4 (CD4) effector Th 
cells. A wide variety of stimuli such as UV irradiation, reactive oxygen species (ROS), microbial 
products, viruses, or other proinflammatory cytokines can induce IL-6 secretion. Several studies 
reported elevated serum level of IL-6 in a wide number of inflammatory diseases including 
asthma (Yokoyama et al., 1995; Kishimoto, 2010), hence IL-6 is considered as a common 
marker of inflammatory diseases including asthma. However, with the progress of research it is 
evident that IL-6 is not a simple pro-inflammatory cytokine or just the end product of lung 
pathology but a critical factor in the pathogenesis of certain inflammatory diseases including 
asthma and chronic obstructive pulmonary disease (COPD) (He et al., 2009).  
The role of IL-6 in asthmatic inflammation is well-established. However, conflicting results 
obtained from the most commonly used ovalbumin (OVA) mouse model require further studies 
to ascertain its role in asthmatic inflammation. Allergic airway inflammation potentiates the 
complexity of IL-6 involvement in the airway diseases. Using this  model initial studies reported 
increased level of lung Th2 cytokines including IL-4, IL-5 and IL-13, eosinophilia and eotaxin 
level in IL-6 deficient mouse; however the same study also showed a decreased level of Th2 
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cytokines and eosinophilia in IL-6 overexpressing transgenic mice (Wang et al., 2000). Hence 
more studies are warranted for better understanding the role of IL-6 in airway diseases.  
Despite remarkable progress in our understanding of IL-6 as a master player in the pathogenesis 
of lung diseases (Neveu et al., 2010) and a key modulator of the overall immune response, the 
mechanisms by which IL-6 interferes with lung function and potentiates airway disease 
pathogenesis is yet unclear. Moreover, due to the pleotropic nature of IL-6 (Kishimoto, 2006), it 
provides a variety of mechanisms by which this cytokine can contribute to specific aspects of 
complex respiratory diseases including asthma. Future studies required to address the clinical 
importance of IL-6 and ascertain its role in asthmatic inflammation. We therefore aim to explore 
the role of IL-6 in asthmatic inflammation using respiratory epithelial and airway smooth muscle 
cells. 
 
1.8.1.1.2 IL-8 
IL-8 is a critical proinflammatory cytokine implicated in asthma. One of the important asthma 
endotypes is neutrophilic (non-eosinophilic) asthma, which is mainly driven by the chemokine 
CXCL8 (IL-8) (Simpson et al., 2009). Neutrophils are implicated in the pathogenesis of many 
inflammatory lung diseases, including acute respiratory distress syndrome, chronic obstructive 
pulmonary disease and asthma. IL-8 is a potent neutrophil recruiting and activating factor (Pease 
and Sabroe, 2002), hence IL-8 detection from the patients with these diseases has led clinicians 
to believe that targeting IL-8 may be a potential therapeutic strategy for the management of these 
diseases. Thus, studies into the molecular pathways that upregulate this neutrophil 
chemoattractant will allow us to gain greater insight of the underlying pathogenic mechanisms 
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and suggest potential pharmacotherapeutic strategies for treating the neutrophilic asthma 
endotype in the future. 
It is reported that IL-8 plays a primary role in the activation of both neutrophils and eosinophils 
in the airways of patients with asthma and COPD. It is also reported that IL-8 concentration in 
the sputum is closely associated with the extent of airflow obstruction in patients with COPD and 
hence it may serve as a marker in evaluating the severity of airway inflammation (Norzila et al., 
2000). The causes of neutrophilic asthma are currently uncertain. Innate immunity dysregulation 
through TLR2 plays an important role (Simpson et al., 2007), as may T-helper17 (Th17) 
regulation (Newcomb and Peebles, 2013) and NACHT, LRR and PYD domains containing 
protein3 (NLRP3) inflammasome activation (Simpson et al., 2013). Activation of these cellular 
pathways has been reported to increase neutrophilic inflammation in the airways in an IL-8-
driven manner; which is the key characteristic of the disease endotype. Airway structural cells 
(such as alveolar epithelium and ASM) serve as important contributors to IL-8 chemokine 
production and in this way they may orchestrate neutrophil chemoattraction in response to 
inflammatory mediators (Henness et al., 2006; Manetsch et al., 2012c; Zijlstra et al., 2012). 
 
1.8.1.2 Chemokines 
Chemokines are a large family of cytokines and are capable of attracting different cell types and 
thereby they mediate inflammatory tissue destruction in a wide variety of human diseases such as 
rheumatoid arthritis, myocardial infarction, adult respiratory distress syndrome and asthma 
(Baggiolini and Dahinden, 1994; Strieter et al., 1996; Lukacs, 2001). Chemokines serve as potent 
leukocyte chemoattractants, cellular activating factors and histamine-releasing factors; hence 
they are important in the pathogenesis of allergic inflammation. Several studies demonstrate that 
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chemokines play a vital role in orchestrating multiple aspects of asthmatic the response including 
injury and repair (Zimmermann et al., 2003).  
The eotaxin subfamily of chemokines appears to be a central regulator of the asthmatic response 
and is relatively selective for eosinophils. Thymus, activation-regulated chemokines (TARCs) 
and macrophage-derived chemokines (MDCs) recruit Th2 cells, which subsequently induce 
asthma via secreting a number of cytokines (Zimmermann et al., 2003). Chemokines bind with a 
wide range of receptors and are promiscuous in the context of asthmatic inflammation (Oliveira 
and Lukacs, 2003). Hence, determining the exact role of individual chemokines and receptors is 
crucial to identifying the effective targets. Exploring the function of eosinophils and their 
chemokine receptors during inflammation may be an excellent approach to understanding the 
determinants of asthma severity and developing novel therapeutic targets. 
 
1.8.1.3 Cysteinyl-leukotrienes 
Cysteinyl leukotrienes are inflammatory molecules derived from mast cells during asthma attack 
and are mainly responsible for bronchoconstriction. It is reported that inhibition of this mediator 
is associated with the improvement in asthma symptoms and lung function (Busse, 1996). 
Leukotrienes are critical both in accelerating acute asthma attacks and in causing long term 
hypersensitivity in chronic asthma (Berger, 1999). Leukotrienes have two distinct families; the 
first group primarily acts on neutrophils dependent of inflammatory conditions, whereas the 
other group of leukotrienes, cysteinyl-leukotrienes, are mainly concerned with the 
bronchoconstriction in asthma induced by mast and eosinophil cells. Leukotrienes selectively 
bind with the receptors located on bronchial smooth muscle and other airway tissues (O'Byrne et 
al., 1997) and cause asthma symptoms. 
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1.8.1.4 Prostanoids 
Prostanoids are a subclass of eicosanoids comprising of both prostaglandins and thromboxanes, 
which are derived from arachidonic acid. Several studies demonstrate the regulatory role of 
prostanoids in allergic inflammation and pathogenesis of allergic bronchial asthma. Some in-vivo 
studies showed that the disruption of the D prostanoid (DP) gene attenuated the allergen-induced 
airway eosinophilic inflammation (Tanaka and Nagai, 2001). Excessive prostanoid production 
and signaling contribute to increase susceptibility to infections and subsequently drive COPD 
exacerbations and inadequate alveolar repair (Zaslona and Peters-Golden, 2015). 
 
1.8.1.5 Nitric oxide 
Mounting evidence indicates that endogenous nitric oxide (NO) plays a significant role in the 
physiological regulation of airway functions and is implicated in airway diseases, including 
asthma (Barnes and Belvisi, 1993; Gaston et al., 1994). It is predominantly produced from 
airway epithelial cells by the action of inducible NO synthase. High concentrations of NO defend 
against microorganisms’ at the same time it is toxic to airway epithelial cells and may contribute 
to epithelial shedding in asthma (Barnes and Liew, 1995). Hence there is increasing evidence 
that high concentrations of NO may have effects on the immune system and the inflammatory 
response. Recent studies demonstrate the association between exhaled nitric oxide levels (FeNO) 
and asthmatic inflammation. Hence measuring the fraction of exhaled NO can be a useful tool to 
monitor the response of anti-asthmatic drugs in asthma treatment (Green et al., 2002). 
 
  Chapter 1 
 
25 
 
1.8.1.6 Immunoglobulin E (IgE) 
IgE is a critical factor involved in allergic inflammation. It plays an important role in the 
pathogenesis of allergic diseases including asthma and the development of persistence 
inflammation (Boyce, 2003; Rosenwasser, 2011). IgE is predominantly found in mast cells and 
activated by the interaction with a specific antigen. Activated IgE initiates acute bronchospasm 
and releases pro-inflammatory cytokines to perpetuate airway inflammation (Boyce, 2003). It is 
reported that reduction of IgE using monoclonal antibodies is effective in asthma treatment, 
which further supports the importance of IgE in asthma (Busse and Lemanske, 2001). 
 
1.8.2 Exogenous inflammatory stimuli 
There are a number of clinically proven exogenous inflammatory stimuli such as TNFα, IFN-γ, 
S1P, LPS, TGFβ, IL-17, IL-1β, bacterial infection (Pam3CSK4) and viral infection, which are 
widely used in asthma research. These stimuli can either initiate or trigger acute or chronic 
inflammation in airway diseases and subsequently cause diseases pathogenesis. In this section 
we will discuss a few well studied exogenous inflammatory stimuli which are widely used in 
asthma research. Most importantly we also used them in this study. 
 
1.8.2.1 TNFα 
TNFα is a pleiotropic pro-inflammatory cytokine of the TNF superfamily. The human TNF 
gene (TNFA) maps to chromosome 6p21.3 and contains 4 exons. Among these four, the last 
exon codes for more than 80% of the secreted protein (Nedwin et al., 1985). The 3' UTR of 
TNFα has an AU-rich element (ARE). TNFα is 233-amino acids in length, containing 
transmembrane proteins arranged in stable homotrimers. Matrix metalloprotease, a TNFα 
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converting enzyme (TACE) mediates proteolytic cleavage and releases soluble homotrimeric 
cytokine (sTNF) from the membrane-integrated form. Both the membrane bound and the 
soluble forms of TNFα have distinct biological activities (Kriegler et al.; Tang et al., 1996). It is 
reported that TNFα has two commonly expressed but specific cell-surface receptors 
(Brockhaus et al., 1990), TNF receptor 1 (TNF-R1) and TNF receptor 2 (TNF-R2), which 
differ in their expression profiles, ligand affinity and downstream signalling pathway activation 
(Matera et al., 2010). TNF-R1 is constitutively expressed in most tissues and cell types, and is 
activated by either the soluble or the membrane-bound trimeric forms of TNFα, whereas TNF-
R2 is largely found in the immune system cells and is preferably activated by the trans-
membrane protein form of TNFα and thereby they differentially regulate signalling pathways, 
leading to physiological and also pathophysiological effects (Al-Lamki et al., 2001). 
TNFα is a critical inflammatory cytokine produced by a number of cells including activated 
macrophages (mostly produced by these cells), immune cells like mast cells, lymphocytes, 
endothelial cells and also by structural cells (which is very important for this study) such as 
fibroblasts, epithelial cells and smooth muscle cells (Wajant et al., 2003; Brightling et al., 
2008). Though TNFα is detectable in healthy individuals, elevated levels of TNFα, mRNA and 
protein were reported in asthmatic airways compared to non-asthmatics (Ying et al., 1991; 
Bradding et al., 1994). TNFα plays key role in the pathogenesis of asthma 
(hyperresponsiveness, airway remodelling) via activating various pro-inflammatory signalling 
pathways, which includes activation of nuclear factor kappa B (NFκB) and activator protein-1 
(AP-1) signalling pathways as well as other transcription factors (Natoli et al., 1997). It is also 
reported that with the response of inflammatory stimuli such as lipopolysaccharide (LPS), IL-1 
and other bacterial products huge amounts of TNFα which is released from skin and mast cells 
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(Wajant et al., 2003). This cytokine is involved in the regulation of a wide spectrum of 
biological processes including cell growth promotion and inhibition, angiogenesis, 
immunomodulation and inflammation, and thereby plays an important role in modulating a 
wide range of inflammatory conditions such as rheumatoid arthritis (Sarzi-Puttini et al., 2005), 
cardiovascular diseases (Sack, 2002), psoriasis (Kleyn and Griffiths, 2006) and cancer (Li et 
al., 2015). TNFα is implicated in several aspects of the airway pathophysiology in respiratory 
diseases (Berry et al., 2007; Brightling et al., 2008; Matera et al., 2010) and we also highlighted 
the inflammatory role of TNFα in asthmatic conditions here in this study. It is well studied and 
clearly demonstrated that TNFα can activate MAPKs signalling pathways (51, 92), and thereby 
upregulate several pro-inflammatory cytokines and chemokines including those which are 
implicated in asthmatic inflammation (Wajant et al., 2003). Interestingly TNFα can also 
upregulate anti-inflammatory proteins MKP-1 (Quante et al., 2008) in ASM cells. Further, it 
has also been shown that p38 MAPK is involved in the biosynthesis of TNFα (Kotlyarov et al., 
1999). In support of the earlier research, in our present study we demonstrate that TNFα is a 
model of inflammatory mediator that secretes significant amount of pro-inflammatory cytokines 
in respiratory epithelial cells (A549, BEAS-2B and ASM cells) and confirmed its role in the 
pathogenesis of inflammatory lung diseases such as asthma. 
 
1.8.2.2 Pam3CSK4 
Pam3CSK4, a synthetic bacterial lipoprotein, has been widely used to mimic bacterial infections 
(gram-positive bacteria) to mediate inflammatory responses via TLR2 (Manukyan et al., 2005; 
Beckett et al., 2012; Manetsch et al., 2012c). Pam3CSK4 is a potent TLR2 agonist, which is 
capable of modulating both Th1 and Th2 responses (Patel et al., 2005). Mounting evidence 
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demonstrates that TLRs are the primary sensors of both innate and adaptive immune systems that 
recognize invading pathogens and their synthesized molecules to coordinate the inflammatory 
responses (Patel et al., 2005). It is also reported that TLRs recognized a number of microbial 
products, which includes LPS, peptidoglycans, lipotechoic acids and bacterial pathogens 
producing lipoproteins (BLPs) (Henderson et al., 1996; Aliprantis et al., 1999). Among all these 
microbial products BLPs play the key role in inducing pro-inflammatory cytokines (Kostyal et 
al., 1994). BLPs are bacterial cell wall components found both in gram-negative and gram-
positive bacteria and mediate their immunomodulatory effects through their amino acid terminus 
(Manukyan et al., 2005). It is well studied and demonstrated that Pam3CSK4 induces the 
production of pro-inflammatory cytokines via activation of MAPK/AP-1 (Thaikoottathil and 
Chu, 2011) and NF-κB (Aliprantis et al., 1999) signalling pathways. However alternative 
mechanisms are also reported. We previously reported that Pam3CSK4 significantly increased 
TNFα-induced IL-6 and IL-8 mRNA expression and protein release and neutrophil chemotactic 
activity via phosphorylation of CREB protein at Ser133 and CRE-mediated transcription but not 
augmentation of NF-κB or MAPK signalling pathways or activation of TLR2 (Manetsch et al., 
2012c). In addition, Pam3CSK4 can also modulate RSV infection in a manner independent of 
TLR2 activation and accelerate acute respiratory disease in infants, immunocompromised 
subjects and the elderly (Nguyen et al., 2010)  
Synthetic lipopeptide is considered an important tool for studying innate immune recognition 
mechanisms as it is not only more easily obtained than the lipopeptide (directly obtained from 
organisms) but is also free of other contaminating bacterial components (Manukyan et al., 2005). 
Several studies demonstrate that TLRs interact with synthetic ligands or bacterial products to 
augment TLR2 function and stimulate pro-inflammatory cytokine secretion from human ASM 
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cells, including eotaxin and IL-6, IL-8 (Sukkar et al., 2006; Manetsch et al., 2012c) . In addition, 
it is reported that corticosteroid insensitivity is linked with certain cytokines and chemokines 
expression including IL-6 and IL-8 in respiratory cells (Bouazza et al., 2012; Chang et al., 2012). 
Hence in our study we used Pam3CSK4 to induce IL-6 and IL-8 expression in the context of 
corticosteroid insensitivity in respiratory epithelial cells to gain insight into the molecular 
mechanisms of this event as well as explore the possible therapeutic target to bypass 
corticosteroid insensitivity. 
 
1.8.2.3 S1P 
S1P is a bioactive sphingolipid metabolite with pleiotropic functions (Spiegel and Milstien, 
2003). S1P is increasingly recognized as playing an important role in asthma and airway 
inflammation (Oskeritzian et al., 2007). A growing body of evidence supports that S1P can 
regulate airway smooth muscle functions associated with asthmatic inflammation and 
remodelling, including cytokine secretion (Ammit et al., 2001). A number of stimuli such as 
cytokines, antigen and receptor tyrosine kinase and G protein-coupled receptors (GPCR) agonists 
can induce S1P expression in multiple cell types (Pyne and Pyne, 2000). S1P is involved in many 
cellular processes, acting both as an extracellular mediator via a family of plasma membrane 
GPCRs, and as an intracellular second messenger for growth factors, by altering the activity of 
specific intracellular target proteins (Pyne and Pyne, 2000). It is reported that S1P can regulate 
cell growth, proliferation, differentiation, and chemotaxis of various cell types. Further, the 
involvement of S1P in certain disease states such as atherosclerosis (Wang et al., 1999) and 
certain cancers (Hong et al., 1999) is also well recognized. Elevated levels of S1P were detected 
in bronchoalveolar lavage (BAL) fluid of asthmatics after challenge with antigen (Ammit et al., 
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2001), which is correlated with the eosinophil numbers in asthmatic subjects. Most importantly, 
S1P is recognized as a key regulator of ASM cell growth, contraction and synthetic functions. 
Further, it is evident that a number of signalling pathways are activated by S1P and thereby it 
regulates physiological and pathophysiological conditions.  
Elevated levels of S1P were also found in the airways of asthmatics and can increase IL-8 
secretion from human alveolar epithelial cells (A549) to regulate neutrophil–epithelial 
interactions in vitro (Milara et al., 2009). That S1P induces secretion of an important chemokine 
(IL-8) responsible for neutrophilia in airway inflammation is relatively unexplored. Therefore, in 
this study we aim to investigate whether S1P induces IL-8 gene expression and secretion to 
enhance neutrophil chemotaxis in vitro, as well as examine the molecular mechanisms 
responsible for repression by the corticosteroid, especially dexamethasone. We believe that our 
understanding of signaling mechanisms underlying S1P induced IL-8 gene regulation will create 
an avenue for the development of anti-inflammatory therapeutic strategies for better asthma 
management.  
 
1.8.3 MAPKs and asthmatic inflammation 
MAPKs are protein kinases that are evolutionary conserved eukaryotic signal transducing 
enzymes. Activation of MAPKs signalling pathways in airway structural cells produce a number 
of pro-inflammatory molecules, which elicit complex inflammatory conditions and cause 
structural changes that ultimately contribute to the hallmark of asthma such as T cell activation, 
eosinophil and mast cell infiltration, bronchial hyperresponsiveness and airway remodelling 
(Pelaia et al., 2005). MAPKs regulate multiple signalling pathways; hence they affect several 
aspects of normal airway functions as well as contribute to asthma pathophysiology (shown in 
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Table 1.3). The MAPKs superfamily comprises of several subgroups such as p38 MAPK, c-Jun 
N-terminal kinase (JNK 1, JNK 2 and JNK) and extracellular signal-regulated kinase (ERK, 
also known as p44/p42 or ERK1/ERK2) (Johnson and Lapadat, 2002). The MAPKs subfamilies 
share a common activation mechanism; they are activated via phosphorylation of three 
sequentially activated kinases. Importantly, like their substrates (other protein kinases and 
transcription factors), MAPKs functions are also regulated by phosphorylation. MAPKs 
activation requires dual phosphorylation at threonine (Thr) and tyrosine (Tyr) residues of the 
Thr-X- Tyr, where X is glutamic acid in the case of ERKs, proline in JNKs, and glycine in p38 
MAPK (Widmann et al., 1999; Pearson et al., 2001; Turjanski et al., 2007). After activation 
MAPKs migrate to the nucleus, where they phosphorylate various transcription factors via 
phosphorylation at their specific sites and thereby control gene expression (Karin, 1998; 
Widmann et al., 1999). 
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Table 1.3 MAPKs activation and their impact in asthmatic inflammation (Johnson and 
Lapadat, 2002; Subhashini et al., 2016). 
MAPKs Activated airway cells (clinical outcomes) 
 
 
 
 
p38 MAPKs 
-Eosinophils (chemotaxis, degranulation) 
-Mast cells (cell migration, production of IL-8) 
- Neutrophils (cell recruitment) 
-Monocytes & macrophages (differentiation, 
chemotaxis, release TNFα and MIP-2) 
-T cells (release IL-5 & IL-13) 
-Epithelial cells (apoptosis, release IL-8 and 
RANTES) 
-Fibroblasts (release IL-6) 
-Smooth muscles (cytokines production) 
 
 
 
ERK MAPKs 
-Eosinophils (chemotaxis) 
-Mast cells (production of IL-8) 
-T cells (Th2 differentiation) 
-Epithelial cells ( release IL-8 and RANTES) 
-Endothelial cells (angiogenesis) 
-Smooth muscles (cytokine production, cell 
proliferation) 
 
JNK MAPks 
-Epithelial cells (release IL-8 and RANTES) 
-Fibroblasts (myofibroblasts differentiation 
-Smooth muscles ( cell proliferation) 
 
Compiling evidence from published data support the importance of MAPKs family members in 
regulating the expression of cytokines, including two important cytokines implicated in 
asthmatic inflammation, IL-6 and IL-8 (Amrani et al., 2001; Henness et al., 2006; Quante et al., 
2008; Moutzouris et al., 2010). Our recent studies also clearly demonstrate the importance of 
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the MAPK superfamily signalling molecules in asthmatic inflammation using airway 
structural cells (A549, BEAS-2B and ASM) ( H e n n e s s  e t  a l . ,  2 0 0 6 ;  Q u a n t e  e t  
a l . ,  2 0 0 8 ) . Hence as part of our ongoing projects in this current study we used the same 
molecular approach to reveal this unexplored avenue to successfully combat asthmatic 
inflammation.  
 
1.8.3.1 p38 MAPKs 
The four isoforms of p38 MAPK subfamily are p38α, p38β, p38γ, and p38δ. Among these 
isoform p38α is well studied and shown to be expressed from most of the cells, whereas the 
others are expressed in a more tissue specific manner (Cuadrado and Nebreda, 2010). It is 
reported that distinct genes are responsible for p38 isoforms expression. p38 MAPKs are 
localized in the nucleus or cytosol or in both compartments and can be activated by several 
pro-inflammatory stimuli; hormones, ligands for GPCRs and cellular stress (such as osmotic 
shock and heat shock). The p38 MAPKs regulate the expression of many cytokines (including 
those which are implicated in asthma and autoimmunity), transcription factors, and cell surface 
receptors (Roux and Blenis, 2004; Keshet and Seger, 2010). In addition, they also play an 
important role in the functional response of immune and inflammatory cells by controlling 
chemotaxis, cell migration and differentiation, apoptosis, and cytokine production (Ono and 
Han, 2000), which suggest that p38 activity is critical for normal immune and inflammatory 
responses. Further, numerous studies demonstrate that p38 MAPKs regulate cell migration, 
proliferation, apoptosis and several inflammatory events in airway structural cells via 
increasing secretion of pro-inflammatory signalling molecules (Moutzouris et al., 2010; 
Munoz et al., 2010), which confirm their involvement in airway diseases pathogenesis. 
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Activation of p38 MAPKs lead to phosphorylation of a number of substrates including 
transcription factors (such as ATF2/6, Chop, Max, MEF2C), nuclear histones (H3), heat shock 
proteins (hsp27), various kinases like MAPKAP-K2 (mitogen-activated protein kinase-activated 
protein kinase 2), MSK1 (mitogen and stress-activated kinase 1), MNK1/2 (MAPK-interacting 
kinase 1/2) and PRAK (p38-regulated/activated protein kinase). Mediator generating enzymes 
such as the inducible isoform of COX-2 are also an important targets of p38 (Lasa et al., 2000). 
Most importantly, p38 MAPKs control the dynamic relation between phosphorylated (inactive) 
and unphosphorylated (active) TTP, a critical anti-inflammatory protein. 
 
1.8.3.2 c-Jun N-terminal kinase (JNK) MAPKs 
The JNK MAPK subgroup is encoded by three genes; JNK1, JNK2 and JNK3 and has ten 
isomers. JNK MAPKs are also known as stress-activated protein kinases due to their activation 
in response to inhibition of protein synthesis (Yan et al., 1994). Like p38 MAPK, JNK MAPKs 
are also responsive to stress stimuli, such as ultraviolet irradiation, cytokines, pro-inflammatory 
cytokines, heat shock, and osmotic shock (Pelaia et al., 2005; Munoz et al., 2010). JNK1 and 
JNK2 are ubiquitously expressed, whereas the JNK3 protein is found mainly in brain, heart and 
testis (Bode and Dong, 2007). Upon activation, JNKs translocate to the nucleus and 
phosphorylate a number of substrates including several transcription factors such as the c-Jun 
component of AP-1, Elk-1 and ATF2 and thereby they play important role in stress responses, 
apoptosis and inflammation (Cowan and Storey, 2003; Pelaia et al., 2005). It is reported that 
JNK is regulated by PP2A and plays an important role in IL-8 production (Kobayashi et al., 
2011; Kobayashi et al., 2012). 
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1.8.3.3 ERK MAPKs 
ERK MAPKs have several isoforms, among which the isoforms ERK1 and ERK2 are two well-
studied types, which are widely expressed and are involved in the regulation of meiosis, mitosis, 
and postmitotic functions in differentiated cells (Johnson and Lapadat, 2002). ERK MAPKs are 
also known as p42/p44 MAP kinases, which are activated by growth factors, mitogens or 
GPCRs, cytokines, virus infection transforming agents, and carcinogens (Sugden and Clerk, 
1997). Upon activation, ERK MAPKs phosphorylate diverse substrates, either in the cytoplasm 
or in the nucleus depending on the prior stimulus. ERK MAPKs have a wide variety of 
substrates including transcription factors (such as cMyc, Elk1, STATs, Ets1, Sap1a, Tal), growth 
factors such as EGF and pro-inflammatory enzymes like cytosolic phospholipase A2 (Widmann 
et al., 1999; Cowan and Storey, 2003). The ERK subgroup of MAPKs plays an important role 
in diverse physiological and pathological processes such as proliferation, differentiation and 
transformation, survival and apoptosis, stress response, inflammation, cell growth and also 
contributes to airway inflammation. Further activation of ERK MAPKs induce cyclin D1 
expression in airway monocytes and regulate ASM progression (Ramakrishnan et al., 1998), 
and thereby they increase ASM mass in asthmatic patients and contributes to bronchial 
remodelling and excessive airway narrowing.  
 
1.9 Endogenous anti-inflammatory proteins 
Inflammation is an immune response which is beneficial under normal physiological 
conditions. Inflammation plays important role in host defence mechanism via eliminating 
harmful foreign organisms or materials (Van Hove et al., 2008). However, persistent 
inflammation is harmful to the host and often accelerates the pathogenesis of a number of 
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diseases including asthma due to overexpression of multiple inflammatory proteins (Barnes, 
2008). There are a number of endogenous anti-inflammatory proteins including MKP-1, TTP 
(Prabhala and Ammit, 2015), and PP2A (Frasca et al., 2010), which play crucial roles in 
alleviating this inflammation. However, a growing body of evidence clearly demonstrates 
that these anti-inflammatory proteins become inactive during acute inflammatory conditions; 
mostly via phosphorylation. Hence understanding their regulation process and underlying 
molecular mechanisms may provide a therapeutic avenue for an alternative anti-inflammatory 
strategy with reduced side effects to fight inflammatory diseases. In this study, we mainly 
focused on some key endogenous anti-inflammatory proteins such as PP2A, TTP and MKP-1 
with the hope of combatting asthmatic inflammation via enhancing the power of these anti-
inflammatory proteins. 
 
1.9.1 Protein phosphatase 2A (PP2A) 
PP2A comprises a family of serine/threonine phosphatases, which have broad substrate 
specificity and diverse cellular functions (Janssens and Rebollo, 2012). Typically, PP2A is a tri-
molecular complex consisting of a catalytic C subunit (PP2A-C) together with a core scaffold 
structural A subunit (PP2A-A). These interact with a third regulatory B subunit (PP2A-B) to 
form PP2A (Janssens et al., 2008; Shi, 2009), as shown in Figure 1.6. The structural subunit is 
required for correct function whereas the catalytic subunit controls phosphatase activity. The 
regulatory subunit confers substrate specificity via reversible methylation and phosphorylation of 
the C-terminal tail of the catalytic subunit (Janssens et al., 2008; Shi, 2009).  
PP2A is a key eukaryotic phosphatase, regulating a wide variety of cellular functions such as 
transcription, DNA replication, RNA splicing, metabolism, translation, cell cycle progression, 
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cell transformation, cell senescence and apoptosis, morphogenesis, development, and 
neurotransmission (Chen et al., 2009). Moreover, PP2A is a master controller of multiple 
inflammatory signalling pathways (Lechward et al., 2001; Van Hoof and Goris, 2003). It is an 
exciting target for anti-cancer therapy (Janssens et al., 2005; Perrotti and Neviani, 2008) and has 
more recently emerged as a druggable target in respiratory disease (Kobayashi et al., 2011; 
Collison et al., 2013a; Kobayashi et al., 2013). Importantly, PP2A is also involved in restoring 
corticosteroid insensitivity (Kobayashi et al., 2013).  
 
 
Figure 1.6 Structure and regulation of PP2A (Cho and Xu, 2007) 
 
Despite the exciting potential of PP2A in asthma, research on PP2A has  primarily focused on its 
role in cancer (Janssens et al., 2005; Perrotti and Neviani, 2008), leaving investigations into the 
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anti-inflammatory function of PP2A in airway disease relatively unexplored. To date, there are 
only a few studies that have investigated PP2A in airway structural cells in the context of 
asthmatic inflammation and corticosteroid insensitivity. As it is evident that the catalytic subunit 
of PP2A plays the key role in cellular functions, in our study we mainly focused on PP2A-C.  
 
1.9.1.1 Regulation of PP2A 
PP2A is a multimeric holoenzyme, which is highly regulated at multiple levels (Virshup and 
Shenolikar, 2009); including transcriptional and post-transcriptional regulation, post-translational 
modifications and ubiquitin-mediated proteasomal degradation. In addition, PP2A enzymatic 
activity is regulated by endogenous inhibitory proteins (red: Figure 1.6) and by the nature and 
identity of the PP2A subunits. The most important regulatory mechanisms modulating cellular 
functions are phosphorylation and dephosphorylation. More than one third of total cellular 
protein is regulated by phosphorylation and dephosphorylation (Olsen et al., 2006). In the 
following section we will briefly discuss the transcriptional and post translational modification of 
PP2A. 
Transcriptional regulation of PP2A: PP2A comprises of a 65 kDa scaffolding protein (known 
as A or PR65 subunit) and a 36 kDa catalytic subunit or C subunit. Molecular cloning revealed 
that in mammalian cells, the catalytic subunit has two isoforms (PP2A-Cα and PP2A-Cβ), which 
share high (97%) sequence similarity and are encoded by the PPP2CA and PPP2CB genes, 
respectively. These isoforms are localized to human chromosome 5q23±q31 for α and to 
8p12±p11.2 for β (Jones et al., 1993). Both isoforms are ubiquitously expressed, but abundantly 
found in brain and heart. Importantly, PP2A-Cα isoform is more abundant than PP2A-Cβ 
(Khew-Goodall and Hemmings, 1988). Further, expression from the PP2A-Cα gene promoter is 
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7±10-fold stronger than from the PP2A-Cβ gene promoter, which may explain the difference in 
protein levels between the isoforms. The PP2A-C subunit has only two isoforms; however the 
number of possible combinatorial associations with different A and B regulatory subunits is very 
large, which provides many possibilities for regulation on PP2A-C. There are two A, two C, four 
B, at least eight Bʹ, four Bʹʹ and two Bʹʹʹ isoforms, which can be generated a total of about 75 
different dimeric and trimeric PP2A holoenzymes.  
Structural subunit A is closely associated with catalytic subunit C and forms a scaffold to which 
regulatory subunit B can bind firmly. Like the catalytic subunit, the structural subunit in 
mammalia also comprises of two distinct isoforms (α and β), which are ubiquitously expressed 
and share 86% sequence identity (Hemmings et al., 1990).  
Molecular cloning revealed that regulatory subunit B is encoded by four genes in mammalia such 
as PR55α, PR55β, PR55γ and PR55δ. Importantly, these genes are expressed in a tissue specific 
manner (Healy et al., 1991; Mayer et al., 1991). PR55α and PR55β are widely distributed 
whereas PR55γ and PR55δ are mainly found in brain (Zolnierowicz et al., 1994). Regulatory 
subunits comprise five degenerate WD-40 repeats, which are conserved as at least 40 amino acid 
sequences (Neer et al., 1994). 
Post-translational modifications of PP2A: Post-translational modification of PP2A-C includes 
phosphorylation and methylation, which are thought to be important regulatory devices. Despite 
remarkable progress in the research of post translational modulation of PP2A-C, many aspects 
are not clear yet. Moreover there are conflicts in regard to the effect of PP2A-C phosphorylation 
and methylation on its catalytic activity. Hence post-translational modification of PP2A-C 
warrant more research for better understanding this event. 
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Phosphorylation: Wide ranging factors are responsible for the phosphorylation of PP2A-C, such 
as tyrosine kinases pp60v-src, pp56lck, epidermal growth factor and insulin receptors. 
Phosphorylation occurs on Tyr307 of the conserved C-terminal of PP2A-C and subsequently 
causes inactivation of the enzyme. The presence of a phosphatase inhibitor such as OA enhances 
the phosphorylation of PP2A-C, which suggests that under normal conditions PP2A can undergo 
autophosphorylation to quickly re-activate itself. It is reported that inflammatory stimuli such as 
IL-1β or TNFα can cause transient tyrosine phosphorylation and inactivation of PP2A-C. 
Concomitant transient inactivation of PP2A-C can cause acceleration of signals transmission 
through kinase cascades and hence PP2A-C plays a pivotal role to modulate signal transduction 
cascades. Regulatory subunit B is also regulated by phosphorylation, especially the Bʹ family. 
Studies reveal that the substrate specificity of regulatory subunits alter due to phosphorylation of 
PR61δ by PKA (Usui et al., 1998). 
Methylation: Methylation plays an important role in post translational regulation of PP2A. 
Methylation occurs on the carboxyl group of the C-terminal residue Leu309. In vivo methylation 
is a reversible process due to the presence of a specific methylesterase. PP2A-C sequences 
contain a T304PDYFL309 motif at their C-terminus. In addition this motif also contains Tyr307 and 
a recognition site (a specific carboxyl methyltransferase) for carboxymethylation (Janssens and 
Goris, 2001). Studies revealed that OA prevents transferase access to its target site via inhibition 
of methylation of PP2A (Floer and Stock, 1994; Li and Damuni, 1994). Importantly, methylation 
of PP2A-C depends on cell type, for example cAMP moderately stimulates PP2A-C methylation 
in Xenipus oocyte extracts; however in pancreatic cells it has no influence (Kowluru et al., 1996) 
and most interestingly it also varies during the cell cycle.  
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PP2A activation: A number of small molecules have been reported to activate PP2A, as shown 
in Table 1.4 (Perrotti and Neviani, 2013). The best known of these is the sphingosine analog, 
FTY720, which is FDA approved and widely used as an immunomodulating drug for treating 
multiple sclerosis (MS) (Kappos et al., 2006). However FTY720 has other targets such as PP1. 
Most notably in the context of respiratory disease, FTY720 can induce S1P signalling. In a 
previous study we reported that S1P is elevated in BAL fluid of asthmatic subjects (Ammit et al., 
2001) and drives development of a pro-inflammatory phenotype, including IL-6 and IL-8 
expression in vitro (Che et al., 2014). Hence there is a compelling need to develop PP2A 
activators that are devoid of S1P agonism. Recent study has developed a chiral analog of 
FTY720 called AAL(S) that does not bind S1P receptors, (Don et al., 2007), and  is as effective 
as FTY720 at activating PP2A complexes in vitro and significantly represses airways disease in 
mouse model in vivo (Collison et al., 2013a).  
PP2A inhibition: There are a number of natural occurring small molecules that potently inhibit 
the catalytic activity of certain PPP-family ser/thr protein phosphatises (such as PP1, PP2B, PP5, 
and PP2A), shown in Table 1.3 (Smallie et al., 2015). Among these small molecules OA is 
widely used to inhibit PP2A phosphatase activity (Bialojan and Takai, 1988; Mao et al., 2005; 
Cornell et al., 2009; Kranias et al., 2010), however OA is a non-selective pharmacological 
inhibitor of PP2A (Swingle et al., 2007; Cornell et al., 2009). In our study we also used OA as a 
pharmacological inhibitor of PP2A. However, as OA is a non-selective inhibitor of PP2A, to 
demonstrate that OA-mediated effects are specific to PP2A, we used precise tools like siRNA 
against PP2A. 
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Table 1.4 Pharmacological activators and inhibitors of PP2A (McConnell and Wadzinski, 
2009) 
PP2A activator molecules PP2A inhibitor molecules 
 FTY720 (Fingolimod) or FTY720P 
 Sphingosine analog such as AAL(S) 
 Forskolin and 1,9-dideoxy forskolin 
 SET Binding Peptides  such as 
COG112, COG/OP449 and apoE 
 Other PP2A activating drugs 
-promethylating agents like the 
Chloroethyl Nitrosourea (CENU) 
-α-tocopheryl succinate (α-TOS) 
-Vorinostat and sorafenib 
-Carnosic acid 
-Methylprednisolone 
-Ceramide 
-Exogenous TGFβ 
o Okadaic acid 
o Calyculin A 
o Dragmacidins 
o Microcystins 
o Nodularins 
o Tautomycin 
o Tautomycetin, 
o Cytostatins 
o Phospholine 
o Leustroducsins 
o Phoslactomycins 
o Fostriecin 
o Cantharidin 
 
1.9.1.2 Relationship between PP2A and TTP 
Several studies demonstrate that PP2A has a dynamic relationship with TTP (Figure 1.7). 
Recently we reported that PP2A inhibition in respiratory epithelial cells (A549 and BEAS-2B) 
has a significant impact on the critical anti-inflammatory protein, TTP (Rahman et al., 2015). 
TTP is an mRNA destabilizing protein that targets numerous cytokines (Brooks and Blackshear, 
2013), including those involved in asthmatic inflammation. Its expression and function are p38 
MAPK-dependent (Mahtani et al., 2001; Sun et al., 2007). There is a dynamic equilibrium 
between unphosphorylated and phosphorylated forms of TTP, shown in Figure 1.7. The 
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unphosphorylated form of TTP is active and capable of decaying cytokine mRNA. However, this 
form of TTP is unstable and undergoes proteosomal degradation, whereas phosphorylated TTP is 
stable but unable to target cytokines mRNA for decay. Importantly, TTP is a direct target of 
PP2A and PP2A phosphatase activity is responsible for dephosphorylation of TTP at two key 
serines (Ser52 and Ser178) (Brook et al., 2006). In this way, PP2A shifts this balance of TTP 
towards unphosphorylated TTP via dephosphorylation (Brook et al., 2006; Sun et al., 2007).  
 
 
Figure 1.7 Relation between PP2A and TTP 
 
1.8.1.3 Relationship between PP2A, TTP and MAPKs 
As mentioned previously, TTP is a critical anti-inflammatory protein and is controlled by 
MAPKs mediated phosphorylation processes. The unphosphorylated form of TTP is active and 
capable of decaying cytokines mRNA (Brooks and Blackshear, 2013), which are implicated in 
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asthmatic inflammation. On the other hand, PP2A dephosphorylates a number of kinases that 
drive inflammatory cell signaling (Shanley et al., 2001; Junttila et al., 2008). Notably, PP2A can 
dephosphorylate members of the MAPK superfamily, including p38 MAPK (Junttila et al., 
2008). By regulating MAPKs, PP2A exerts significant control over cytokine regulatory 
networks; although the molecular mechanisms responsible remain relatively unexplored in 
airway inflammation.  
As shown in Figure 1.8, p38 MAPK shifts the TTP balance towards the phosphorylated state 
(inactive but stable) via phosphorylation of two key serines such as Ser52 and Ser178. 
Interestingly, PP2A shifts this balance towards the unphosphrylated state (active but unstable) 
via dephosphorylating the same serine sites. Therefore it is evident that MAPKs (especially p38, 
ERK and JNK mediated) signalling pathways play critical roles in the relationship between 
PP2A and TTP. Recently we reported that inhibition of basal PP2A activity by OA releases 
restraint on MAPKs and thereby increase MAPK-mediated pro-asthmatic cytokines, including 
IL-6 and IL-8 (Rahman et al., 2015).  
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Figure 1.8 Interrelations between PP2A, TTP and MAPKs 
 
1.9.2 TTP 
TTP is a critical endogenous anti-inflammatory protein. TTP is also known as zinc finger protein 
36 homolog (ZFP36), because it is encoded by the ZFP36 gene in humans, mice and rats 
(DuBois et al., 1990). Zinc ion serves to stabilize the integration of the protein itself but not 
involved in targets binding. The “finger” refers to the secondary structures consisting of α-helix 
and β-sheet, which are held together by the Zn ion. Zinc finger containing domains typically 
serve as interactors, binding DNA, RNA, proteins or small molecules (Laity et al., 2001). TTP is 
a destabilizing RNA binding protein that binds to AU-rich elements within the 3’-untranslated 
region and increases mRNA decay of inflammatory cytokines such as IL-6, IL-8, IL-2, GM-CSF, 
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GROα, TNFα and many more. Importantly all these cytokines are implicated in asthmatic 
inflammation and drive airway remodeling. TTP is largely controlled by phosphorylation. 
Several studies demonstrate that various inflammatory stimuli mediated MAPKs (especially p38) 
signaling rapidly and robustly activate TTP gene expression (Tchen et al., 2004; Brook et al., 
2006) and at the same time p38 MAPK also activates downstream kinase MK2. Upon activation 
MK2 phosphorylates TTP protein on two key serine residues (Ser52 and Ser178) (Hitti et al., 
2006) and thereby prevents the recruitment of the deadenylase complex (Marchese et al., 2010) 
and stops the initiation of mRNA decay. Therefore, the anti-inflammatory function of the 
destabilising RNA binding protein TTP is dictated by the phosphorylation status of TTP at Ser52 
and Ser178. 
Taylor et al clearly demonstrate the role of TTP as a critical anti-inflammatory protein using 
knock-in mice (Taylor et al., 1996). TTP deficient mice appear normal at birth, but develop a 
profound inflammatory phenotype with severe arthritis, cachexia and autoimmunity, resulting 
from increased mRNA stability of the cytokine TNFα, and excessive levels of circulating TNFα 
protein (Carrick et al., 2004). Several studies demonstrate that in addition to TNFα, TTP also 
targets many other clinically relevant cytokines, which are implicated in chronic inflammatory 
disease (Lai et al., 2006; Tudor et al., 2009). To date, research on TTP has primarily focused on 
its role in rheumatoid arthritis, leaving investigations into the anti-inflammatory function of TTP 
in airway disease relatively unexplored. Moreover TTP has dynamic relation with PP2A as 
described in relevant section. Hence in this study we aim to explore the molecular mechanisms 
of TTP anti-inflammatory functions in the context of asthmatic inflammation and eventually find 
out the strategy to enhance its anti-inflammatory function during asthmatic inflammation. 
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1.9.3 MAPK phosphatase 1 (MKP-1) 
Cellular functions are greatly affected by the strength and duration of MAPKs activation. 
Therefore, controlling functional outcomes of MAPKs is very important, and can be achieved 
by balancing the MAPK activation by diverse environmental and chemical stimuli and the 
negative feedback mechanism mediated by protein phosphatases such as MAPK phosphatases 
(MKPs) (Owens and Keyse, 2007). MKPs are classified into three major groups depending on 
the preference of the relative MKPs to dephosphorylate tyrosine, serine/threonine, or both the 
tyrosine and threonine residues in the activation loop “Thr-X- Tyr-motif” of these signalling 
enzymes. As these phosphatases dephosphorylate both the threonine and the tyrosine residues, 
they are also called dual-specificity phosphatases (DUSPs). To date there have been at least 10 
DUSP genes identified in the human and other mammalian genomes (Theodosiou and 
Ashworth, 2002; Jeffrey et al., 2007). Though MKPs vary in substrate specificity, subcellular 
localization tissue distribution and also in their response to various stimuli, all of them contain 
highly conserved typical structural elements (Lang et al., 2006). MKPs comprise a subfamily of 
10 catalytically active proteins with a common structure that consists of an N-terminal non-
catalytic domain and a C-terminal catalytic domain. The kinase interaction motif (KIM), 
situated in the N-terminal half, is very important for the quality of the interaction between 
MKPs and MAPKs and, thereby, plays a crucial role in the regulation of the enzymatic 
specificity (Farooq and Zhou, 2004; Kondoh and Nishida, 2007).  
MKP-1 is a 367 amino acid protein expressed by an immediate early gene located in the nuclear 
compartment. As it is located in the nuclear compartment, upon activation with diverse stimuli it 
can induce transcription instantly. MKPs share a number of stimuli with MAPKs (Keyse, 2000; 
Wong et al., 2005; Kondoh and Nishida, 2007); hence MKP-acts on MAPKs via a negative 
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feedback mechanism to control the strength and duration of MAPKs-mediated signalling. 
Diverse stimuli and pro- inflammatory mediators cause activation of MAPKs; thus they play a 
significant regulatory role in inflammatory and innate immune responses (Abraham and 
Clark,  2006), and subsequently in inflammatory airway diseases, such as asthma. MKP-1 is a 
promising target to attenuate the inflammatory responses mediated by MAPK activation. The 
inhibitory effect of MKP-1 on p38 MAPK, JNK and ERK (p38>JNK>>ERK (Franklin and 
Kraft, 1997)) activation as well as the modulation of pro-inflammatory processes indicate the 
importance of MKP-1 in these cellular pathways. 
As MKP-1 regulates pro-remodelling signal transduction via negative feedback mechanisms, 
exploring the underlying molecular mechanisms of MKP-1 in the context of asthmatic 
inflammation and airway remodelling may be an alternative and novel anti-inflammatory 
strategy. Recent studies demonstrate that exogenous stimuli especially ROS and infection (both 
bacterial and viral) cause MKP-1 inactive via oxidation and thereby develop resistance or 
corticosteroid insensitivity in asthmatic patients (Aeberli et al., 2006; Cao et al., 2008; Wancket 
et al., 2012). In addition, MAPKs mediated pro-inflammatory signaling pathways has a profound 
impact on asthma pathogenesis and MKP-1 inhibits these MAPKs mediated pro-remodeling 
functions; however the underlying molecular mechanisms are still unclear.  
In this study we aim to investigate the molecular mechanisms that mimic bacterial infection 
(Pam3CSK4) induced corticosteroid insensitivity taking MKP-1 oxidation into consideration. At 
the same time we will also check whether PP2A activators can bypass corticosteroid sensitivity, 
which is hindered by Pam3CSK4 in asthmatic inflammation. We expect that our work may 
reveal the mechanistic basis of corticosteroid insensitivity and explore novel alternative anti-
inflammatory strategies for treating and preventing airway inflammation. 
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1.10 Corticosteroid insensitivity 
Corticosteroids are the mainstay of anti-inflammatory therapy in respiratory disease. Although 
corticosteroids (glucocorticoids) have proven clinical efficacy in the treatment of chronic 
inflammatory diseases, such as asthma, some patients show poor response either due to an 
inherent difference in the glucocorticoid sensitivity as part of the disease process or due to 
exogenous stressors such as cigarette smoke and other oxidative insults. Hence increasing 
knowledge in relation to the underlying molecular mechanisms of corticosteroid insensitivity in 
respiratory diseases is crucial to achieve future therapeutic targets. 
Based on research to date we know that relative responsiveness to corticosteroids depends on 
exogenous (such as cigarette smoking, obesity and even social stress) or endogenous (genomic 
difference) factors (Hew and Chung, 2010; Marwick and Chung, 2010; Keenan et al., 2012). 
Most importantly these factors may interfere with the components of the corticosteroids’ anti-
inflammatory pathways and modify their functions, as shown in Figure 1.9. That's why more 
research is warranted to wholly understand the mechanistic basis of corticosteroids’ insensitivity 
and to identify the effective therapeutic target to restore their responsiveness or develop an 
alternative anti-inflammatory strategy to bypass corticosteroid insensitivity. 
Viral and bacterial infections are the most common modulators of respiratory inflammation that 
eventually lead to asthma exacerbation via interfering with our innate immune system. 
Importantly, this infection associated asthma exacerbation is controlled by various pattern 
recognition receptors including TLRs. To date TLR2 is well studied and it is evident that TLR2 
plays key role in innate immunity (Takeda and Akira, 2005) and evokes inflammatory responses 
in recognition of bacterial and viral components (Mogensen, 2009).  
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Pam3CSK4, a synthetic bacterial lipoprotein, has been widely used to mimic bacterial infections 
(gram-positive bacteria) to mediate inflammatory responses via TLR2 (Beckett et al., 2012; 
Manetsch et al., 2012c). In our study, we modeled bacterial exacerbation in vitro using the 
synthetic bacterial lipoprotein Pam3CSK4 to mimic bacterial infection and TNFα to simulate 
inflammation and explore their role in corticosteroid (particularly dexamethasone) insensitivity. 
Compiling evidence from recent studies show that both Pam3CSK4 and TNFα increase IL-6, IL-
8 and exotoxin secretion via TLR2 pathway (Tliba and Panettieri, 2009). Hence in our study we 
measured the relative secretion of IL-6 and IL-8 using the same inflammatory stimuli. 
 
 
Figure 1.9 Mechanisms of glucocorticosteroid (GC) insensitivity (Petsky et al., 2012) 
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Pharmacological approaches to restore corticosteroid sensitivity have revealed that there are 
three principle mechanisms involved in this phenomenon. These are: glucocorticoid receptor 
(GR) post-translational modification, GR-mediated recruitment of transcriptional co-repressors 
and post-transcriptional regulation (Ammit, 2013). Recent evidence demonstrates that post-
translational modifications of GR have a functional role in glucocorticoid responsiveness. GR 
isoforms have a number of key sites for post-translational modification (including sumoylation, 
ubiquitylation, acetylation and phosphorylation) that can affect their translocation, transcriptional 
activity and degradation and thus eventually their function (Galliher-Beckley and Cidlowski, 
2009). 
To date serine (Ser) phosphorylation is well studied in the context of GR function in respiratory 
disease, which eventually identified two critical phosphorylation sites (Ser211 and Ser226) for GR 
transcriptional activity. Most importantly, studies have also revealed that these sites can be 
regulated via dephosphorylation by Ser/threonine protein phosphatases 2A and 5 (PP2A and 
PP5), which have emerged as exciting mechanisms responsible for glucocorticoid insensitivity. 
Another promising approach to bypass corticosteroid sensitivity is activation of MKP-1. Several 
studies demonstrate that exogenous stimuli, especially ROS and infection (both bacterial and 
viral), cause MKP-1 inactivation via oxidation and thereby develop resistance or corticosteroid 
insensitivity in asthmatics (Aeberli et al., 2006; Cao et al., 2008; Wancket et al., 2012). Hence, 
MKP-1 is also an exciting target in corticosteroid insensitivity. 
In our present study, we therefore aim to unveil the fascinating role of endogenous PP2A and its 
activators (FTY720 and AAL(S)) to pinpoint their role in glucocorticoid insensitivity as a source 
of future alternative anti-inflammatory strategy in asthma and COPD. We also aim to explore the 
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role of a critical endogenous anti-inflammatory protein (MKP-1) in corticosteroid insensitivity to 
unveil the therapeutic avenue for alternative anti-inflammatory strategies. 
 
1.11 Targeting PP2A in corticosteroid insensitivity 
PP2A dephosphorylates a number of kinases that drive inflammatory cell signalling (Shanley et 
al., 2001; Junttila et al., 2008). Thus its inhibition allows unrestrained action of a number of 
downstream effectors. MAPKs family members (p38 MAPK, ERK and JNK) are important 
regulators of cytokine expression and are known to drive expression of two important cytokines 
implicated in asthmatic inflammation, IL-6 and IL-8 (Amrani et al., 2001; Henness et al., 2006; 
Quante et al., 2008; Moutzouris et al., 2010). By regulating MAPKs, PP2A exerts significant 
control over cytokine regulatory networks. Few recent studies support the role of PP2A in 
respiratory disease and demonstrate the promise of PP2A as a druggable target. It is reported  
that activating PP2A represses the hallmark of allergic and rhinovirus-induced airway disease in 
in vivo models (Collison et al., 2013a). Kobayashi et al (Kobayashi et al., 2011) has shown that 
defects in PP2A cause corticosteroid insensitivity in severe asthma and activation of PP2A can 
repress expression of pro-inflammatory chemokines, the neutrophil chemoattractant IL-8 in 
particular (Kobayashi et al., 2012). Intriguingly, PP2A activity was increased in the lungs of 
people with emphysema and in response to cigarette smoke exposure in mice (Wallace et al., 
2012). This was considered evidence of a homeostatic mechanism that serves to restrain or 
resolve oxidative lung injury. This was supported by a study showing that intra-tracheal 
transfection of PP2A prevented smoke-induced lung inflammation in vivo and knock-down of 
PP2A exacerbated smoke-mediated responses in vitro (Wallace et al., 2012). These studies serve 
to underscore the key role played by PP2A in the control of inflammation in respiratory disease, 
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and in corticosteroid responsiveness. Thus, modulating PP2A has the potential to treat asthmatic 
inflammation and bypass corticosteroid sensitivity. We examined this in this study and 
demonstrated that enhancing the power of endogenous PP2A activity can repress MAPKs 
mediated inflammatory cytokines and increase active TTP level; demonstrating an alternative 
anti-inflammatory strategy in corticosteroid sensitivity in airway structural cells. 
 
1.12 Targeting MKP-1 in corticosteroid insensitivity 
MKP-1 is an important anti-inflammatory protein that plays a vital role in limiting the strength 
and duration of MAPK signalling pathways (Manetsch et al., 2012a). A growing body of 
evidence demonstrates that glucorticoids-induced MKP-1 is partially responsible for anti-
inflammatory functions in clinically relevant airway cell types (Kang et al., 2008; Kaur et al., 
2008; Quante et al., 2008; Newton et al., 2010). Though several studies have shown that long-
acting β2-agonists alone and in combination with corticosteroid can increase both MKP-1 
mRNA and protein and limit inflammatory gene expression in asthma (Kaur et al., 2008; Newton 
et al., 2010), MKP-1 function is dysregulated in asthma. In addition it is reported that ROS and 
infection can cause dephosphorylation/inactivation of one important anti-inflammatory protein, 
MKP-1, which is associated with corticosteroid insensitivity (Sakai et al., 2004; Wancket et al., 
2012; Pinart et al., 2014). Therefore, in this study we aim to explore whether Pam3CSK4 is able 
to induce MKP-1 oxidation and subsequent corticosteroid insensitivity in respiratory structural 
cells.  
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1.13 Aim of this study 
Asthma is a clinically and socioeconomically significant chronic airway disease driven by 
inflammation. Inflammation plays multifaceted roles in asthma pathogenesis and exacerbation. 
Therefore anti-inflammatory strategies are still considered the most effective approach to combat 
asthmatic inflammation as well as asthma management. Corticosteroids are the mainstay of anti-
inflammatory therapy in respiratory disease and although they have proven clinical efficacy in 
asthma, many asthmatic inflammatory conditions (e.g. infection, exacerbation) are not 
responsive to them. Moreover, typical asthma management insists on long term use of 
corticosteroids, which can often lead to severe side effects. Therefore, alternative anti-
inflammatory strategies are urgently needed and enhancing the function of endogenous 
phosphatases, especially PP2A, offers great promise.  
The overall aim of this study is to explore the underlying molecular mechanisms and reveal the 
potential of endogenous PP2A to combat asthmatic inflammation using airway structural cells. 
It is hoped that our present study will offer better understanding about the endogenous PP2A 
in the context of its relationship with TTP and MAPKs and a therapeutic avenue of 
alternative anti- inflammatory strategy. We addressed our aim in the following projects: 
 
(1) Sphingosine 1-Phosphate Induces Neutrophil Chemoattractant IL-8: Repression by 
Steroids 
In searching for alternative anti-inflammatory strategies, we initially aimed to confirm the role of 
one important imflammatory mediator, bioactive sphingolipid S1P, in asthmatic inflammation. 
Several studies demonstrate an increase in the amount of S1P in the airways of asthmatics. It is 
also reported that S1P can regulate airway smooth muscle functions associated with asthmatic 
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inflammation and remodeling, including cytokine secretion. To date, however, whether or not 
S1P induces secretion of an important chemokine responsible for neutrophilia in airway 
inflammation IL-8 remained unexplored. In this project we explored this and found that S1P may 
contribute to the development of IL-8-driven neutrophilia in airway inflammation. 
 
(II) Basal protein phosphatase 2A activity restrains cytokine expression: role for MAPKs 
and tristetraprolin  
Next, we proposed to reveal the potential of basal endogenous phosphatase, PP2A as a potential 
target of an alternative anti-inflammatory strategy. PP2A is a master controller of multiple 
inflammatory signalling pathways driven by MAPKs. It is a target in asthma; however the 
molecular mechanism by which PP2A controls airway inflammation is yet unclear. A growing 
body of evidence support that PP2A has important role in respiratory disease and demonstrate 
the promise of PP2A as a druggable target. Despite the exciting potential of PP2A in asthma 
treatment, research into PP2A has primarily focused on its role in cancer (Janssens et al., 2005; 
Perrotti and Neviani, 2008), leaving investigations into the anti-inflammatory function of PP2A 
in airway disease relatively unexplored. We addressed this issue in this study. 
 
(III) Activating Protein Phosphatase 2A (PP2A) Enhances Tristetraprolin (TTP) Anti-
Inflammatory Function in A549 Lung Epithelial Cells 
In aim (II) we described the anti-inflammatory role of basal PP2A and highlighted its potential 
link with the critical anti-inflammatory protein TTP. As our next target we will therefore explore 
the interrelationship between PP2A and TTP. TTP function induces mRNA decay of cytokines 
frequently overexpressed in inflammation; including cytokines that have been implicated in 
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asthma. TTP is controlled by phosphorylation and in the unphosphorylated state is capable of 
inducing mRNA decay of cytokines. It is evident that PP2A has a dynamic relation with TTP. 
However the underlying molecular mechanisms and interrelationship between the anti-
inflammatory function of PP2A and TTP dephosphorylation remains unclear. We have addressed 
this in this project. 
 
(IV) TLR2 ligation induces corticosteroid insensitivity in A549 lung epithelial cells: anti-
inflammatory impact of PP2A activators 
Our studies successfully demonstrate that PP2A activators offer a great promise as alternative 
anti-inflammatory strategies in asthmatic inflammation. Though corticosteroids have proven 
efficacy in asthmatic inflammation, bacterial and viral infection mediated asthma exacerbation is 
insensitive to corticosteroids. Hence the aim was to check whether alternative anti-inflammatory 
molecules/PP2A activators known (FTY720) and novel (Theophylline) are effective when 
corticosteroid insensitivity exists. In this section we also aimed to explore the underlying 
molecular mechanisms of mimic bacterial infection, Pam3CSK4-induced corticosteroid 
insensitivity.  
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Chapter 2 
General Materials and Methods 
 
2.1 Materials 
Unless otherwise specified, all chemicals and reagents used in this study were purchased from 
Sigma-Aldrich (St. Louis, MO). 
 
2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Solutions 
Cell culture/feeding media for the culture of primary ASM cells is composed of Dulbecco’s 
Modified Eagle’s Medium (DMEM) with phenol red, enriched with 200 mM L-glutamine, 1 
M HEPES (4-(2-hydroxyethyl)-1- piperazineethanesulfonic acid), antibiotic-antimycotic liquid 
(containing 10,000 units/mL penicillin, 10,000 µg/mL streptomycin and 25 µg/mL amphotericin 
B) (Invitrogen, Carlsbad, CA) and 10 % heat-inactivated (56°C for 30 min) foetal bovine serum 
(FBS) (Interpath Services, Heidelberg West, VIC, Australia). Starving media used in cell culture 
consists of 0.1 % (v/v) BSA (30% w/v solution, sterile) in DMEM. 
Whereas, airway epithelial cells, A549 (originated from cancerous lung) and BEAS2B 
(originated from normal lung) were cultured in Ham's F-12K (Kaighn's) Medium (Invitrogen, 
Carlsbad, CA) supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml), and fetal 
bovine serum to a final concentration of 10%.  
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2.2.1.2 Culture of primary human ASM cells 
Human bronchi from the large bronchial airways were obtained from patients undergoing 
surgical resection for carcinoma or lung transplant donors in accordance with procedures 
approved by the Central Sydney Area Health Service and the Human Ethics Committee of the 
University of Sydney. Primary ASM cells were dissected, purified and cultured as previously 
described by Johnson et al. ( J o h n s o n  e t  a l . ,  1 9 9 5 ) . Specific to our settings, after 
dissection of the bronchi from the surrounding tissue and removing of the epithelium layer 
individual ASM tissue bundles were plucked out and placed into 25cm
2 
tissue culture flask 
(Sarstedt, Nümbrecht Germany) with DMEM containing phenol red and supplemented with 
2 mM L-Glutamine, 20 mM HEPES, 10% heat inactivated FBS and 2% Antibiotic-
Antimycotic mix (200 U/L Penicillin G, 0.5 µg/mL Amphotericin B and 200 µg/mL 
Streptomycin sulphate). The flasks were then placed in a 5% CO2 humidified incubator at 
37°C. Cells grew to confluence over 14-21 days and were passaged when confluent. 
 
2.2.1.3 Passaging ASM cells  
Before trypsinizing the cells (2 min at 37°C) the media was aspirated and the cells were washed 
two times with sterile PBS (Ca
2+
/Mg
2+
-free) to remove all traces of FBS. Cell passaging was 
completed using a trypsin solution (0.5 g/l porcine trypsin and 0.2 g/l EDTA in Hank's balanced 
salt solution with phenol red).  The cell attachment was checked microscopically (Olympus 
CKX31, Olympus, Center Valley, PA) and if necessary the detachment was facilitated by 
agitation.  After detachment, feeding media was added to inhibit further tryptic activity.  Cell 
numbers were assessed on a haemocytometer using trypan blue solution. Cells were plated 
at a density of 1x10
6  
cells/T175 flask (Sarstedt, Nümbrecht, Germany) placed at 5% CO2 in 
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air at 37°C, media change every week and passage into further T175 flasks (split 1:3) every 2 
weeks, depending on cell need. For all experiments in this thesis, smooth muscle cells were used 
between passage 4 and 8. Primary ASM cells tipically use maximum passage number 8 to 10. 
 
2.2.1.4 Passaging A549 and BEAS2B cells 
Before trypsinizing the cells (2 min at 37°C) the media was aspirated and the cells were washed 
two times with sterile PBS (Ca
2+
/Mg
2+
-free) to remove all traces of FBS. Cell passaging was 
completed using a trypsin solution (0.5 g/l porcine trypsin and 0.2 g/l EDTA in Hank's balanced 
salt solution with phenol red).  The cell attachment was checked microscopically (Olympus 
CKX31, Olympus, Center Valley, PA) and if necessary the detachment was facilitated by 
agitation. After detachment, feeding media was added to inhibit further tryptic activity. Cells 
were splited 1/3 two times per week (e.g. Monday and Thursday or Tuesday and Friday) and 
placed at 5% CO2 in air at 37°C.  
 
2.2.1.5 Plating and starvation ASM cells  
Cells were plated at a density of 1.0 x 10
4 
cells/cm
2 
according to the guidelines in Table 2.1 
and commonly grown for one week. Feeding media was changed approximately 72 hours after 
plating. Before performing the experiments the cells were growth arrested. The feeding media 
was aspirated, the cells were washed twice with sterile PBS, and then starving media was 
added for 48 h. 
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Table 2.1 Guidelines for plating of ASM cells for experiments 
TYPE OF PLATE PLATING DENSITY MEDIA PER WELL 
6-well 96,000 cells/well 2 mL 
100 mm 785,000 cells/well 10 mL 
 
2.2.1.6 Plating and starvation A549 and BEAS2B cells 
Cells were plated at a density of 250,000/ml so that when 2 mL is added to 6 well dishes 500,000 
cells/well is achieved
 
according to the guidelines in Table 2.2. Commonly cells were allowed to 
settle for 4-6 h and growth arrested before performing the experiments. The feeding media was 
aspirated, the cells were washed twice with sterile PBS, and then starving media was added 
for 14-16 h. 
 
Table 2.2 Guidelines for plating of A549 and BEAS2B cells for experiments 
TYPE OF PLATE PLATING DENSITY MEDIA PER WELL 
6-well 500,000 cells/well 2 mL 
100 mm 2500,000 cells/well 10 mL 
 
2.2.1.7 ASM cell characterization 
To characterize primary ASM cells, after the first passage, the Respiratory Research Group 
performs an immunoassay for the expression of the muscle cell markers for α-smooth muscle 
actin and calponin as previously described by Johnson et al. (Johnson et al., 1995). In following 
passages the cells were visually examined and kept showing the, for primary ASM cells, typical 
hill-and-valley morphology, were elongated, thin, spindle-shaped and showed concentric, oval 
nuclei. 
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2.2.2 Western blotting 
2.2.2.1 Solutions 
5x Cell lysis/sample buffer is composed of TrisHCl 250 mM, DTT 500 mM, SDS 10% 
(w/v), bromophenol blue 0.5% (w/v), glycerol 50%, pH 6.8 and was used to collect cell lysates. 
The separating gel (8% if not otherwise specified) consisted of a 30% acrylamide- 0.8% 
bisacrylamide- solution, TRIS (pH 8.8). 
1.5 M, SDS 10 %, N,N,N’,N’ tetramethylethylenediamine (TEMED) and a 30% (w/v) 
ammonium persulfate (APS) solution. The stacking gel (5%) consisted of a 30% acrylamide- 
0.8% bisacrylamide- solution TrisHCl (pH 6.8) 1 M, SDS 10%, TEMED and a 30% APS 
solution. The electrophoresis buffer (pH 8.3) contained TRIS 25 mM, glycine 250 mM, and SDS 
0.5 %. The transfer buffer (pH 8.5) used for electro transfer consisted of TRIS 25 mM, glycine 
192 mM and 20% (v/v) methanol. The transfer buffer used for diffusion transfer is composed of 
NaCl 50mM, EDTA 2mM, Tris-HCl pH 7.5 10 mM and DTT.  Tris- buffered saline solution 
with tween (TBS-T) pH 7.6 is composed of Tris 20 mM, NaCl 137 mM, and 0.1% (v/v) Tween 
20. Blocking buffer contained 5% (w/v) skim milk powder in TBS-T (pH 7.6).  
 
2.2.2.2 Sample preparation and immunoblotting 
According to cell needs and experimental plans, ASM cells were plated in petridishes, 6 well 
plates (BD Bioscience, Franklin Lakes, NJ) and cultured until they reached confluence. After 
growth arresting for 48 hours, cells were treated according to the experimental plans as indicated 
in the respective Chapters. Cells were then washed two times with ice-cold PBS, 1x sample 
buffer was added and after scraping, the lysates were collected in eppendorf tubes and boiled 
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for 5 min. To fractionize the samples by size and to detect specific proteins of interest, a 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was performed. The 
SDS-PAGE was run at 200 V constant using the Power Pac 200 (Bio-Rad, Hercules, CA) until 
the bromophenol blue in the sample buffer completely reached the end of the gel. Proteins were 
then transferred onto a nitrocellulose membrane (Pall Corporation, Port Washington, NY) by 
electrotransfer (100 V constant on the Power Pac 200, 1 hour). To check the uniformity and the 
overall effectiveness of the protein the membranes were stained with Ponceau. After blocking 
the membranes for 1 hour at room temperature with blocking buffer on the rocking platform 
mixer (Ratek Instruments, Boronia, VIC, Australia) and subsequent washing with TBS-T the 
membranes were incubated with the primary antibody specific to the target protein (see Table 
2.2). After 3 other wash steps, primary antibodies were detected with goat anti-mouse 
horseradish peroxidase-conjugated secondary antibodies (see Table 2.2) and visualized by 
enhanced chemiluminescence (PerkinElmer, Wellesley, MA). The blots were exposed to a 
medical film (Fujifilm, Tokyo, Japan) and then developed with an x-ray processor (SRX-101A, 
Konica, Tokyo, Japan). 
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Table 2.3 Primary and secondary antibodies used for Immunoblotting 
 Buffer Incubation Company C/N Dilution 
Primary antibody 
TTP Blocking buffer Over night Andy Clark Sak21 1:1000 
Phospho-p38 Primary antibody 
dilution buffer 
Over night Cell signaling 9211 1:1000 
Total p38 Primary antibody 
dilution buffer 
Over night Cell signaling 9212 1:1000 
Phospho-ERK Primary antibody 
dilution buffer 
Over night Cell signaling 9101 1:1000 
Total ERK Primary antibody 
dilution buffer 
Over night Cell signaling 9102 1:1000 
Phospho-JNK Primary antibody 
dilution buffer 
Over night Cell signaling 9251 1:1000 
Total JNK Blocking buffer Over night Cell signaling 9258 1:1000 
MKP-1 Blocking buffer Over night SantaCruz 
Biotechnology 
G301
3 
1:50 
I2PP2A Blocking buffer Over night SantaCruz 
Biotechnology 
Sc-
25564 
1:1000 
PP2A-C Blocking buffer 1 h RT Millipore 05-
421 
1µg/10
ml 
GRα Blocking buffer Over night Abcam Ab53
692 
1:1000 
α-Tubulin Blocking buffer 30 min RT Santacruz 
Biotechnology 
sc-
32293 
1:10000 
Lamin B Blocking buffer 1 h RT Cell signaling 2031 1:10000 
Secondary antibody 
Anti-mouse IgG Blocking buffer 1 h RT Cell signaling 7076 1:10000 
Anti-rabbit IgG Blocking buffer 1 h RT Cell signaling 7074 1:10000 
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2.2.3 Nuclear and Cytoplasmic protein extraction 
2.2.3.1 Cell culture and sample collection 
To prepare highly enriched fractions of cytoplasmic and nuclear proteins from cultured cells for 
subsequent Western blot studies, cytoplasmic and nuclear protein extraction was performed 
using the NE-PER nuclear and cytosolic extraction reagents from Pierce (Thermo Fischer 
Scientific Rockford, IL). 
A549 cells were cultured in 100 mm petri dishes according to the standard protocol described 
earlier and then growth-arrested 14-16 hours prior to the planned experiment. After aspirating 
the feeding media the cells were washed two times with PBS and Trypsin-EDTA was added to 
the petri dishes to detach and harvest the cells. After incubation for approximately 2 min at 
37°C, the cell attachment was checked microscopically and if necessary the detachment was 
facilitated by agitation. Feeding media was added to inactivate the trypsin and the cell 
suspensions were transferred to a 1.5 mL microcentrifuge tube. After centrifugation for 5 min at 
1100 rpm the cell pellet was washed with PBS and another centrifugation step (5 min at 1100 
rpm) was performed. 
 
2.2.3.2 Cytoplasmic and nuclear protein extraction 
To avoid dilution of the CER I (Cytoplasmic Extraction Reagent I) lysis buffer, and therefore a 
decrease in cell lysis efficiency, all PBS had to be removed. Protease inhibitor cocktail 
(provided with the kit) had to be added to CER I and NER  (Nuclear  Extraction  Reagent)  
before  use  to  maintain  integrity  and function of the extracted proteins. 
For the extraction, ice-cold CER I had to be added to the cell pellet. After vortexing the pellet 
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on the highest setting for 15 sec, the cell suspension had to be incubated on ice for 10 min. In 
a second step CER II (Cytoplasmic Extraction Reagent II) was added to the tube and after 
vortexing on the highest setting for 5 sec, the tubes were incubated on ice for 1 min. Following 
vortexing the tubes were centrifuged for 5 min at maximum speed (4°C, 13,000 rpm). The 
supernatants (cytoplasmic fraction) were transferred to pre-chilled tubes and placed on ice until 
use or stored at -80°C. 
To get the nuclear fraction the remaining the cell pellet (insoluble fraction that contains the 
nuclei) was washed with PBS and centrifuged for 5 min at maximum speed (4°C, 13,000 rpm). 
After removing all PBS ice-cold NER was added to the tubes. Following vortexing on the 
highest settings for 15 sec the tubes were placed on ice for 10 min and for a total of 40 min the 
vortexing was continued f o r  1 5  s e c  e v e r y  1 0  m i n . After subsequent centrifugation a t  
maximum speed (4°C, 13,000 rpm) for 10 min the supernatants containing the nuclear extracts 
were transferred to pre-chilled tubes and placed on ice until use or stored at -80°C. 
 
2.2.3.3 Western blot preparation 
Before analysing the samples using Western blotting, equal amounts of cell sample buffer had 
to be added to the cytosolic and nuclear fraction and the samples had to be boiled for 5 min. 
Western blotting was performed as described in Chapter 2.2.2 but to check equal loading the 
membranes were probed with Lamin A/C for the nuclear and α-tubulin (see Table 2.2) for 
the cytosolic fraction. α-tubulin should not give a signal for nuclear protein samples to ensure 
the nuclear fraction is not contaminated with the cytosolic fraction. 
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2.2.4 RT-PCR 
2.2.4.1 RNA sample collection and RNA extraction 
ASM cells were plated in 6-well plates at a density of 10
4 
cells/cm
2
, cultured for one week and 
growth-arrested for 48 hours prior to the experiment. On the day of  the  experiment  the  cells  
were  treated  according  to  the  experimental protocol. For the extraction of total RNA an 
adapted protocol from Qiagen protocol: RNeasy® Mini Handbook (Qiagen, Valencia, CA) 
was used. After completely aspirating the cell-culture medium and washing the wells 2 times 
with PBS, RLT lysis buffer, containing guanidine thiocyanate and ß- mercaptoethanol was 
added to the wells, to lyse the cells and to immediately inactivate RNases to ensure purification 
of intact RNA. The lysates were collected with a rubber scraper (Sarstedt, Nümbrecht, 
Germany) and pipetted into a 1.5 mL microcentrifuge tube. A syringe and a needle were used to 
fully lyse and homogenize the cells. To shear the DNA the lysates were passed through a 23-
gauge needle attached to a sterile plastic syringe (needle and syringe both from: Livingstone  
International,  Rosebery,  NSW, Australia)  at least 5-10 times. To provide appropriate binding 
conditions for the RNA to the RNeasy membrane, 70% ethanol was added to the homogenized 
lysates and mixed well by pipetting up and down. After transferring the samples to a provided 
RNeasy spin column placed in a 2 mL collection tube, the samples were centrifuge for 15 sec 
>10,000 rpm in a microcentrifuge (Centrifuge 5415R, Eppendorf AG, Hamburg Germany). In 
this step the total RNA binds to the membrane and any contaminants are efficiently washed 
away. After 3 more wash steps the total RNA was eluted by placing the RNeasy spin column in 
a new  1.5  mL  collection  tube,  adding  RNase-free  water  directly  to the  spin column 
membrane and after centrifugation for 1 min at >10,000 rpm the high- quality RNA was 
collected. To check the integrity of the RNA 5µl of each sample (5 µL of extracted RNA + 1 
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µL of RNA loading buffer) were run on a 1% agarose/TAE gel in 1x TAE (Tris-acetate-
EDTA) at 100 V for about 30 min. The RNA integrity was assessed using the denaturing agarose 
gel electrophoresis method followed by ethidium bromide staining. Assessing the gels on the 
transilluminator, both 18S and 28S rRNA appeared as sharp, distinct bands after electrophoresis 
of total eukaryotic RNA and therefore the RNA was considered to be intact. 
 
2.2.4.2 Reverse transcription and polymerase chain reaction 
After this control step reverse transcription was performed to prepare single- stranded DNA 
from the RNA samples using the Fermentas RevertAid™ First Strand cDNA Synthesis Kit 
(Fermentas, Thermo Scientific, Burlington, Canada). To avoid any contamination and to ensure 
the preparation of a high- quality complementary DNA (cDNA) all tubes used were autoclaved 
and only filter tips were used for the preparation of the samples. All the following reactions were 
prepared on ice. The water/primer master mix, containing Random Hexamer Primer and bottled 
water (Livingstone International, Rosebery, NSW, Australia), was prepared and aliquoted to the 
appropriate number of autoclaved, thin-walled 200 µl PCR tubes. Then the extracted RNA 
samples were added to each PCR tube. The tubes were placed into the PCR machine (MJ 
Research, PTC-200 Thermal Cycler, GMI inc, Ramsey, Mn) and heated at 70°C for 5 min for 
denaturation and to provide the right annealing conditions for the primers. After that step the 
tubes were placed on ice and reaction buffer, RNase inhibitor and dNTPs were added to the 
samples and the tubes were heated at 25°C for 5 min in the PCR machine. After adding the 
reverse transcriptase (RevertAid™ M-MuLV Reverse Transcriptase, Fermentas, Thermo 
Scientific, Burlington, Canada) to each tube the rest of the program was run to obtain the cDNA. 
The conditions were the following:  25°C for 10 min then 42°C for 60 min, 70°C for 10 min, 
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and then the samples were cooled to 4°C and the cDNA was collected. Subsequent mRNA 
expression of the target genes was quantified by real-time RT-PCR using an ABI Prism 7500 
real-time PCR machine (Applied Biosystems, Foster City, CA) and the appropriate primer set 
(Assays on Demand; Applied Biosystems, Foster City, CA). The samples were multiplexed with 
a eukaryotic 18S rRNA endogenous control probe (Applied Biosystems, Foster City, CA) and 
subjected to the following cycle parameters: 50°C for 2 min, 1 cycle; 95°C for 10 min, 1 
cycle; 95°C for 15 sec, 60°C for 1 min, 40 cycles. 
 
2.2.5 Enzyme-linked immunosorbent assay (ELISA) 
For all ELISAs conducted during this study a protocol adapted from BD Biosciences protocol: 
Human IL-6/ IL-8 ELISA was used and capture antibody, detection antibody, protein standards 
and streptavidin-HRP were all provided by BD Bioscience Systems Human IL-6/ IL-8 ELISA 
Set (BD Bioscience, Franklin Lakes, NJ). 
To perform an ELISA a 96-well ELISA plate (NUNC Maxisorp Immuno Plate F96; Noble 
Park North, VIC, Australia) was coated with a capture antibody diluted in coating buffer 
(0.1 M sodium carbonate, pH 9.5) specific for the target protein. For all recommended 
antibody dilutions in, the manufacturers’ lot-specific I n s t r u c t i o n /Analysis C e r t i f i c a t e  
w a s  c o n s u l t e d .  The p l a t e  w a s  sealed and incubated overnight at 4°C. The wells were 
washed 3 times with wash buffer (PBS with 0.05% Tween-20) to wash off possible unbound 
capture antibody. Subsequently the plate was blocked with assay diluent (PBS with 10% 
FBS, pH 7.0) and incubated for 1 h at RT to block all unbound sites and therefore to prevent 
false positive results. After 3 other wash steps the standards and cell supernatant dilutions 
(prepared in 0.1% BSA in DMEM) were added as set out in the experimental protocol, the 
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plate was sealed and incubated for 2 h at RT. During this incubation the protein of interest binds 
to the capture antibody. Following 5 other wash steps a biotinylated detection antibody together 
with a streptavidin-horseradish peroxidase conjugates (SAv- HRP) in assay diluent was added, in 
a one-step incubation, to the wells. The plate was again sealed and incubated for 1 h at RT. 
Subsequent 7 wash steps were performed to wash off unbound Biotin/Streptavidin reagent and 
the plate was incubated with the substrate solution (TMB 2-Component Microwell peroxidase 
substrate system; KPL, Inc., Gaithersburg, MD) for 30 min at room temperature in the dark. 
During this incubation the enzyme streptavidin-horse radish peroxydase (HRP), bound to the 
detection antibody, converts the added substrate in to a coloured product and the colour is 
proportional to the amount of bound protein. To stop this process an acidic stop solution was 
added to the wells and the colour was measured using a spectrometer at 450 nm wave length 
(Microplate Reader, Model 680, Bio-rad, Hercules, CA). 
 
2.2.6 Transient transfection 
A549 cells (5 × 105 cells/well) were transfected with 1 µg of pEGFP HA-PP2A-C (PP2A-C WT) 
or pEGFP-TTP-S52A/S178A (TTP knock-in) or pEGFP-TTP (TTP WT) or empty vector 
control, using Lipofectamine 2000 (Invitrogen). After transfection, cells were cultured for 24 h in 
media without antibiotics, and then growth-arrested for 16 h in Ham's F-12K supplemented with 
0.1% BSA, supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml), before cells 
were assayed. 
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2.2.7 siRNA transfection 
A549 cells (5 × 105 cells/well) were transfected with siRNA against PP2A-C or TTP, or 
scrambled control, by reverse transfection with RNAiMAX according to the manufacturer’s 
protocols (Invitrogen, NY, USA). Specifically, for each well of 6-well plates, 800 ng of ON-
Target plus Control Non-targeting siRNA (scrambled control) or ON-target plus SMART pool 
Human PPP2CA siRNA (aka PP2A-C, both from Dharmacon, Thermo-Fisher Scientific, 
Waltham, MA) or ON-target plus SMART pool Human TTP siRNA (aka Zfp36: both from 
Dharmacon, Thermo-Fisher Scientific, Waltham, MA) were diluted in 500 μL of Opti-MEM 
Reduced Serum Media (Invitrogen). This was followed by the addition of 5 μL of RNAiMAX 
reagent (Invitrogen) into each well and incubation at room temperature for 20 min. After 
transfection, cells were cultured for 24 h in media without antibiotics, and then growth-arrested 
for 16 h in Ham's F-12K supplemented with 0.1% BSA, supplemented with penicillin (100 
U/ml), streptomycin (100 μg/ml), before stimulation with TNFα (4 ng/ml). 
 
2.2.8 PP2A activity assay 
PP2A activity was determined using the PP2A immunoprecipitation phosphatase assay kit 
(Merck Millipore, Darmstadt, Germany) according to the manufacturer's instructions. In brief, 
whole-cell lysates were prepared in 20 mM imidazole-HCl, 2 mM EDTA, 2 mM EGTA pH 7.0, 
protease inhibitor cocktail (10 µl/ml ) and 1 mM PMSF. PP2A-C was immunoprecipitated from 
250 μg of cell lysate by 4 μg of anti-PP2A-C mAb (Upstate, clone 1D6) and protein-A agarose 
slurry for 2 h at 4 °C. Lysates were washed in Tris-buffered saline followed by serine-threonine 
phosphatase assay buffer (50 mM Tris HCl, 100 μM CaCl2, pH 7.0). Threonine phosphopeptide 
(K-R-pT-I-R-R) was added to a final concentration of 750 μM. and incubated for 15 min at 30 
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°C. Samples were centrifuged briefly, 25 μl of supernatant was transferred to a half-volume 96-
well plate, and 100 μl Malachite Green detection solution was added for 10 min at room 
temperature. Amount of phosphate cleaved by PP2A was then determined by absorbance at 655 
nm on a microplate reader (Model 680, Bio-Rad Laboratories). 
 
2.2.9 Neutrophil chemotaxis 
Neutrophils were purified from anti-coagulated venous blood of a healthy volunteer by positive 
selection using magnetic-activated cell sorting (MACS) as previously described (Baines et al., 
2009). Written informed consent from the volunteer was obtained for use of this sample in 
research in accordance with procedures approved by the Human Research Ethics Committee of 
the University of Sydney. Briefly, erythrocytes were removed by dextran sedimentation followed 
by ficoll centrifugation to separate mononuclear cells from granulocytes. Remaining erythrocytes 
were lysed by osmotic shock and the pellet which contains eosinophils/neutrophils was mixed 
with anti-CD16 conjugated immunomagnetic beads (Miltenyi Biotec, Sunnyvale, CA) and 
incubated for 30 min at 4 ºC. The cells were then separated using MACS where the eluent was 
discarded. Neutrophils bound to the micro-beads were taken out of the magnetic field, flushed 
and prepared at a cell density of 2 x 106/ml in DMEM + 0.1% BSA to be used in chemotaxis 
assays. Neutrophil chemotaxis towards conditioned media from treated ASM cells was 
quantified microscopically using a 96-well microchemotaxis chamber (Neuroprobe, 
Gaithersburg, MD) as previously published (Henness et al., 2006). 
2.2.10 NF-B activity assays  
NF-B activity assays were performed with the NF-B reporter vector, pNF-B-Luc, according 
to our previously published methods (Henness et al., 2006; Moutzouris et al., 2010).  
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The NF-κB reporter vector, pNF-κB-Luc, was purchased from Clontech (BD Biosciences). 
Transient transfection of ASM cells was performed using Lipofectamine 2000 (Invitrogen). In 
brief, ASM cells were plated onto six-well plates at a density of ∼2.5 × 105 cells/well for 24 h 
and then transfected with 2.4 μg of pNF-κB-Luc as well as 1.4 μg of pSV-β-galactosidase control 
vector (Promega) to normalize transfection efficiencies. After transfection, cells were cultured 
for 8 h and then growth-arrested for 16 h in DMEM supplemented with 0.1% BSA, 100 units/ml 
penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml amphotericin B (Invitrogen). Cells were then 
treated with vehicle or TNF-α (10 ng/ml), in the absence or presence of S1P (1 µM), for 6 h. 
Cells were then harvested, and luciferase and β-galactosidase activities were assessed according 
to manufacturer's instructions (Promega). Data represent normalized luciferase activity, relative 
to vehicle-treated cells (expressed as fold difference). 
 
2.2.11 Statistical analysis 
Statistical analysis was performed using either the Student's unpaired t test, one-way ANOVA or 
two-way ANOVA followed by Bonferroni’s post-test. P values <0.05 were sufficient to reject 
the null hypothesis for all analyses. 
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Chapter 3 
S1P-induces neutrophil chemoattractant IL-8: 
repression by steroids 
 
3.1 Introduction 
Asthma can be considered a heterogeneous syndrome made up of a number of disease 
phenotypes characterized by their underlying pathophysiology into “asthma endotypes” 
(Anderson, 2008; Lötvall et al., 2011). Defining asthma in this way will enable the design of 
tailored therapeutic strategies that specifically target the fundamental mechanisms responsible 
for the disease endotypes. One important asthma endotype is non-eosinophilic (neutrophilic) 
asthma. Neutrophilic asthma is driven by the chemokine CXCL8 (Simpson et al., 2009); thus 
studies into the molecular pathways that upregulate this neutrophil chemoattractant will allow us 
to gain greater insight into the underlying pathogenic mechanisms and suggest potential 
pharmacotherapeutic strategies for treating the neutrophilic asthma endotype in the future. 
The causes of neutrophilic asthma are currently uncertain. Innate immunity dysregulation 
through TLR2 plays an important role (Simpson et al., 2007), as may Th17 regulation 
(Newcomb and Peebles Jr) and NLRP3 inflammasome activation (Simpson et al., 2013). 
Activation of these cellular pathways has been reported to increase neutrophilic inflammation in 
the airways in an IL-8-driven manner; key characteristics of the disease endotype. Airway 
structural cells (such as alveolar epithelium and ASM) serve as important contributors to IL-8 
chemokine production and in this way may orchestrate neutrophil chemoattraction in response to 
inflammatory mediators (Henness et al., 2006; Manetsch et al., 2012c; Zijlstra et al., 2012).  
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In this study we focus on primary ASM cells in order to examine whether IL-8 is produced in 
response to stimulation with S1P. S1P is a bioactive sphingolipid found elevated in the airways 
of asthmatics (Ammit et al., 2001) and can increase IL-8 secretion from human alveolar 
epithelial cells (A549) to regulate neutrophil–epithelial interactions in vitro (Milara et al., 2009). 
Herein we are the first to show that S1P induces IL-8 secretion from primary ASM cells and 
demonstrate the molecular mechanisms responsible. We show that the anti-inflammatory 
corticosteroid dexamethasone inhibits S1P-induced IL-8 driven neutrophil chemotaxis and show 
that the molecular pathways responsible for corticosteroid-mediated repression converge on 
MSK1. These studies may provide further insight into the pathogenic mechanisms responsible 
for the neutrophilic asthma endotype.  
 
3.2 Materials and Methods 
3.2.1 ASM cell culture 
Human bronchi were obtained from patients undergoing surgical resection for carcinoma or lung 
transplant donors in accordance with procedures approved by the Sydney South West Area 
Health Service and the Human Research Ethics Committee of the University of Sydney. Written 
informed consent from the donor was obtained for use of this sample in research. Primary ASM 
cells were dissected, purified and cultured as previously described by Johnson et al.  (Johnson et 
al., 1995). A minimum of three different ASM primary cell lines were used for each experiment. 
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3.2.2 Chemicals 
S1P (Biomol) was purchased through Enzo Life Sciences (Exeter, UK) and tumour necrosis 
factor  (TNF) purchased from R&D Systems (Minneapolis, MN). Unless otherwise specified, 
all chemicals were from Sigma-Aldrich (St. Louis, MO).  
 
3.2.3 ELISAs 
Cell supernatants were collected and stored at -20˚C for later analysis by ELISA. IL-8 ELISAs 
were performed according to the manufacturer’s instructions (BD Biosciences Pharmingen, San 
Diego, CA).  
 
3.2.4 Real-time RT-PCR 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen Australia, Doncaster, VIC, 
Australia) and reverse transcription performed by using the RevertAid First strand cDNA 
Synthesis Kit (Fermentas Life Sciences, Hanover, MD) as per the manufacturer’s protocol. 
MKP-1 mRNA levels were measured using real-time RT-PCR on an ABI Prism 7500 (Applied 
Biosystems, Foster City, CA) with the IL-8 (Hs00174103_m1) TaqMan® Gene Expression 
Assay and the eukaryotic 18S rRNA endogenous control probe (Applied Biosystems) subjected 
to the following cycle parameters: 50°C for 2 min, 1 cycle; 95°C for 10 min, 1 cycle; 95°C for 15 
s, 60°C for 1 min, 40 cycles.  
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3.2.5 NF-B activity assays  
NF-B activity assays were performed with the NF-B reporter vector, pNF-B-Luc, according 
to our previously published methods (Henness et al., 2006; Moutzouris et al., 2010). For detailed 
description, see Chapter 2.2.10. 
 
3.2.6 siRNA knock-down 
Primary ASM cells were transiently transfected using nucleofection with 1 μg MSK1-specific 
SMART pool siRNA as described previously (Che et al., 2014) and cell supernatants removed 
for IL-8 protein measurement by ELISA and lysates utilized for MSK1 Western blotting (Cell 
Signaling Technology, Danvers, MA) .  
 
3.2.7 Neutrophil chemotaxis 
Neutrophils were purified from anti-coagulated venous blood of a healthy volunteer by positive 
selection using magnetic-activated cell sorting (MACS) as previously described (Baines et al., 
2009). Written informed consent from the volunteer was obtained for use of this sample in 
research in accordance with procedures approved by the Human Research Ethics Committee of 
the University of Sydney. Briefly, erythrocytes were removed by dextran sedimentation followed 
by ficoll centrifugation to separate mononuclear cells from granulocytes. Remaining erythrocytes 
were lysed by osmotic shock and the pellet which contains eosinophils/neutrophils was mixed 
with anti-CD16 conjugated immunomagnetic beads (Miltenyi Biotec, Sunnyvale, CA) and 
incubated for 30 min at 4 ºC. The cells were then separated using MACS where the eluent was 
discarded. Neutrophils bound to the micro-beads were taken out of the magnetic field, flushed 
and prepared at a cell density of 2 x 106/ml in DMEM + 0.1% BSA to be used in chemotaxis 
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assays. Neutrophil chemotaxis towards conditioned media from treated ASM cells was 
quantified microscopically using a 96-well microchemotaxis chamber (Neuroprobe, 
Gaithersburg, MD) as previously published (Henness et al., 2006). 
 
3.2.8 Statistical analysis 
Statistical analysis was performed using Student's unpaired t test, one-way ANOVA then 
Fisher’s post-hoc multiple comparison test, or two-way ANOVA then Bonferroni's post-test. P 
values <0.05 were sufficient to reject the null hypothesis for all analyses.  
 
3.3 Results 
3.3.1 The bioactive sphingolipid S1P induces secretion of IL-8 from ASM cells, but this 
can be repressed by the corticosteroid dexamethasone in a concentration-dependent 
manner 
In our previous studies we have shown that the bioactive sphingolipid S1P is increased in the 
airways of asthmatics (Ammit et al., 2001) and as airway neutrophilia has shown to be linked to 
asthmatic inflammation we were interested to explore whether S1P increases secretion of the 
neutrophilic chemoattractant IL-8 from ASM cells. To address this, primary ASM cells were 
stimulated with 1 µM S1P for 24 h and the resultant IL-8 secretion measured by ELISA. As 
shown in Figure 3.1A, S1P significantly increases secretion of IL-8 (P<0.05). Importantly, S1P-
increased IL-8 secretion from ASM cells can be repressed by the corticosteroid dexamethasone 
in a concentration-dependent manner (Figure 3.1B: P<0.05).  
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Figure 3.1 The bioactive sphingolipid S1P induces secretion of IL-8 from ASM cells, but 
this can be repressed by the corticosteroid dexamethasone in a concentration-dependent 
manner. (A) Growth-arrested primary ASM cells were treated with vehicle or S1P (1 µM) for 
24 h and IL-8 secretion measured by ELISA. Statistical analysis was performed using the 
Student's unpaired t test, where § denotes a significant effect of S1P (P<0.05). (B) To 
demonstrate corticosteroid-mediated repression of S1P-induced IL-8 secretion we then pre-
treated growth-arrested primary ASM cells for 1 h with vehicle or dexamethasone (0.0001-1 
M), before stimulation for 24 h with S1P (1 µM). IL-8 protein was measured by ELISA and 
results expressed as % S1P-induced IL-8 secretion at 24 h. Statistical analysis was performed 
using one-way ANOVA then Fisher’s post-hoc multiple comparison test, where * denotes 
significant repression by dexamethasone (P<0.05). Data are mean+SEM values from n=12 
primary ASM cell lines. 
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3.3.2 Time course of S1P-induced IL-8 mRNA expression and protein secretion and its 
repression by dexamethasone 
In order to explore the molecular mechanism of repression by dexamethasone we first performed 
an analysis of the temporal kinetics of S1P-induced IL-8 mRNA expression and subsequent 
protein secretion and its repression by dexamethasone. As shown in Figure 3.2A, S1P robustly 
increases IL-8 mRNA expression as early as 1 h after stimulation. This expression is sustained 
from 2-8 h, before receding to baseline levels by 24 h (P<0.05). This upregulation is repressed 
by dexamethasone pre-treatment with S1P-induced IL-8 mRNA expression being significantly 
inhibited by dexamethasone at 2 h (P<0.05). The pattern of protein secretion follows the same 
course with significant amounts of IL-8 being secreted from primary ASM cells by 8 h and 
accumulating further at 24 h (Figure 3.2B: P<0.05). Secretion of IL-8 was substantially and 
significantly repressed by the corticosteroid dexamethasone at 24 h (Figure 3.2B: P<0.05). 
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Figure 3.2 Time course of S1P-induced IL-8 mRNA expression and protein secretion and 
its repression by dexamethasone. Growth-arrested primary ASM cells were pre-treated for 1 h 
with vehicle or 100 nM dexamethasone, followed by treatment with vehicle or S1P (1 µM) for 0, 
1, 2, 4, 8, and 24 h. (A) IL-8 mRNA expression was quantified by real-time RT-PCR and results 
expressed as fold increase compared to vehicle-treated cells at 0 h. (B) IL-8 protein secretion was 
measured by ELISA and results expressed as % S1P-induced IL-8 secretion at 24 h. Statistical 
analysis was performed using two-way ANOVA then Bonferroni's post-test where * indicates 
significant repression by dexamethasone, compared to vehicle-treated cells at the same time 
point (P<0.05). Data are mean+SEM values from n=7 primary ASM cell lines. 
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3.3.3 Dexamethasone totally inhibits S1P-induced IL-8 protein secretion, but only 
partially inhibits TNFα-induced IL-8 induced in the presence of S1P 
As we had observed (in Figures 3.1 & 3.2) that dexamethasone represses S1P-induced IL-8 
expression relatively effectively, S1P secretion alone cannot solely account for the more 
corticosteroid insensitive phenotype associated with neutrophilic asthma. As numerous 
inflammatory mediators can be found elevated in asthma at the same time, it is of interest to 
examine the relative corticosteroid sensitivity of IL-8 induced by another inflammatory mediator 
added in combination with S1P. TNF is a key example (Broide et al., 1992). Therefore we 
stimulated cells with S1P + TNF in order to determine if the model is more corticosteroid 
resistant under these experimental conditions. We first performed a side-by-side comparison of 
IL-8 secretion in response to S1P or TNF, added separately or in combination. As shown in 
Figure 3.3A, and in confirmation of our earlier studies (Henness et al., 2006), TNF potently and 
significantly increases IL-8 secretion. Notably, TNFα-induced IL-8 secretion is significantly 
potentiated in the presence of S1P (Figure 3.3A: P<0.05). We then compared the relative 
corticosteroid sensitivity of IL-8 induced by each stimulant, alone or in combination. As shown 
in Figure 3.3B, IL-8 induced by S1P can be completely repressed by dexamethasone. 
Dexamethasone concentrations as low as 0.01 µM can repress S1P-induced IL-8 secretion to 
unstimulated levels. In contrast, TNF-induced IL-8 cannot be is relatively resistant to 
repression by dexamethasone (Figure 3.3C). Even after 1 µM dexamethasone pretreatment, 
TNF-induced IL-8 secretion cannot be completely repressed (Figure 3.3C). Accordingly, when 
then the two pro-inflammatory mediators are added together, S1P in addition to the potent pro-
inflammatory cytokine TNF induces IL-8 expression that is relatively corticosteroid resistant 
(Figure 3.3D).  
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Figure 3.3 Dexamethasone totally inhibits S1P-induced IL-8 protein secretion, but only 
partially inhibits TNFα-induced IL-8 induced in the presence of S1P. (A) To compare IL-8 
secretion, growth-arrested primary ASM cells were treated with vehicle, S1P (1 µM), TNFα (10 
ng/ml), or S1P (1 µM) in combination with TNFα (10 ng/ml) (B-C). To examine the relative 
corticosteroid sensitivity, cells were pre-treated for 1 h with vehicle or dexamethasone (0.0001, 
0.01, 1 M) then: (B) stimulated with S1P (1 µM); (C) stimulated with TNFα (10 ng/ml); (D) 
stimulated with S1P (1 µM) + TNFα (10 ng/ml). After 24 h, secreted IL-8 was measured by 
ELISA. Statistical analysis was performed using one-way ANOVA then Fisher’s post-hoc 
multiple comparison test, where § denotes a significant upregulation of IL-8, and * denotes a 
significant effect of dexamethasone on IL-8 secretion (P < 0.05). Data are mean+SEM values 
from n=7 primary ASM cell lines. 
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3.3.4 S1P does not activate NF-B in ASM cells 
In order to examine whether the difference in corticosteroid sensitivity between mediators is due 
to the involvement of NF-B signaling pathway in mediating IL-8 expression we utilized an NF-
B reporter vector, pNF-B-Luc. As shown in Figure 3.4, TNF activates NF-B; in 
confirmation of our earlier studies (Ammit et al., 2002). Importantly, S1P alone does not increase 
NF-B-luciferase activity, nor increase TNF-induced NF-B activity. As NF-B activity in 
ASM cells is relatively insensitive to repression by corticosteroids (Amrani et al., 1999; Catley et 
al., 2006; Quante et al., 2008), our in vitro results may  reflect the in vivo situation where 
multiple inflammatory mediators orchestrate chemokine expression and is consistent with airway 
neutrophilia being corticosteroid resistant. 
 
Figure 3.4 S1P does not activate NF-B in ASM cells. Primary ASM cells transfected with a 
NF-B reporter vector, pNF-B-Luc, were growth-arrested, then treated with vehicle or TNF 
(10 ng/ml), in the absence or presence of S1P (1 M) for 6 h. Cells were then harvested and 
luciferase and β-galactosidase activities assessed. Data represent normalized luciferase activity, 
relative to vehicle-treated cells (expressed as fold difference). Statistical analysis was performed 
using the Student's unpaired t test (where § denotes significant effect of TNFα on NF-B activity 
(P<0.05)). Data are mean+SEM values from n=6 primary ASM cell lines. 
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3.3.5 S1P-induced IL-8 protein secretion is repressed by inhibitors of the p38 MAPK- and 
ERK-mediated pathways 
We had previously shown that S1P rapidly activates all members of the MAPK superfamily (Che 
et al., 2012) and had earlier implicated p38 MAPK and ERK pathways in IL-8 secretion in 
response to another stimulus – TNF (Moutzouris et al., 2010). For these reasons we now 
explored the role of the p38 MAPK and ERK pathways in S1P-induced IL-8 secretion. We 
utilized well-established pharmacological inhibitors of p38 MAPK and ERK, i.e. 1 µM 
SB2035680 and 10 µM PD98059, respectively, and investigated their repressive effects on S1P-
induced IL-8 protein secretion from primary ASM cells. We routinely utilize these inhibitors to 
repress p38 MAPK and ERK signalling in ASM cells in vitro (Henness et al., 2006; Quante et 
al., 2008; Moutzouris et al., 2010; Munoz and Ammit, 2010; Manetsch et al., 2012a; Che et al., 
2013) as they specifically inhibit p38 MAPK and ERK phosphorylation in primary ASM cells at 
these concentration (Che et al., 2012). As shown in Figure 3.5, S1P-induced IL-8 protein 
secretion was significantly repressed by both SB203580 and PD98059 pre-treatment (P<0.05).  
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Figure 3.5 S1P-induced IL-8 protein secretion is repressed by inhibitors of the p38 MAPK- 
and ERK-mediated pathways. Growth-arrested primary ASM cells were pre-treated for 30 min 
with vehicle, 1 M SB203580, or 10 M PD98059 to inhibit p38 MAPK and ERK, respectively. 
Cells were then stimulated with 1 M S1P for 24 h. IL-8 protein was measured by ELISA and 
results expressed as % S1P-induced IL-8 secretion at 24 h. Statistical analysis was performed 
using the Student's unpaired t test, where * denotes significant inhibition (P<0.05). Data are 
mean+SEM values from n=10 primary ASM cell lines. 
 
3.3.6 IL-8 induced by S1P causes human neutrophil chemotaxis in vitro and this can be 
repressed by corticosteroids or by blocking the p38 MAPK- or ERK-mediated pathways 
Taken together, our results thus far demonstrate that S1P induces IL-8 secretion from primary 
ASM cells and that this secretion can be repressed by the corticosteroid dexamethasone and 
pharmacological inhibitors of the mitogen- and stress-activated protein kinases; p38 MAPK and 
ERK. IL-8 is a key neutrophil chemoattractant cytokine and in Figure 3.6 we show that human 
neutrophils undergo significant chemotaxis towards conditioned media from cells stimulated 
with S1P. Importantly, this S1P-induced chemotaxis was significantly reduced when cells were 
pre-treated with dexamethasone, SB203580 or PD98059 prior to S1P stimulation (Figure 6: 
P<0.05). These data suggest that the bioactive sphingolipid S1P may play a role in IL-8-driven 
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neutrophilic inflammation and implicate molecular pathways that may be targeted to reduce 
expression of this chemokine. 
 
 
Figure 3.6 IL-8 induced by S1P causes human neutrophil chemotaxis in vitro and this can 
be repressed by corticosteroids or by blocking the p38 MAPK- or ERK-mediated 
pathways. Chemotaxis of human neutrophils toward conditioned media from growth-arrested 
primary ASM cells pre-treated with vehicle, dexamethasone (100 nM), SB203580 (1 µM) or 
PD98059 (10 µM), followed by treatment with vehicle or S1P (1 µM) for 24 h, was measured 
using microchemotaxis chambers. Results are expressed as cells per high-power (x200) field. 
Statistical analysis was performed using the Student's unpaired t test where § denotes a 
significant effect of S1P on neutrophil chemotaxis, while * denotes significant repression 
(P<0.05). Data are mean+SEM values using conditioned media from n=3 primary ASM cell 
lines. 
 
3.3.7 S1P induces IL-8 secretion via a MSK1-dependent pathway and MSK1 knock-down 
by siRNA attenuates S1P-induced neutrophil chemotaxis 
S1P-induced IL-8 is mediated via p38 MAPK and ERK-mediated pathway. One of the important 
downstream effectors of these mitogen- and stress-activated kinases is MSK1. We have recently 
demonstrated that S1P activation leads to MSK1 phosphorylation in primary ASM cells (Che et 
al., 2013). Thus, to address whether S1P-induced IL-8 secretion is mediated via a MSK1-
dependent pathway we transiently transfected primary ASM cells using nucleofection with 
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scrambled control or MSK1 siRNA and assessed the impact of reduced MSK1 on IL-8 secretion 
induced by S1P. Figure 3.7A demonstrates successful knock-down of MSK1 with siRNA. As 
shown in Figure 3.7B, the degree of IL-8 secretion was significantly less in cells transfected with 
MSK1 siRNA as compared to scrambled control (P<0.05). Accordingly, by reducing S1P-
induced IL-8 secretion MSK1 knock-down also reduces S1P-induced neutrophil chemotaxis. 
This is demonstrated in Figure 3.7C, where neutrophil chemotaxis in supernatants from cells 
nucleofected with MSK1 siRNA was 57.2±18.2% when compared to supernatants from 
scrambled control cells (designated as 100%)(P<0.05). 
 
 
 
 
   Chapter 3 
90 
 
 
Figure 3.7 S1P induces IL-8 secretion via a MSK1 dependent pathway and MSK1 knock-
down by siRNA attenuates S1P-induced neutrophil chemotaxis. Primary ASM cells were 
transiently transfected using nucleofection with scrambled control or MSK1 siRNA, growth-
arrested, then treated for 24 h with vehicle or S1P (1 µM). (A) To confirm that MSK1 siRNA 
reduces protein levels of MSK1, cells were lysed and immunoblotted for MSK1 (90 kDa), using 
α-tubulin (55 kDa) as the loading control. To measure the effect of MSK1 knock-down on IL-8 
inducibility and neutrophil chemotaxis, supernatants were removed and (B) IL-8 protein 
measured by ELISA and (C) neutrophil chemotaxis assessed using microchemotaxis chambers. 
Results are expressed as: (A)  representative Western blots; (B) % S1P-induced IL-8 secretion in 
cells transfected with scrambled control; or (C) % S1P-induced neutrophil chemotaxis in the 
corresponding conditioned media (data are mean+SEM values from n=6 primary primary ASM 
cell lines). Statistical analysis was performed using the Student's unpaired t test where * indicates 
that knocking down MSK-1 significantly attenuates S1P-induced effects (P<0.05).  
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3.4 Discussion 
S1P is found elevated in airways of asthmatics and in this study we explore its stimulatory effect 
on an important chemokine responsible for neutrophilia in airway inflammation – IL-8. We 
demonstrate that stimulation of primary ASM cells with S1P results in IL-8 gene expression and 
protein secretion. We determine the temporal kinetics of IL-8 upregulation and show that mRNA 
expression and protein secretion can be repressed by the corticosteroid dexamethasone. 
Additionally, we reveal that S1P-induced IL-8 secretion is p38 MAPK- and ERK-dependent and 
that these key phosphoproteins act on the downstream effector MSK1 to control secretion of the 
neutrophil chemoattractant cytokine IL-8. We demonstrate the functional relevance of our in 
vitro data by performing neutrophil chemotaxis assays. We show that S1P-induced effects can be 
significantly attenuated by pre-treatment with dexamethasone, pharmacological inhibition of p38 
MAPK- or ERK-mediated pathways, or by knocking down MSK-1 with siRNA. Taken together 
these studies help us appreciate the molecular pathways responsible for IL-8 secretion from 
primary ASM cells in response to S1P and indicate ways in which its impact on IL-8-driven 
neutrophilia may be repressed. 
S1P is increasingly recognized as playing an important role in asthma and airway inflammation. 
We were the first to show that the levels of this bioactive sphingolipid were increased in the 
broncho-alveolar lavage fluid of allergic asthmatics (Ammit et al., 2001) and since that time the 
important immunomodulatory role for S1P in asthma and airway remodelling has clearly 
emerged (reviewed in (Lai et al., 2011; Olivera and Rivera, 2011; Yang and Uhlig, 2011)). The 
source of S1P in allergic asthma is considered to be the mast cell (Jolly et al., 2002; Olivera and 
Rivera, 2011). This is of relevance to the current study, where we focus on the 
immunostimulatory effects of S1P on airway structural cells, because we have previously shown 
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that increased numbers of mast cells are close proximity to ASM in airways of sensitized 
individuals (Ammit et al., 1997); a finding confirmed in the airways of asthmatics (Brightling et 
al., 2002). These studies suggest that S1P released from mast cells may act upon the surrounding 
airway tissue to initiate, perpetuate or perhaps amplify airway responses, including cytokine 
secretion. In support, we have previously shown that S1P potently induces secretion of IL-6 from 
primary ASM (Ammit et al., 2001; Che et al., 2013) and herein show that expression of IL-8 is 
also stimulated by S1P. Our study is in accord with a recent publication that demonstrated that 
S1P also enhanced IL-8 secretion from alveolar epithelial cells (Milara et al., 2009). These 
studies suggest that the bioactive sphingolipid S1P can orchestrate cytokine production in airway 
inflammation and in the current study we extend our investigation to demonstrate that S1P can 
enhance neutrophil chemoattraction. This study is of clinical relevance given the contribution of 
airway neutrophilia to asthma pathophysiology. 
Our recent papers in primary ASM cells have highlighted some of the key signalling pathways 
activated by S1P in primary ASM cells. S1P rapidly activates all members of the MAPK 
superfamily and also induces robust and sustained phosphorylation of the cAMP-dependent 
transcription factor CREB (Che et al., 2012; Che et al., 2013). Taken together with the 
knowledge that IL-8 secretion from ASM cells can be inhibited by SB203580 and PD98059 
(Moutzouris et al., 2010), but is independent of the cAMP/CREB-mediated pathway (Manetsch 
et al., 2013), we were able to narrow our focus for investigation in this study and reveal for the 
first time that S1P-induced IL-8 secretion is mediated by p38 MAPK- and ERK-dependent 
pathways. This is important as we have recently shown that the downstream effector of these 
mitogen- and stress-activated protein kinases – MSK1 - plays an essential role in controlling 
histone H3 phosphorylation, enhanced chromatin relaxation and regulation of gene expression. 
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Thus, by stimulating p38 MAPK/ERK, S1P induces IL-8 expression in primary ASM cells in an 
MSK1-dependent pathway. This was confirmed by knocking-down MSK1 with siRNA and 
showing that S1P-induced IL-8 secretion was attenuated.  
Our study also reveals that the corticosteroid dexamethasone can reduce S1P-induced IL-8 gene 
expression, and resultant protein secretion, in a time- and concentration-dependent manner. Our 
recent study (Che et al., 2013) explored the signalling pathways responsible for secretion of 
another cytokine released by ASM cells after S1P stimulation, namely IL-6, and revealed how 
corticosteroids act to exert their anti-inflammatory effects. We know now that corticosteroids 
mediate their anti-inflammatory actions, in part, via upregulation of the anti-inflammatory 
protein-MKP-1 (Quante et al., 2008; Che et al., 2013). Importantly, inhibition of the 
MSK1/histone H3 pathways is one of the key ways in which corticosteroids mediate their 
repressive effects in ASM cells. This was shown in our recent study (Che et al., 2013) where 
corticosteroid-induced MKP-1 attenuated S1P-induced IL-6 secretion by dephosphorylating p38 
MAPK and ERK-mediated activation of MSK1 and histone H3 phosphorylation. We propose 
that S1P-induced IL-8 is controlled in a similar MSK1-dependent manner. We illustrate the 
clinical relevance of targeting MSK1 by demonstrating that knocking-down MSK1 significantly 
represses IL-8-driven neutrophil chemotaxis induced by S1P. Thus MSK1 inhibition may 
represent a feasible therapeutic option for controlling S1P-mediated pro-inflammatory actions in 
the future.  
The role of neutrophils in airway inflammation has recently come to the fore and therefore in this 
study we examined whether the asthma-related sphingolipid S1P increased secretion of the 
neutrophil chemoattractant IL-8 from primary ASM cells. Demonstration of S1P-induced 
neutrophil chemotaxis is clinically relevant given the important role played by IL-8-driven 
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airway neutrophilia. Interestingly, the degree of reduction in neutrophil chemotaxis achieved 
with the MAPK pharmacological inhibitors is greater than the attenuation of IL-8 secretion. This 
may indicate that other MAPK-dependent chemokines may also be upregulated by S1P. 
Although IL-8 is the classical chemotaxin for neutrophils, other chemokines such as GRO 
(CXCL1) and regulated on activation normal T cell expressed and secreted (CCL5: also known 
as RANTES) can also contribute to airway neutrophilia (Kaur and Singh, 2013). These 
chemokines can be secreted by ASM cells (John et al., 1997; Ammit et al., 2002; Henness et al., 
2006; Issa et al., 2006) and their expression is regulated by p38 MAPK/ERK- dependent 
pathways (Amrani et al., 2001; Henness et al., 2006; Issa et al., 2006). We are the first to reveal 
the signalling pathways activated by S1P in primary ASM cells (Che et al., 2012; Che et al., 
2013), but based on our demonstration that S1P induces IL-8 to enhance neutrophil chemotaxis 
in a p38 MAPK/ERK-manner we predict that other chemokines regulated by these signalling 
molecules may repressed by pharmacological inhibition in a similar manner. This study may 
have implications for revealing the pathogenic mechanisms responsible for neutrophilic asthma 
endotype, although to date, whether S1P levels are increased in BAL fluids from patients 
characterised with neutrophilic asthma is an open question.  
Together, these studies indicate that inflammatory mediators such as S1P may contribute to the 
development of IL-8-driven neutrophilia in airway inflammation and suggests that further studies 
into the causal role played by S1P in the neutrophilic asthma endotype are warranted. Most 
importantly, these studied clearly demonstrate the role of MAPKs in asthmatic inflammation and 
the role of one important corticosteroid, dexamethasone in repressing neutrophilic asthma. 
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Chapter 4 
Basal PP2A activity restrains cytokine 
expression: role for MAPKs and TTP 
 
4.1 Introduction 
PP2A is the key controller of a number of inflammatory signalling pathways mediated by 
MAPKs. Moreover, it controls a critical anti-inflammatory protein, TTP via dephosphorylation. 
Here in this study we therefore aim to explore the role basal PP2A in the expression of MAPKs 
and regulation of TTP.  
PP2A is a ubiquitously expressed serine/threonine phosphatase that exists as a tri-molecular 
complex of a catalytic subunit (C), a structural subunit (A), and a variable regulatory subunit (B) 
of which there are at least 3 different families (B55, B56, B”) each with several isoforms (Cho 
and Xu, 2007). PP2A has generated much excitement as a target for anti-cancer therapy 
(reviewed in (Perrotti and Neviani, 2013)) and has more recently emerged as a druggable target 
in respiratory disease (Collison et al., 2013a; Hatchwell et al.). But in order to accelerate the 
development of PP2A activators as a future pharmacotherapeutic strategy in respiratory 
medicine, it is essential that we gain an advanced understanding of the regulation and function of 
PP2A in cellular models of asthmatic inflammation in vitro.  
PP2A dephosphorylates a number of kinases that drive inflammatory cell signaling (Shanley et 
al., 2001; Junttila et al., 2008). Notably, PP2A can dephosphorylate members of the MAPK 
superfamily, including p38 MAPK (Junttila et al., 2008). By regulating MAPKs, PP2A exerts 
significant control over cytokine regulatory networks; although the molecular mechanisms 
responsible remain relatively unexplored in airway inflammation.  
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We address this herein by utilizing the human alveolar epithelial cell line (A549); a transformed 
cancer cell line widely used to examine cytokine expression in the context of asthmatic 
inflammation (Cornell et al., 2009; King et al., 2009b; Papi et al., 2013). Confirmatory 
experiments were also performed with the human bronchial epithelial cell line (BEAS-2B) (Kaur 
et al., 2008; Cornell et al., 2009; Collison et al., 2013a). PP2A is a ubiquitously expressed 
phosphatase and our study shows that under unstimulated conditions there is a high level of 
PP2A enzymatic activity. This basal PP2A activity serves to restrain downstream effectors 
regulated by MAPKs. Inhibition of PP2A releases restraint and thereby increases MAPK-
mediated pro-inflammatory cytokines, including IL-6 and IL-8, as well as disables the anti-
inflammatory function of TTP, a destabilizing RNA binding protein regulated at multiple levels 
by p38 MAPK.   
 
4.2 Materials and Methods 
4.2.1 Chemicals 
Okadaic acid (OA) was purchased from Enzo Life Sciences (Farmingdale, NY). FTY720 was 
purchased from Cayman Chemical Company (Ann Arbor, MI) and AAL(s) was synthesized 
(Don et al., 2007; Collison et al., 2013a; Hatchwell et al., 2014). TNF is from R&D Systems 
(Minneapolis, MN). Unless otherwise specified, all chemicals used in this study were purchased 
from Sigma-Aldrich (St. Louis, MO). 
 
4.2.2 Cell culture 
The human alveolar epithelial cancer cell line (A549) and human bronchial epithelial normal cell 
line (BEAS-2B) were cultured in Ham's F-12K (Kaighn's) Medium (Invitrogen, Carlsbad, CA) 
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supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml), and fetal calf serum (10%), 
in accordance with culture conditions reported by Cornell et al. (Cornell et al., 2009). All 
experiments were performed after an overnight serum-starvation period (14-16 h) in Ham's F-
12K supplemented with sterile BSA (0.1%). A minimum of three experimental replicates 
performed on separate days were used for each experiment. 
 
4.2.3 PP2A activity assay 
PP2A activity was determined using the PP2A immunoprecipitation phosphatase assay kit 
(Merck Millipore, Darmstadt, Germany) according to the manufacturer's instructions. For 
detailed description, see Chapter 2.2.8. 
 
4.2.4 Western blotting 
Western blotting was performed using rabbit monoclonal or polyclonal antibodies against 
phosphorylated (Thr180/Tyr182) and total p38 MAPK, phosphorylated (Thr202/Tyr204) and total 
ERK, phosphorylated (Thr183/Tyr185) and total JNK (all from Cell Signalling Technology, 
Danvers, MA). PP2A-C was detected with a mouse monoclonal antibody (IgG2bκ, clone 1D6: 
Merck Millipore, Darmstadt, Germany). TTP was measured by Western blotting using rabbit 
antisera against TTP (Sak21). Detection of α-tubulin was used as the loading control (mouse 
monoclonal IgG1, DM1A: Santa Cruz Biotechnology, Santa Cruz, CA). Primary antibodies were 
detected with goat anti-rabbit and anti-mouse HRP-conjugated secondary antibodies (Cell 
Signaling Technology, Danvers, MA) and visualized by enhanced chemiluminescence 
(PerkinElmer, Wellesley, MA).  
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4.2.5 Real-time RT-PCR 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen Australia, Doncaster, VIC, 
Australia) and reverse transcription performed by using the RevertAid First strand cDNA 
Synthesis Kit (Fermentas Life Sciences, Hanover, MD) according to the manufacturer’s protocol. 
IL-6, IL-8 and TTP mRNA levels were measured using real-time RT-PCR on an ABI Prism 
7500 (Applied Biosystems, Foster City, CA) with IL-6 (Hs00174131_m1), IL-8 
(Hs00174103_m1) and TTP (Zfp36, Hs00185658_m1) TaqMan gene expression assays and the 
eukaryotic 18S rRNA endogenous control probe (Applied Biosystems) subjected to the 
following cycle parameters: 50°C for 2 min, 1 cycle; 95°C for 10 min, 1 cycle; 95°C for 15 s, 
60°C for 1 min, 40 cycles and mRNA expression (fold increase) quantified by delta delta Ct 
calculations. 
 
4.2.6 ELISAs  
IL-6 and IL-8 ELISAs were performed according to the manufacturer’s instructions (BD 
Biosciences Pharmingen, San Diego, CA). For detailed description, see Chapter 2.2.5. 
 
4.2.7 Transient transfection 
A549 cells (5 × 105 cells/well) were transfected with 1 µg of pEGFP HA-PP2A-C, or empty 
vector control, using Lipofectamine 2000 (Invitrogen). After transfection, cells were cultured for 
24 h in media without antibiotics, and then growth-arrested for 16 h in Ham's F-12K 
supplemented with 0.1% BSA, supplemented with penicillin (100 U/ml), streptomycin (100 
μg/ml), before cells were assayed.  
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4.2.8 siRNA transfection 
A549 cells (5 × 105 cells/well) were transfected with siRNA against PP2A-C, or scrambled 
control, by reverse transfection with RNAiMAX according to the manufacturer’s protocols 
(Invitrogen, NY, USA). Specifically, for each well of 6-well plates, 800 ng of ON-Target plus 
Control Non-targeting siRNA (scrambled control) or ON-target plus SMART pool Human 
PPP2CA siRNA (aka PP2A-C: both from Dharmacon, Thermo-Fisher Scientific, Waltham, MA) 
was diluted in 500 μL of Opti-MEM Reduced Serum Media (Invitrogen). This was followed by 
the addition of 5 μL of RNAiMAX reagent (Invitrogen) into each well and incubation at room 
temperature for 20 min. After transfection, cells were cultured for 24 h in media without 
antibiotics, and then growth-arrested for 16 h in Ham's F-12K supplemented with 0.1% BSA, 
supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml), before stimulation with 
TNFα (4 ng/ml).  
 
4.2.9 Statistical analysis 
Statistical analysis was performed using either the Student's unpaired t test, one-way or two-way 
ANOVA followed by Bonferroni’s post-test. P values <0.05 were sufficient to reject the null 
hypothesis for all analyses. Data are mean±SEM of n≥3 independent replicates. 
 
4.3 Results 
4.3.1 Temporal regulation of basal PP2A enzymatic activity by OA 
OA is a non-selective pharmacological inhibitor of PP2A (Swingle et al., 2007; Cornell et al., 
2009) and widely used to potently inhibit PP2A phosphatase activity (Bialojan and Takai, 1988; 
Mao et al., 2005; Cornell et al., 2009; Kranias et al., 2010). To examine the temporal regulation 
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of basal PP2A enzymatic activity by OA, A549 cells were treated with 1 µM OA for 15 min or 
45 min, then washed and left for a further 1 h before measuring PP2A enzymatic activity. PP2A 
is a ubiquitously expressed phosphatase and, as shown in Figure 4.1, the basal PP2A enzymatic 
activity in A549 cells is 863.7±98.9 pmol free phosphate. This activity can be significantly 
repressed by 45 min treatment with OA, while treatment for a shorter time period (i.e. 15 min) 
was without effect. These data indicate in part, the temporal regulation of basal PP2A activity by 
OA. Results from cells treated for both time points will be included throughout the study to 
demonstrate  the link between repression of basal PP2A activity and effects on functional 
outcomes such as cell signalling and cytokine expression. 
 
 
Figure 4.1 Temporal regulation of basal PP2A enzymatic activity by OA. PP2A enzymatic 
activity was measured in A549 cells treated for 15 min or 45 min with 1 µM OA, compared to 
vehicle-treated cells. Cells were washed and then PP2A enzymatic activity (measured as pmol 
free phosphate) detected at 1 h. Statistical analysis was performed using the Student's unpaired t 
test where * denotes a significant decrease in PP2A activity compared to vehicle (1 µM DMSO)-
treated cells  (P<0.05). Data are mean+SEM values from n=3 independent experiments. 
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4.3.2 Inhibition of basal PP2A phosphatase activity allows unrestrained action of MAPK 
phosphoproteins 
PP2A dephosphorylates a number of kinases that drive inflammatory cell signaling; thus its 
inhibition allows unrestrained action of a number of downstream effectors. MAPKs family 
members (p38 MAPK, ERK and JNK) are important regulators of cytokine expression and are 
known to drive expression of two important cytokines implicated in asthmatic inflammation, IL-
6 and IL-8 (Amrani et al., 2001; Henness et al., 2006; Quante et al., 2008; Moutzouris et al., 
2010; Kobayashi et al., 2011). Accordingly, we examined the effect of OA on p38 MAPK, ERK 
and JNK phosphorylation by Western blotting. As shown in Figure 4.2A, treating cells for 45 
min with OA robustly increased p38 MAPK phosphorylation at 0.5 and 1 h. ERK 
phosphorylation was enhanced at 30 min, and to a lesser extent at 1 h (Figure 4.2B). JNK is 
reported as an important inflammatory gene regulated by PP2A. It is also called early 
inflammatory gene (Shanley et al., 2001), in support of this statement we also found that 
inhibition of basal PP2A by OA enhanced early activation /phosphorylation of JNK at 30 min 
under these conditions (Figure 4.2C). Cells treated for the shorter time period of 15 min with OA 
did not show enhanced activity of MAPK phosphoproteins. 
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Figure 4.2 Inhibition of basal PP2A phosphatase activity allows unrestrained action of 
MAPK phosphoproteins. A549 cells were treated for 15 min or 45 min with 1 µM OA, 
compared to vehicle (1µM DMSO). Cells were washed and then lysates prepared at 0, 0.5 h, and 
1 h, to compare temporal kinetics of (A) p38 MAPK (43 kDa), (B) ERK (42, 44 kDa) and (C) 
JNK (46, 54 kDa) phosphorylation by Western blotting (representative results (from n=5 
independent experiments) are shown as cropped blots and full-length blots are presented in 
Supplementary Figure 1A (p38 MAPK), 1B (ERK) and 1C (JNK)).  
 
4.3.3 Treating A549 cells with OA for 45 min, but not 15 min, significantly increases IL-6 
mRNA expression and protein secretion  
We then examined whether the inhibition of basal PP2A with OA has an effect on IL-6 mRNA 
expression and protein secretion. As shown in Figure 4.3B, 45 min treatment with OA induced 
significant upregulation of IL-6 mRNA expression in a temporally distinct manner, with the peak 
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of expression observed at 1 h (Figure 4.3B: P<0.05). This resulted in significant increase in IL-6 
secretion observed at 8 and 24 h (Figure 4.3D: P<0.05).  IL-6 production is p38 MAPK-
mediated (Amrani et al., 2001; Quante et al., 2008), thus, taken together with our earlier results, 
these data indicate that significant repression of basal PP2A activity by 45 min treatment with 
OA allows p38 MAPK activation and corresponding increases in p38 MAPK-mediated cytokines 
such as IL-6. This PP2A-dependency of these results is confirmed by the lack of IL-6 mRNA 
expression and protein secretion in cells where basal PP2A activity was unaffected (see negative 
results in cells treated for only 15 min with OA (Figure 4.3A and 4.3C)).  
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Figure 4.3 Treating A549 cells with OA for 45 min, but not 15 min, significantly increases 
IL-6 mRNA expression and protein secretion. A549 cells were treated for (A, C) 15 min or 
(B, D) 45 min with 1 µM OA, compared to vehicle (1µM DMSO). Cells were washed and then 
(A, B) IL-6 mRNA expression (results expressed as fold increase compared to vehicle-treated 
cells at 0 h) and (C, D) IL-6 protein secretion  measured at 0, 1, 2, 4, 8, and 24 h. Statistical 
analysis was performed using two-way ANOVA then Bonferroni's post-test (where * denotes a 
significant effect compared to vehicle-treated cells (P<0.05)). Data are mean±SEM values from 
n=4 independent experiments. 
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4.3.4 Treating A549 cells with OA for 45 min, but not 15 min, significantly increases IL-8 
mRNA expression and protein secretion 
We then examined the effect of OA on IL-8 mRNA expression and protein secretion. Figure 
4.4A reveals that 15 min treatment with OA has no effect on IL-8 mRNA expression but 45 min 
treatment significantly increased IL-8 mRNA at 1 h and 2 h time point (Figure 4.4B: P<0.05). 
Similarly, treatment with OA for 15 min did not increase IL-8 secretion above that achieved in 
cells treated with vehicle alone (Figure 4.4C), while significant increases in IL-8 secretion were 
observed at 4, 8, and 24 h after 45 min treatment with OA, compared to vehicle-treated cells 
(Figure 4.4D).   
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Figure 4.4 Treating A549 cells with OA for 45 min, but not 15 min, significantly increases 
IL-8 mRNA expression and protein secretion. A549 cells were treated for (A, C) 15 min or 
(B, D) 45 min with 1 µM OA, compared to vehicle (1µM DMSO). Cells were washed and then 
(A, B) IL-8 mRNA expression (results expressed as fold increase compared to vehicle-treated 
cells at 0 h) and (C, D) IL-8 protein secretion measured at 0, 1, 2, 4, 8, and 24 h. Statistical 
analysis was performed using two-way ANOVA then Bonferroni's post-test (where * denotes a 
significant effect compared to vehicle-treated cells (P<0.05)). Data are mean±SEM values from 
n=4 independent experiments. 
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4.3.5 Treating human bronchial epithelial cells (BEAS-2B) with OA for 45 min, but not 
15 min, decreases PP2A enzymatic activity and significantly increases IL-6 and IL-8 
mRNA expression and protein secretion 
In order to confirm these findings  in a second immortalized cell line, we utilized the human 
epithelial cell line BEAS-2B as they are commonly used in in vitro studies examining airway 
inflammation with relevance to asthma (Kaur et al., 2008; Cornell et al., 2009; King et al., 
2009a; Holden et al., 2010; Collison et al., 2013a; Joshi et al., 2014). We conducted a series of 
confirmatory experiments (Figure 4.5) to demonstrate that treating BEAS-2B cells with OA for 
45 min, but not 15 min, decreases PP2A enzymatic activity (Figure 4.5A) and significantly 
increases IL-6 mRNA expression (Figure 4.5C) and IL-6 secretion (Figure 4.5E) (P<0.05). IL-8 
mRNA expression and protein secretion was also affected by 45 min treatment with OA (Figures 
4.5G and 4.5I, respectively: P<0.05). These results confirm observations observed in A549 cells 
(Figures 4.3 and 4.4). 
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Figure 4.5 Treating human bronchial epithelial cells (BEAS-2B) with OA for 45 min, but 
not 15 min, decreases PP2A enzymatic activity and significantly increases IL-6 and IL-8 
mRNA expression and protein secretion. (A) PP2A enzymatic activity was measured in 
BEAS-2B cells treated for 15 min or 45 min with 1 µM OA, compared to vehicle (1µM DMSO)-
treated cells. Cells were washed and then PP2A enzymatic activity (measured as pmol free 
phosphate) detected at 1 h. Statistical analysis was performed using the Student's unpaired t test 
where * denotes a significant decrease in PP2A activity compared to vehicle-treated cells  
(P<0.05). BEAS-2B cells were treated for (B, D, F, H) 15 min or (C, E, G, I) 45 min with 1 µM 
OA, compared to vehicle. Cells were washed and then (B, C) IL-6 and (F, G) IL-8 mRNA 
expression (results expressed as fold increase compared to vehicle-treated cells at 0 h) and (D, E) 
IL-6 and (H, I) IL-8 protein secretion measured at 0, 1, 2, 4, 8, and 24 h. Statistical analysis was 
performed using two-way ANOVA then Bonferroni's post-test (where * denotes a significant 
effect compared to vehicle-treated cells (P<0.05)). Data are mean±SEM values from n=3 
independent experiments. 
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4.3.6 Treating A549 cells with OA for 45 min, but not 15 min, significantly increases TTP 
mRNA expression and upregulation of TTP protein that is hyperphosphorylated 
TTP is an important anti-inflammatory protein that is a direct target of PP2A (Brook et al., 2006) 
and can be regulated at multiple levels by p38 MAPK. TTP is an immediate early response gene 
whose expression is p38 MAPK-dependent (Mahtani et al., 2001) and once expressed its protein 
stability is regulated post-translationally by p38 MAPK-mediated phosphorylation of two key 
serines (Mahtani et al., 2001; Brook et al., 2006; King et al., 2009b). Importantly, this latter step 
also controls TTP function as an RNA destabilizing protein (phosphorylated – OFF; 
unphosphorylated – ON). Because PP2A controls TTP, we were interested to examine the impact 
of repression of PP2A activity on this TTP expression and function.  
Firstly, we examined TTP mRNA expression, and as shown in Figure 4.6A, 15 min treatment 
with OA had no effect on the time course of TTP mRNA expression. In contrast, 45 min 
treatment with OA significantly increased TTP mRNA expression at 1 h (Figure 4.6B: P<0.05). 
Secondly, we measured TTP protein expression and phosphorylation with the rabbit antisera 
Sak21 (Mahtani et al., 2001; King et al., 2009b). As shown in Figure 4.6C, treating cells with 
OA for 45 min but not for 15 min, increases TTP protein level. Notably, we observe that the 
higher molecular weight immunoreactive bands for TTP predominate, especially at 1 h. This is 
consistent with earlier reports that inhibition of PP2A results in an equilibrium shift towards 
phosphorylated TTP, which is stable and builds up as a hyperphosphorylated (inactive) TTP 
(Brook et al., 2006; Sun et al., 2007).  
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Figure 4.6 Treating A549 cells with OA for 45 min, but not 15 min, significantly increases 
TTP mRNA expression and upregulation of TTP protein that is hyperphosphorylated. 
A549 cells were treated for 15 min or 45 min with 1 µM OA, compared to vehicle (1µM 
DMSO). Cells were washed and at the indicated times (A, B) TTP  mRNA expression (results 
expressed as fold increase compared to vehicle-treated cells at 0 h) and (C) TTP (43 to 49 kDa) 
protein upregulation was measured by Western blotting with α-tubulin as the loading control 
(representative results are shown as cropped blots and full-length blots are presented in 
Supplementary Figure 2). Please note that bands of immunoreactivity for TTP at higher 
molecular weight indicate phosphorylated forms of TTP. Statistical analysis was performed 
using two-way ANOVA then Bonferroni's post-test (where * denotes a significant effect 
compared to vehicle-treated cells (P<0.05)). Data are mean+SEM values from n=4 independent 
experiments. 
 
 
   Chapter 4 
113 
 
4.3.7 The PP2A activator FTY720 overcomes OA-mediated inhibition of basal PP2A 
phosphatase activity and significantly represses IL-6 and IL-8 mRNA expression and 
cytokine secretion 
Collectively, our data thus far implicates PP2A as a key regulator of cytokine expression via a 
MAPK/TTP-regulated network. That is, when PP2A is inhibited, cytokine secretion ensues. To 
demonstrate this further, we used a PP2A activator FTY720 (Roberts et al., 2010)) to overcome 
the effect of the PP2A inhibitor (OA). A549 cells were pre-treated with FTY720 before 
treatment for 45 min with OA, or vehicle. Firstly, we quantitated PP2A enzymatic activity and 
found that in FTY720-treated cells, OA is unable to inhibit PP2A activity to the same extent 
(Figure 4.7A: P<0.05). Secondly, we measured IL-6 and IL-8 mRNA expression at 1 h and 
protein secretion at 24 h under these conditions. Cells pre-treated with FTY720 had less 
significantly IL-6 (Figure 4.7B) and IL-8 (Figure 4.7C) mRNA expression than OA-treated 
controls. IL-6 and IL-8 protein secretion results also followed this pattern, as shown in Figure 
4.7D and 4.7E, respectively. 
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Figure 4.7 The PP2A activator FTY720 overcomes OA-mediated inhibition of basal PP2A 
phosphatase activity and significantly represses IL-6 and IL-8 mRNA expression and 
cytokine secretion. A549 cells were treated for 6 h with 2.5 µM FTY720 prior to 45 min with 1 
µM OA, compared to vehicle (1µM DMSO). Cells were washed and then (A) PP2A activity 
measured at 1 h, (B, C) IL-6 and IL-8 mRNA expression measured at 1 h (results expressed as 
fold increase compared to vehicle-treated cells) and (D, E) IL-6 and IL-8 protein secretion  
measured at 24 h. Statistical analysis was performed using one-way ANOVA then Bonferroni's 
post-test (where * denotes a significant effect of OA or § FTY720) (P<0.05)). Data are 
mean+SEM values from n=3 independent experiments. 
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4.3.8 The PP2A activator devoid of sphingosine 1- phosphate agonism - AAL(S) - 
overcomes OA-mediated inhibition of basal PP2A phosphatase activity and significantly 
represses IL-6 and IL-8 mRNA expression and cytokine secretion 
Although FTY720 is a known activator of PP2A, it also has other targets. Most notably in the 
context of asthma, FTY720 can induce S1P signalling and we have previously shown that S1P is 
elevated  in allergic asthma (Ammit et al., 2001), drives development of the pro-asthmatic 
phenotype, and can induce IL-6 and IL-8 expression (Ammit et al., 2001; Rahman et al., 2014) . 
Although we did not observe upregulation of cytokine production with FTY720 in A549 cells, 
we still performed further experimentation with the FTY720 derivative AAL(S) (Don et al., 
2007; Collison et al., 2013a; Hatchwell et al., 2014) because AAL(S) is devoid of S1P agonism.  
The data shown in Figure 4.8 serve to confirm that these effects are specific to PP2A by 
demonstrating that PP2A activation with AAL(S) can overcome OA-mediated inhibition of basal 
PP2A phosphatase activity and significantly repress IL-6 and IL-8 mRNA expression and 
cytokine secretion.   
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Figure 4.8 The PP2A activator devoid of sphingosine 1- phosphate agonism - AAL(S) -
overcomes OA-mediated inhibition of basal PP2A phosphatase activity and significantly 
represses IL-6 and IL-8 mRNA expression and cytokine secretion. A549 cells were treated 
for 6 h with 2.5 µM AAL(S) prior to 45 min with 1 µM OA, compared to vehicle (1µM DMSO). 
Cells were washed and then (A) PP2A activity measured at 1 h, (B, C) IL-6 and IL-8 mRNA 
expression measured at 1 h (results expressed as fold increase compared to vehicle-treated cells) 
and (D, E) IL-6 and IL-8 protein secretion  measured at 24 h. Statistical analysis was performed 
using one-way ANOVA then Bonferroni's post-test (where * denotes a significant effect of OA 
or § AAL(s) (P<0.05)). Data are mean+SEM values from n=3 independent experiments. 
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4.3.9 Overexpression of the catalytic subunit of PP2A (PP2A-C) overcomes OA-mediated 
inhibition of basal PP2A phosphatase activity and significantly represses IL-6 and IL-8 
mRNA expression and cytokine secretion 
As further substantiation of the role of PP2A in the control of cytokine secretion we 
overexpressed PP2A-C and measured the impact on IL-6 and IL-8 expression induced by OA. 
We first confirmed expression of PP2A-C in cells transfected with empty vector or PP2A-C 
(Figure 4.9A) and then examined the impact of OA treatment (45 min) on PP2A phosphatase 
activity and cytokine expression. As shown in Figure 4.9B, in cells where PP2A-C is 
overexpressed, OA is unable to inhibit PP2A activity to the same extent as controls. Further, 
cells transfected with PP2A-C plasmid significantly repressed OA-induced IL-6 and IL-8 mRNA 
expression (Figure 4.9C and 4.9D) and protein secretion (Figure 4.9E and 4.9F), respectively.  
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Figure 4.9 Overexpression of the catalytic subunit of PP2A (PP2A-C) overcomes OA-
mediated inhibition of basal PP2A phosphatase activity and significantly represses IL-6 
and IL-8 mRNA expression and cytokine secretion. A549 cells were transfected with empty 
vector or plasmid expressing PP2A-C, prior to 45 min with 1 µM OA, compared to vehicle (1µM 
DMSO). Cells were washed and then (A) PP2A-C (36 kDa) overexpression confirmed by 
Western blotting (representative results are shown as cropped blots and full-length blots are 
presented in Supplementary Figure 3), (B) PP2A activity measured at 1 h, (C, D) IL-6 and IL-8 
mRNA expression measured at 1 h (results expressed as fold increase compared to vehicle-
treated cells) and (E, F) IL-6 and IL-8 protein secretion  measured at 24 h. Statistical analysis 
was performed using one-way ANOVA then Bonferroni's post-test (where * denotes a 
significant effect of OA or § PP2A-C) (P<0.05)). Data are mean+SEM values from n=3 
independent experiments. 
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4.3.10 OA inhibits TNF-induced PP2A phosphatase activity and increases TNF-
induced IL-6 and IL-8 mRNA expression and protein secretion 
Our study thus far shows the important role played by basal PP2A enzymatic activity in 
restraining cytokine expression in unstimulated cells. To mimic the inflammatory milieu in 
asthma we now examined the impact of OA (for 45 min) on IL-6 and IL-8 expression stimulated 
by TNF – a pro-inflammatory cytokine implicated in asthma. As shown in Figure 4.10A, TNF 
increases PP2A activity and this can be significantly repressed by OA. We then examined the 
time course of TNF-induced IL-6 (Figure 4.10B) and IL-8 (Figure 4.10C) mRNA expression 
and found that OA treatment significantly increased TNF-induced cytokine expression at a 
number of time-points and that this resulted in significant increase in TNF-induced IL-6 and 
IL-8  secretion at 24 h (Figures 4.10D and 4.10E, respectively: P<0.05). 
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Figure 4.10 OA inhibits TNFα-induced PP2A phosphatase activity and increases TNFα-
induced IL-6 and IL-8 mRNA expression and protein secretion. (A) PP2A enzymatic activity 
was measured in A549 cells treated for 45 min with vehicle (1µM DMSO) or 1 µM OA. Cells 
were washed before stimulation with TNF (4 ng/ml) and then PP2A enzymatic activity 
(measured as pmol free phosphate) was detected at 1 h. Statistical analysis was performed using 
one-way ANOVA then Bonferroni's post-test (where § denotes a significant effect of OA on on 
TNF-induced effects). (B-E) A549 cells were treated for 45 min with vehicle or 1 µM OA. 
Cells were washed before stimulation with TNF (4 ng/ml). (B) IL-6 and (C) IL-8 mRNA 
expression was measured at 0, 1, 2, 4, 8, and  24 h (results expressed as fold increase compared 
to vehicle-treated cells at 0 h) and (D) IL-6 and (E) IL-8 protein secretion measured at 24 h. 
Statistical analysis was performed using two-way ANOVA then Bonferroni's post-test (where 
§denotes a significant effect of OA on TNF-induced effects (P<0.05)). Data are mean±SEM 
values from n=3 independent experiments. 
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4.3.11 Specific knockdown of PP2A with siRNA reduces TNFα-induced PP2A protein 
levels and activity and results in increased TNFα-induced IL-8 and IL-6 mRNA 
expression and protein secretion 
Finally, to demonstrate that these OA-mediated effects were specific to PP2A, A549 cells were 
transfected with scrambled control or siRNA against PP2A-C before TNF stimulation. When 
PP2A-C was knocked down (confirmed by Western blotting in Figure 4.11A) we observed 
significant reduction in TNF-induced PP2A enzymatic activity (Figure 4.11B) with a 
corresponding upregulation of TNF-induced IL-6 and IL-8 mRNA expression and protein 
secretion from A549 cells (Figures 4.11C-4.11F, respectively: P<0.05) 
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Figure 4.11 Specific knockdown of PP2A with siRNA reduces TNFα-induced PP2A protein 
levels and activity and results in increased TNFα-induced IL-8 and IL-6 mRNA expression 
and protein secretion. A549 cells transfected with scrambled control or siRNA against PP2A-C 
were stimulated with TNF (4 ng/ml) before: (A) PP2A-C (36 kDa) knockdown at 1 h was 
confirmed by Western blotting (representative results are shown as cropped blots and full-length 
blots are presented in Supplementary Figure 4); (B) PP2A enzymatic activity detected at 1 h 
(measured as pmol free phosphate); (C) IL-6 and (D) IL-8 mRNA expression measured at 1 h 
(results expressed as % of TNF-induced mRNA expression in scrambled control (designated as 
100%)) ; and (E, F) IL-6 and IL-8 protein secretion  measured at 24 h (results expressed as % of 
TNF-induced protein secretion in scrambled control (designated as 100%)). Statistical analysis 
was performed using Student’s unpaired t test (where § denotes a significant effect of siRNA 
against PP2A-C on TNF-induced effects (P<0.05)). Data are mean±SEM values from n=3 
independent experiments.  
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4.4 Discussion 
To explore the role of basal PP2A in cytokine expression in human lung epithelial cells, we took 
multiple approaches to modulate PP2A phosphatase activity by using a PP2A inhibitor, OA; two 
PP2A activators, FTY720 and AAL(S); an expression plasmid to overexpress PP2A-C; and 
siRNA to knockdown PP2A-C. These studies reveal the important role played by PP2A in 
cytokine regulation in the context of airway inflammation and demonstrate the link between 
perturbation of PP2A activity and effects on functional outcomes such as cell signalling and 
cytokine expression.   
Several studies have demonstrated that PP2A serves as a negative regulator of MAPKs (Sontag 
et al., 1993; Prickett and Brautigan, 2007; Junttila et al., 2008) and in support we found that 
inhibition of PP2A by OA upregulates p38 MAPK, ERK and JNK phosphorylation in A549 
cells. These results demonstrate that the basal activity of PP2A in untreated cells restrains 
MAPK-mediated cell signalling in A549 cells. In our previous studies we demonstrated that IL-6 
and IL-8 are the two major cytokines upregulated via MAPK-mediated pathways (Amrani et al., 
2001; Henness et al., 2006; Quante et al., 2008; Moutzouris et al., 2010).  JNK has been reported 
to be regulated by PP2A and play a role in IL-8 production in models of TNF and 
lipopolysaccharide-induced lung inflammation, with an important consequence for severe asthma 
(Kobayashi et al., 2011; Kobayashi et al., 2012). 
Notably, PP2A inhibition also has a significant impact on the critical anti-inflammatory protein - 
TTP. TTP is an mRNA destabilizing protein that targets numerous cytokines (Brooks and 
Blackshear, 2013), including those involved in asthmatic inflammation. Its expression and 
function are p38 MAPK-dependent (Mahtani et al., 2001; Sun et al., 2007). There is a dynamic 
equilibrium between unphosphorylated and phosphorylated forms of TTP. The unphosphorylated 
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form of TTP is active and capable to decay cytokine mRNA. However, this form of TTP is 
unstable and undergoes proteosomal degradation, whereas phosphorylated TTP is stable but 
unable to target cytokines mRNA for decay. Importantly, TTP is a direct target of PP2A; as 
PP2A phosphatase activity is responsible for dephosphorylation of TTP at two key serines (Ser52 
and Ser178) (Brook et al., 2006). In this way, PP2A shifts this balance of TTP towards 
unphosphorylated TTP via dephosphorylation (Brook et al., 2006; Sun et al., 2007). Our study 
demonstrates that inhibition of PP2A (with OA for 45 min) significantly induces TTP mRNA 
expression but the resulting TTP protein has electrophoretic mobility in immunoblots indicative 
of hyperphosphorylated forms of TTP. Our study concurs with previous reports that demonstrate 
that inhibition of PP2A phosphatase activity causes accumulation of hyperphosphorylated and 
stable TTP protein (Brook et al., 2006; Clement et al., 2011), suggesting that in the absence of 
PP2A activity, the balance is shifted towards stable, but inactive, phosphorylated forms of TTP. 
Our study utilizing OA demonstrates the important anti-inflammatory control exerted by PP2A 
phosphatase basal activity in A549 lung epithelial cells. These studies were confirmed in BEAS-
2B cells. Given that OA is a non-selective pharmacological inhibitor, we have directly 
implicated PP2A with PP2A-C overexpression as well as PP2A activators. A number of small 
molecules have been reported to activate PP2A (Perrotti and Neviani, 2013). To date the best 
known of these is the sphingosine analog FTY720 (fingolimod) and we have utilized it herein 
overcome OA-mediated repression of PP2A enzymatic activity and repress cytokine expression. 
But it is important to note that FTY720 is also an agonist/antagonist of the S1P pathway and we 
and others have shown that S1P is pro-inflammatory and pro-asthmatic (Ammit et al., 2001; 
Roviezzo et al., 2007; Nishiuma et al., 2008; Rahman et al., 2014). Therefore we utilized 
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AAL(S), a PP2A activator devoid of S1P agonism (Don et al., 2007; Collison et al., 2013a; 
Hatchwell et al., 2014) to confirm the anti-inflammatory effect of basal PP2A in A549 cells.  
Our study demonstrates that basal PP2A activity restrains cytokine expression in a cellular model 
of asthmatic inflammation and highlights an important role for MAPKs and TTP. Moreover, 
PP2A plays an important role in cytokine expression in cells stimulated with TNF; we show 
that inhibition of PP2A with OA, and more specifically with PP2A-C knockdown by siRNA, 
results in significant increases in cytokine production. Taken together our study has revealed, in 
part, the molecular mechanisms of PP2A anti-inflammatory function and highlight the potential 
of boosting the power of endogenous phosphatases as novel anti-inflammatory strategies to 
combat asthmatic inflammation.  
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Chapter 5 
Activating Protein Phosphatase 2A 
(PP2A) Enhances Tristetraprolin (TTP) 
Anti-Inflammatory Function in A549 
Lung Epithelial Cells 
 
This work has been published in the article entitled “Activating Protein Phosphatase 2A (PP2A) 
Enhances Tristetraprolin (TTP) Anti-Inflammatory Function in A549 Lung Epithelial Cells. Md. 
Mostafizur Rahman, Nowshin N. Rumzhum, Jonathan C. Morris, Andrew R. Clark, Nicole M. 
Verrills and Alaina J. Ammit. Cell Signal. 2016 Apr;28(4):325-34.” 
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Chapter 5 
Activating PP2A Enhances TTP Anti-
Inflammatory Function in A549 Lung Epithelial 
Cells 
 
5.1 Introduction 
In Chapter 4, we successfully demonstrate the anti-inflammatory role of basal PP2A and confirm 
the possible link with TTP activation. Besides, we propose that enhancing the power of 
endogenous PP2A may have potential to act as an alternative anti-inflammatory strategy in 
asthmatic inflammation. Based on the results of our studies and previously published reports 
(Perrotti and Neviani, 2008; Wallace et al., 2012) we hypothesize that activating PP2A may 
boost the anti-inflammatory function of TTP. We aim to confirm this hypothesis here in this 
study. 
TTP is an mRNA destabilizing molecule that acts at the post-transcriptional level to inhibit the 
expression of many pro-inflammatory cytokines responsible for respiratory disease pathogenesis 
(reviewed in (Prabhala and Ammit, 2015)). TTP is regulated by phosphorylation at a number of 
levels; gene expression, mRNA and protein stability is p38 MAPK-dependent (Mahtani et al., 
2001; Ross et al., 2015) and its anti-inflammatory action is controlled by the phosphorylation 
status of TTP protein at Ser52 and Ser178 (Mahtani et al., 2001; Marchese et al., 2010; Ross et al., 
2015). There is a dynamic equilibrium between unphosphorylated and phosphorylated TTP. In 
the unphosphorylated state, TTP is active and can induce mRNA decay however; this form of 
TTP is also subject to degradation by the ubiquitin-proteasome system (Brook et al., 2006; Ross 
et al., 2015). When TTP is phosphorylated, the protein is stabilized (Tchen et al., 2004; Brook et 
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al., 2006; Hitti et al., 2006), but this phosphorylated form of TTP is unable to cause mRNA 
decay, and therefore is inactive (Marchese et al., 2010).  
When active, TTP has a substantial repressive impact on airway inflammation (Ross et al., 
2015). However, under respiratory disease conditions, although TTP is present, it is likely held in 
a dormant, inactive form due to the high levels of p38 MAPK phosphorylation (Renda et al., 
2008). Therefore developing a strategy to activate TTP under inflammatory conditions could be 
therapeutically useful. This dynamic equilibrium provides us with important points of regulatory 
control that we propose to exploit to enhance TTP function. However, blocking p38 MAPK with 
inhibitors in an attempt to promote greater amounts of unphosphorylated (active) TTP  doesn’t 
work because TTP is a p38 MAPK-responsive gene and this will result in less TTP mRNA 
expression (Mahtani et al., 2001; Prabhala et al., 2015). A better approach is to allow TTP to be 
expressed and then activate its mRNA destabilizing function. This is the promise of PP2A, a 
serine/threonine phosphatase responsible for dephosphorylation of TTP at Ser52 and ser178 (Sun 
et al., 2007); amongst other molecules (Shanley et al., 2001; Miskolci et al., 2003; Junttila et al., 
2008). PP2A is a ubiquitously expressed enzyme and in a recent publication (Rahman et al., 
2015) we demonstrated the important regulatory role exerted by PP2A under basal (unstimulated 
conditions) in the A549 lung epithelial cell line. When PP2A basal enzymatic activity was 
removed, i.e. with the PP2A inhibitor okadaic acid or via specific knockdown of PP2A-C with 
siRNA, TTP was hyper-phosphorylated and rendered non-functional (Rahman et al., 2015). 
Hence, proinflammatory cytokine production ensued. Therefore it follows that if TTP is switched 
off when PP2A activity is reduced, the corollary of these results is that TTP will be switched on 
by PP2A activators. This was the case under unstimulated conditions (Rahman et al., 2015), but 
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whether PP2A activators can switch TTP on and repress cytokine production under inflammatory 
conditions mimicked in vitro was currently unknown.  
We address this herein by utilizing a cellular model of airway inflammation using A549 lung 
epithelial cells (Cornell et al., 2009; King et al., 2009b; Rahman et al., 2015) stimulated with 
TNF to mimic pro-inflammatory conditions in vitro (Cornell et al., 2009; Rahman et al., 2015). 
We measure the impact on two key TTP targets implicated in respiratory disease, IL-8 and IL-6, 
as a functional outcome. We examine the ability of the sphingosine analog, FTY720, and the 
chiral analog of FTY720 devoid of S1P agonism, AAL(S) (Don et al., 2007; Collison et al., 
2013a; Hatchwell et al., 2014; Rahman et al., 2015) to activate PP2A and repress TNF-induced 
cytokine production in a TTP- dependent manner. Thus, in this study we address the hypothesis 
that PP2A activators can switch TTP on and repress cytokine production in an in vitro model of 
airway inflammation, and show for the first time that the PP2A activators FTY720 and AAL(S) 
repress TNF-induced IL-8 and IL-6 mRNA expression and protein secretion in a TTP-
dependent manner.  
 
5.2 Materials and Methods 
5.2.1 Chemicals 
FTY720 was purchased from the Cayman Chemical Company (Ann Arbor, MI) and AAL(S) was 
synthesized (Don et al., 2007; Collison et al., 2013a; Hatchwell et al., 2014; Rahman et al., 
2015). TNF is from R&D Systems (Minneapolis, MN). Unless otherwise specified, all 
chemicals used in this study were purchased from Sigma-Aldrich (St. Louis, MO). 
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5.2.2 Cell culture 
Please see Chapter 4.2.2 
 
5.2.3 PP2A activity assay 
For detailed description, see Chapter 2.2.8. 
 
5.2.4 Real-time RT-PCR 
Please see Chapter 4.2.5 
 
5.2.5 ELISA 
IL-8 and IL-6 ELISAs were performed according to the manufacturer’s instructions (BD 
Biosciences Pharmingen, San Diego, CA). For detailed description, see Chapter 2.2.5. 
 
5.2.6 Western blotting 
TTP was measured by Western blotting using rabbit antisera against TTP (Sak21) (Mahtani et 
al., 2001). Detection of α-tubulin was used as the loading control (mouse monoclonal IgG1, 
DM1A: Santa Cruz Biotechnology, Santa Cruz, CA). Primary antibodies were detected with goat 
anti-rabbit and anti-mouse HRP-conjugated secondary antibodies (Cell Signaling Technology, 
Danvers, MA) and visualized by enhanced chemiluminescence (PerkinElmer, Wellesley, MA). 
Densitometry analysis was performed using ImageJ. 
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5.2.7 siRNA 
A549 cells (5 × 105 cells/well) were transfected with siRNA against TTP, or scrambled control, 
by reverse transfection with RNAiMAX according to the manufacturer’s protocols (Invitrogen, 
NY, USA). Untransfected controls were also performed. Specifically, for each well of 6-well 
plates, 800 ng of ON-Target plus Control Non-targeting siRNA (scrambled control) or ON-target 
plus SMART pool Human TTP siRNA (aka Zfp36: both from Dharmacon, Thermo-Fisher 
Scientific, Waltham, MA) was diluted in 500 μL of Opti-MEM Reduced Serum Media 
(Invitrogen). This was followed by the addition of 5 μL of RNAiMAX reagent (Invitrogen) into 
each well and incubation at room temperature for 20 min. After transfection, cells were cultured 
for 24 h in media without antibiotics, and then growth-arrested for 16 h in Ham's F-12K 
supplemented with 0.1% BSA, supplemented with penicillin (100 U/ml), streptomycin (100 
μg/ml), before stimulation with TNFα (4 ng/ml). 
 
5.2.8 Statistical analysis 
Statistical analysis was performed using either the Student's unpaired t test, one-way or two-way 
ANOVA followed by Bonferroni’s post-test. P values <0.05 were sufficient to reject the null 
hypothesis for all analyses. Data are mean+SEM of n≥3 independent replicates. 
 
5.3 Results 
5.3.1 PP2A activators, FTY720 and AAL(S), enhance TNFα-induced PP2A phosphatase 
activity in A549 cells 
PP2A is a ubiquitous enzyme that exerts basal phosphatase activity. In confirmation of our 
earlier study (Rahman et al., 2015), we show in Figure 5.1 that this basal activity can be 
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significantly increased by stimulation for 1 h with TNF (P<0.05). We then examined the impact 
of two PP2A activators: 1) the classical PP2A activator - FTY720; 2) the novel PP2A activator 
and chiral analog of FY720 devoid of S1P agonism – AAL(S). Notably, both PP2A activators 
can significantly augment TNF-induced PP2A activity (Figures 5.1A & 5.1B: P<0.05), but are 
without effect when added to unstimulated cells. 
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Figure 5.1 PP2A activators, FTY720 and AAL(S), enhance TNFα-induced PP2A 
phosphatase activity in A549 cells. A549 cells were pre-treated with (A) 2.5 µM FTY720 or 
(B) 2.5 µM AAL(S) for 6 h, compared to vehicle (2.5 µM DMSO)-treated controls. Cells were 
treated with vehicle or TNFα (4 ng/ml) and then PP2A enzymatic activity (measured as pmol 
free phosphate) detected at 1 h. Statistical analysis was performed using one-way ANOVA then 
Bonferroni’s post-test (where * denotes a significant effect of TNF compared to vehicle-treated 
cells, and § denotes a significant effect of PP2A activators on TNFα-induced PP2A activity 
(P<0.05)). Data are mean+SEM values from n=3 independent experiments. 
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5.3.2 PP2A activators, FTY720 and AAL(S), significantly repress TNFα-induced IL-8 and 
IL-6 mRNA expression and protein secretion 
We then wished to examine the impact of PP2A activation with FTY720 and AAL(S) on TNF-
induced expression kinetics of two TTP targets - IL-8 (Figure 5.2) and IL-6 (Figure 5.3). As 
shown in Figure 5.2, TNF significantly increased IL-8 mRNA expression (Figures 5.2A & 
5.2C) and protein secretion (Figures 5.2B & 5.2D) from A549 cells (P<0.05). Significant levels 
of IL-8 mRNA expression was first observed at 1 h and remained elevated throughout the 24 h 
period (P<0.05). Protein production ensued with significantly elevated levels of IL-8 secretion 
detected from 4 h (P<0.05). Notably, TNF-induced cytokine production could be repressed by 
pretreatment with PP2A activators. FTY720 significantly repressed TNF-induced IL-8 mRNA 
expression (Figure 5.2A) and cytokine secretion (Figure 5.2B) (P<0.05). IL-8 mRNA expression 
(Figure 5.2C) and cytokine secretion (Figure 5.2D) was similarly repressed by pretreatment with 
AAL(S). To extend these observations, we also examined the impact of PP2A activators on 
another pro-inflammatory cytokine implicated in chronic respiratory disease - IL-6 - and results 
shown in Figure 5.3 confirm that PP2A activators significantly repress TNF-induced IL-6 
mRNA expression (Figures 5.3A & 5.3C) and protein secretion (Figures 5.3B & 5.3D) from 
A549 cells (P<0.05).  
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Figure 5.2 PP2A activators, FTY720 and AAL(S), significantly repress TNFα-induced IL-8 
mRNA expression and protein secretion. A549 cells were pre-treated with (A, B) 2.5 µM 
FTY720 or (C, D) 2.5 µM AAL(S) for 6 h, compared to vehicle (2.5 µM DMSO)-treated 
controls. Cells were treated with vehicle or TNFα (4 ng/ml) and then (A, C) IL-8  mRNA 
expression (results expressed as fold increase compared to vehicle-treated cells at 0 h) and (B, D) 
IL-8 protein secretion  measured  (results expressed as a percentage of TNF-induced IL-8 
secretion at 24 h) at the indicated times. Statistical analysis was performed using two-way 
ANOVA then Bonferroni's post-test (where * denotes a significant effect of TNF compared to 
vehicle-treated cells, and § denotes significant repression of TNFα-induced cytokine production 
by PP2A activators (P<0.05)). Data are mean+SEM values from n=4-5 independent experiments. 
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5.3.3 Specific knockdown of TTP with siRNA increases TNFα-induced IL-8 and IL-6 
mRNA expression and protein secretion 
So far we have shown that PP2A activators - FTY720 and AAL(S) - increase PP2A activity and 
significantly inhibit TNF-induced IL-8 and IL-6 mRNA expression and cytokine secretion 
(Figures 5.1-5.3). We hypothesize that PP2A activators mediate their anti-inflammatory effect in 
a TTP-dependent manner. Towards testing this link, we first needed to show the impact of TTP 
on cytokine production under inflammatory conditions. To do this, we transiently transfected 
A549 cells with siRNA against TTP and stimulated cells with TNF, compared to relevant 
controls (Figure 5.4). As expected, TNFα significantly increased TTP mRNA and TTP protein 
expression after just 1 h (P<0.05). As shown in Figure 5.4A, siRNA against TTP significantly 
repressed TNF-induced TTP mRNA expression (P<0.05). TNF-induced TTP protein 
production was similarly knocked down by siRNA against TTP as demonstrated by Western blot 
(Figure 5.4B). Importantly, when TTP was reduced by siRNA, there was a corresponding 
increase in IL-8 and IL-6 mRNA expression (Figures 5.4C & 5.4E) and cytokine secretion 
(Figures 5.4D & 5.4F) from A549 cells (P<0.05). These results demonstrate that TTP represses 
cytokine production in airway inflammatory conditions modeled in vitro. 
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Figure 5.3 PP2A activators, FTY720 and AAL(S), significantly repress TNFα-induced IL-6 
mRNA expression and protein secretion. A549 cells were pre-treated with (A, B) 2.5 µM 
FTY720 or (C, D) 2.5 µM AAL(S) for 6 h, compared to vehicle (2.5 µM DMSO)-treated 
controls. Cells were treated with vehicle or TNFα (4 ng/ml) and then (A, C) IL-6  mRNA 
expression (results expressed as fold increase compared to vehicle-treated cells at 0 h) and (B, D) 
IL-6 protein secretion  measured  (results expressed as a percentage of TNF-induced IL-6 
secretion at 24 h) at the indicated times. Statistical analysis was performed using two-way 
ANOVA then Bonferroni's post-test (where * denotes a significant effect of TNF compared to 
vehicle-treated cells, and § denotes significant repression of TNFα-induced cytokine production 
by PP2A activators (P<0.05)). Data are mean+SEM values from n=4-5 independent experiments. 
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Figure 5.4 Specific knockdown of TTP with siRNA increases TNFα-induced IL-8 and IL-6 
mRNA expression and protein secretion. A549 cells were either left untransfected or 
transfected with scrambled control (scr) or siRNA against TTP (siRNA), then treated with 
vehicle or TNF (4 ng/ml) before: (A, B) knockdown of TTP mRNA and TTP protein (43 to 49 
kDa) expression confirmed at 1 h by (A) RT-PCR and (B) Western blotting (compared to -
tubulin as loading control); (C, E) IL-8 and IL-6 mRNA expression measured at 1 h (results 
expressed as fold increase compared to untransfected vehicle-treated controls); and (D, F) IL-8 
and IL-6 protein secretion measured at 24 h. Statistical analysis was performed using Student's 
unpaired t test (where * denotes a significant effect of TNF compared to untransfected vehicle-
treated controls, and § denotes a significant effect of siRNA against TTP compared to 
untransfected controls treated with TNF (P<0.05)). Data are mean+SEM values from n=3 
independent experiments.  
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5.3.4 PP2A activators do not enhance TTP mRNA expression; rather they modify TTP’s 
dynamic equilibrium 
Given we showed that PP2A regulates TTP (Rahman et al., 2015), and that PP2A activators 
inhibited IL-6 and IL-8 production (Figures 5.2 & 5.3), we next sought to determine if PP2A 
activators affected TTP expression/activity. We demonstrate that it was not via an increase in 
TTP mRNA expression. As shown in Figure 5.5A, TNF significantly increased TTP mRNA 
expression with a peak at 1 h (P<0.05); however, this was unaffected by pre-treatment with 
FTY720. Pre-treatment with AAL(S) was similarly without effect on TNF-induced TTP 
mRNA expression (Figure 5.5B). We then wished to examine the effect of PP2A activators on 
TTP protein levels. We initially established the temporal kinetics of TTP protein upregulation 
induced by TNF. TTP’s anti-inflammatory function is controlled by phosphorylation and there 
is a dynamic equilibrium between unphosphorylated/active and phosphorylated/active TTP. As 
shown in Figure 5.5C, and in confirmation of earlier studies in A549 (King et al., 2009b; 
Rahman et al., 2015) and other cell types (Mahtani et al., 2001; Prabhala et al., 2015), the rabbit 
antisera Sak21 detects different phospho-forms of TTP with immunoreactive bands at higher 
molecular weight indicating phosphorylated TTP (inactive), while lower bands are 
unphosphorylated (active). TTP is an immediate-early gene (Carballo et al., 1998) and can be 
detected at 1 h in both phosphorylated and unphosphorylated forms. By 2 h, phosphorylated TTP 
predominates and reduces over time (Figure 5.5C). In order to examine the effect of PP2A 
activators on these phospho-forms of TTP we focused in on the 1 h (Figure 5.5D) and 2 h time 
points (Figure 5.5E). As demonstrated by Western blotting and quantitated by densitometry, 
PP2A activators reduced the amount of TTP protein upregulated in response to TNF. This is 
seemingly counterintuitive, but we offer an explanation that is supported by recent in vivo studies 
   Chapter 5 
140 
 
(Ross et al., 2015; Smallie et al., 2015). We propose that PP2A activators affect TTP’s dynamic 
equilibrium; shifting the equilibrium from phosphorylated (inactive) towards unphosphorylated 
(active) TTP. Because the phosphorylation of TTP both inactivates TTP and protects it from 
proteasome-mediated degradation, we predicted that PP2A agonists that promoted TTP 
dephosphorylation would decrease total TTP protein levels. This was exactly the outcome 
observed in Figures 5.5D & 5.5E. 
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Figure 5.5 PP2A activators do not enhance TTP mRNA expression; rather they modify 
TTP’s dynamic equilibrium. (A, B) A549 cells were pre-treated with (A) 2.5 µM FTY720 or 
(B) 2.5 µM AAL(S) for 6 h, compared to vehicle (2.5 µM DMSO)-treated controls. Cells were 
treated with vehicle or TNFα (4 ng/ml) and then TTP mRNA expression measured (results 
expressed as fold increase compared to vehicle-treated cells at 0 h) at the indicated times. 
Statistical analysis was performed using two-way ANOVA then Bonferroni's post-test (where * 
denotes a significant effect of TNF compared to vehicle-treated cells (P<0.05)). Data are 
mean+SEM values from n=4-5 independent experiments. (C-E) A549 cells were either: (C) 
treated with TNF (4 ng/ml) for 0, 1, 2, 4, 8, 24 h; or (D, E) pre-treated with vehicle, 2.5 µM 
FTY720 or 2.5 µM AAL(S) for 6 h, then treated with vehicle or TNFα (4 ng/ml) for 1 h or 2 h. 
Western blotting for TTP (43 to 49 kDa) was performed (compared to -tubulin as loading 
control). Please note two bands of immunoreactivity for TTP: bands at higher molecular weight 
indicate stable phosphorylated TTP (inactive), while lower bands are unphosphorylated (active) 
but unstable. Results are representative Western blots or densitometry analysis (normalized to α-
tubulin and expressed as % TNF-induced TTP protein upregulation at either 1 h (D) or 2 h (E)). 
Statistical analysis was performed using one-way ANOVA then Bonferroni’s post-test (where * 
denotes a significant effect of TNF, and § denotes a significant effect of PP2A activators on 
TNF-induced effects (P<0.05)). Data are mean+SEM values from n=3-4 independent 
experiments.  
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5.3.5 Specific knockdown of TTP with siRNA reverses repression of TNF-induced IL-8 
and IL-6 mRNA expression and protein secretion by the PP2A activator FTY720 
Finally, we demonstrated a link between PP2A activation and TTP-mediated cytokine 
repression. We examined whether FTY720-mediated repression was TTP-dependent by 
knocking-down TTP with siRNA and observing the resultant effect on cytokine production. 
Figure 5.6A confirms that siRNA against TTP reduces TTP mRNA expression. In confirmation 
of earlier data, FTY720 significantly repressed TNF-induced IL-8 mRNA expression (Figure 
5.6B) and protein secretion (Figure 5.6C) (P<0.05). IL-6 mRNA expression and protein secretion 
was also significantly repressed by FTY720 (Figures 5.6D & 5.6E: P<0.05). Notably, specific 
knockdown of TTP with siRNA reverses repression of IL-8 and IL-6 mRNA expression and 
protein secretion by FTY720 (Figures 5.6B-5.6E). These data support our hypothesis that PP2A 
activators mediate their anti-inflammatory effect in a TTP-dependent manner. 
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Figure 5.6 Specific knockdown of TTP with siRNA reverses repression of TNFα-induced 
IL-8 and IL-6 mRNA expression and protein secretion by the PP2A activator FTY720. 
A549 cells were either left untransfected or transfected with scrambled control (scr) or siRNA 
against PP2A-C, and then pre-treated for 6 h with vehicle (2.5 µM DMSO) or with 2.5 µM of 
FTY720. Cells were stimulated with TNF (4 ng/ml) before: (A) knockdown of TTP mRNA 
expression confirmed or (B, D) IL-8 and IL-6 mRNA expression measured at 1 h (results 
expressed as a percentage of TNF-induced mRNA expression in untransfected controls); (C, E) 
IL-8 and IL-6 protein secretion measured at 24 h (results expressed as a percentage of TNF-
induced protein secretion in untransfected controls). Statistical analysis was performed using 
Student's unpaired t test (where: * denotes significant effect of TTP against siRNA and § 
significant repression of TNFα-induced cytokine production by FTY720 (compared to 
untransfected controls);  denotes that specific knockdown of TTP with siRNA reverses 
repression of TNF-induced IL-8 and IL-6 mRNA expression and protein secretion by FTY720 
(compared to untransfected controls) (P<0.05). Data are mean+SEM values from n=3 
independent experiments. 
   Chapter 5 
144 
 
5.4 Discussion  
PP2A is a tri-molecular holoenzyme responsible for dephosphorylating (and hence activating) 
TTP, amongst many other targets. Small molecule PP2A activators have been developed and in 
this study we use two key examples – FTY720 and AAL(S) – to show that PP2A activators can 
enhance TTP’s anti-inflammatory function to inhibit cytokine production in a cellular model of 
airway inflammation in vitro.  
PP2A is best known for its role as a tumour suppressor responsible for the regulation of a range 
of cellular signalling pathways involved in proliferation, survival and migration in cancer 
(Perrotti and Neviani, 2013). Notably, PP2A expression/activity is reduced in a number of 
cancers (Roberts et al., 2010; Cristobal et al., 2014). Thus, restoration of PP2A tumour-
suppression activity by PP2A activators has emerged as a novel therapy for treating cancer. 
Excitingly, the knowledge gained from understanding of PP2A in cancer has propelled research 
into its role and function in respiratory disease. PP2A levels (and therefore activity) were 
reduced in mouse models of allergen- and rhinovirus-induced asthma (Collison et al., 2013a) and 
could be reinstated pharmacologically with AAL(S) to repress hallmark features of airway 
disease (Collison et al., 2013a; Hatchwell et al.). Notably, defects in PP2A cause corticosteroid 
insensitivity in severe asthma (Kobayashi et al., 2011). Reduced PP2A activity induces 
corticosteroid resistance and this can be reversed by the long-acting β2-agonist formoterol 
(Kobayashi et al., 2012). Cornell et al. (Cornell et al., 2009) showed that blocking PP2A robustly 
increased IL-8 expression in A549 cell via post-transcriptional mRNA stabilization; TTP was 
implicated but not directly examined. With these studies, we and others have underscored the 
importance of investigations into the regulation and pharmacological modulation of PP2A in 
airway inflammation. But PP2A dephosphorylates a number of kinases that drive inflammatory 
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pathways (Shanley et al., 2001; Miskolci et al., 2003; Junttila et al., 2008); whether TTP was 
involved remained an open question. 
We address this herein. PP2A is the phosphatase responsible for TTP dephosphorylation (Sun et 
al., 2007). Our earlier studies have shown the impact of PP2A inhibitors on TTP. Brook et al. 
(Brook et al., 2006) used a non-specific PP2A inhibitor calyculin A and demonstrated 
accumulation of the hyperphosphorylated in active form of TTP. More recently (Rahman et al., 
2015), we showed that when PP2A is reduced (either by a non-specific pharmacological inhibitor 
okadaic acid, or more specifically with siRNA against PP2A-C) TTP is hyperphosphorylated and 
rendered inactive; hence the homeostatic restraint that the ubiquitous enzyme PP2A exerts under 
basal conditions is lost and cytokine secretion ensues.  In the current study we build upon these 
observations and exploit the capacity of known PP2A activators to enhance PP2A phosphatase 
activity; effectively shifting the equilibrium from phosphorylated/inactive towards 
unphosphorylated/active TTP. 
A number of small molecules have been reported to activate PP2A (Perrotti and Neviani, 2013). 
To date the best known of these is the sphingosine analog FTY720 (fingolimod; Gilenya 
(Novartis)). However FTY720 has other targets. FTY720 is also a functional antagonist of the 
S1P pathway. FTY720 becomes phosphorylated (by sphingosine kinase 2 (Spk2)) to FTY720-P. 
FTY720-P is then released from cells to then act back on S1P receptors (S1PR1, 3, 4, 5, but not 
S1PR2), internalizing the receptors and preventing them from being activated again by native 
ligand S1P (functional antagonism). In the context of respiratory disease, this is not desirable as 
we  have shown that S1P is elevated in asthma (Ammit et al., 2001) and drives development of a 
pro-inflammatory phenotype, including IL-8 and IL-6 expression in vitro (Ammit et al., 2001; 
Rahman et al., 2014). Accordingly, there is a compelling need to develop PP2A activators that 
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are devoid of S1P agonism. To this end, a chiral analog of FTY720 that does not bind S1P 
receptors, called AAL(S) was developed (Don et al., 2007), and we showed that it is just as 
effective as FTY720 at activating PP2A complexes in vitro and significantly represses airways 
disease in mouse models in vivo (Collison et al., 2013a). AAL(S) is an improvement on FTY720, 
being devoid of S1P agonism, and we now utilize these PP2A activators in A549 lung epithelial 
cells to show that although they do not activate PP2A when added alone, they increased TNF-
induced PP2A activity to inhibit epithelial cell cytokine production in a TTP-mediated manner. 
Further understanding of the molecular mechanism of PP2A regulation in respiratory 
inflammation is required, but it could be speculated that PP2A activators may repress 
inflammation under inflamed (mimicked here with TNF), rather than non-inflamed conditions. 
Taken together our study confirms that PP2A is a druggable target in respiratory disease 
(Collison et al., 2013a; Hatchwell et al.) and establishes a link with TTP. Use of PP2A activators 
underscores the potential of enhancing TTP function with small molecules to reduce airway 
inflammation in respiratory disease. This new knowledge advances our understanding of the 
mechanistic basis of airway inflammation and suggests molecular strategies and avenues for 
future pharmacotherapeutic approaches based on exploiting the anti-inflammatory function of 
TTP 
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Chapter 6 
TLR2 ligation induces corticosteroid insensitivity 
in A549 lung epithelial cells: anti-inflammatory 
impact of PP2A activators 
 
6.1 Introduction 
In Chapter 4 and 5 we successfuly demonstrate the anti-inflammatory role of PP2A and establish 
a link with TTP. These studies corroborate the potential of PP2A activators, as alternative anti-
inflammatory strategies in asthmatic inflammation. We therefore aim to explore the role of PP2A 
activators, known (FTY720) and novel (Theophylline) in the context of corticosteroid 
insensitivity. At the same time, we aim to explore the underlying molecular mechanisms of 
mimic bacterial infection, Pam3CSK4-induced conticosteroid insensitivity. 
Corticosteroids are front-line anti-inflammatory therapies that are widely used to treat people 
with chronic lung disease. In asthma, although corticosteroids have proven clinical efficacy, it is 
increasingly recognized that their anti-inflammatory effectiveness can vary widely depending on 
disease context (such as when people with asthma are experiencing respiratory infections). This 
is known as corticosteroid insensitivity. In severe asthma, the degree of insensitivity increases to 
become corticosteroid resistance; a steroid-refractory condition experienced by 10% of people 
with asthma. Thus, the impact of corticosteroid insensitivity is increasingly recognized as a 
major problem limiting the efficacy of anti-inflammatory therapy in chronic respiratory disease 
(reviewed in (Ammit, 2013; Chung, 2013)). Moreover, corticosteroids are much less effective in 
COPD than in asthma, and this is considered due to relative corticosteroid insensitivity that 
exists in COPD (Marwick and Chung, 2010). To combat inflammation, steroid dose can be 
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increased, but this is not ideal. Thus, alternative anti-inflammatory strategies that could 
effectively treat inflammation when corticosteroid insensitivity exists are urgently required. 
Cellular models of corticosteroid insensitivity are invaluable in vitro tools in our quest to develop 
novel and efficacious pharmacotherapeutic strategies to treat respiratory disease in the future. 
They are an essential first step towards elucidating the mechanisms responsible for respiratory 
infections and the exacerbation of chronic lung diseases. This was highlighted in a recent review 
by Saturni et al. (Saturni et al., 2015), and demonstrated by Papi et al. (Papi et al., 2013), where 
A549 lung epithelial cells exposed in vitro to rhinoviral infection resulted in corticosteroid 
insensitivity.  The molecular mechanisms responsible were explored and shown to be due to 
reduced nuclear translocation of the receptor for corticosteroids – the GR (Papi et al., 2013). 
Ligand-activated GR translocation is a critical step in corticosteroid function; without this, GRs 
are unable to interact in a cis- or trans-manner to exert transcriptional control. Although GR has 
two isoforms GRα and GRβ, to be functionally active GRβ has to be more abundant than GRα. 
However no cells in asthmatics contain higher levels of GRβ than GRα (Gagliardo et al., 2001). 
Notably, upregulation of a critical, corticosteroid-induced, anti-inflammatory protein –MKP-1 - 
was attenuated by rhinoviral infection and contributed to corticosteroid insensitivity. While the 
impact of respiratory viruses on corticosteroid insensitivity have begun to be uncovered 
(reviewed in (Saturni et al., 2015)), the influence of bacterial infection warrants further 
investigation. 
Accordingly, we have established an in vitro cellular model of bacterial exacerbation utilizing 
the synthetic bacterial lipoprotein Pam3CSK4 (Manetsch et al., 2012c; Hirota et al., 2013; 
Alkhouri et al., 2014). The impact of this TLR2 ligand on corticosteroid insensitivity and the role 
played by GR translocation and MKP-1 upregulation was previously unknown. We address this 
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herein and show that Pam3CSK4 induces corticosteroid insensitivity in A549 lung epithelial 
cells. Interestingly, the mechanism is not via retardation of GR translocation into the nucleus. 
Instead we reveal that while the total amount of anti-inflammatory MKP-1 produced in response 
to corticosteroid in the context of TLR2 ligation was unaffected, a proportion of MKP-1 was 
rendered inactive by oxidation of the catalytic cysteine. MKP-1 is one of the major ways in 
which corticosteroids achieve anti-inflammatory action (Issa et al., 2007; Quante et al., 2008; 
King et al., 2009a; Manetsch et al., 2012c; Che et al., 2014; Rahman et al., 2014). Given that this 
anti-inflammatory pathway is less effective under in vitro conditions mimicking bacterial 
exacerbation, we were compelled to uncover alternative, non-steroidal anti-inflammatory 
strategies. Notably, we show that PP2A activators can repress inflammation when corticosteroid 
insensitivity exists. 
 
6.2 Material and Methods 
6.2.1 Chemicals 
Pam3CSK4 was purchased from InVivoGen (San Diego, CA), TNFα was from R&D Systems 
(Minneapolis, MN) and FTY720 was from Cayman Chemical Company (Ann Arbor, MI). 
Unless otherwise specified, all chemicals used in this study were purchased from Sigma-Aldrich 
(St. Louis, MO). 
 
6.2.2 Cell culture 
Please see Chapter 4.2.2 
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6.2.3 ELISA 
IL-6 ELISA was performed according to the manufacturer’s instructions (BD Biosciences 
Pharmingen, San Diego, CA).  
 
6.2.4 Western blotting 
To examine GR translocation, cytoplasmic and nuclear protein extraction was performed using 
NE-PER nuclear and cytosolic extraction kit according to the manufacturer's instructions 
(Thermo Fisher Scientific, Rockford, IL). Western blotting was performed using rabbit 
polyclonal IgG antibodies raised against GR (E-20: Santa Cruz Biotechnology, Santa Cruz, CA), 
compared to α-tubulin (mouse monoclonal IgG1, DM1A: Santa Cruz Biotechnology) and a 
rabbit polyclonal antibody to lamin A/C (Cell Signalling Technology, Danvers, MA) as a 
loading control for the cytosolic and nuclear fractions, respectively. To measure MKP-
1upregulation in whole cell lysates, MKP-1 was quantified by Western blotting using a rabbit 
polyclonal antibody against MKP-1 (C-19: Santa Cruz Biotechnology) with α-tubulin utilized as 
the loading control. Primary antibodies were detected with goat anti-rabbit and anti-mouse HRP-
conjugated secondary antibodies (Cell Signalling Technology) and visualized by enhanced 
chemiluminescence (PerkinElmer, Wellesley, MA).  
 
6.2.5 MKP-1 oxidation 
The method used to measure oxidized MKP-1 was an adaptation of the PROP (purification of 
reversibly oxidized proteins) technique developed by Templeton et al. (Templeton et al., 2010; 
Victor et al., 2012). A549 cells were subjected to oxidative stress conditions (see experimental 
text) before commencing the PROP procedure. Briefly, the non-oxidized thiols were blocked 
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using N-ethylmaleimide, then the oxidized thiols were reduced with dithiothrietol and eluted 
with thiol affinity chromatography (thiopropyl sepharose 6B: GE Healthcare, Little Chlafont, 
UK). Oxidized MKP-1 was then measured using Western blot and the degree of oxidation 
compared to native MKP-1 measured in whole cell lysates run in parallel. 
6.2.6 Statistical analysis 
Statistical analysis was performed using either the Student's unpaired t test, one-way or two-way 
ANOVA followed by Bonferroni’s post-test. P values <0.05 were sufficient to reject the null 
hypothesis for all analyses. Data are mean+SEM of n≥3 independent replicates. 
 
6.3 Results 
6.3.1 TLR2 ligand Pam3CSK4 induces corticosteroid insensitivity in A549 cells 
Hererin we adapt a clinically-relevant model of corticosteroid insensitivity (Papi et al., 2013) to 
mimic bacterial exacerbation in vitro and demonstrate that exposure to a synthetic bacterial 
lipoprotein (TLR2/TLR1 ligand; Pam3CSK4) induces relative corticosteroid insensitivity. This is 
demonstrated in Figure 6.1, where we show that the dose-dependent repression of TNF-induced 
IL-6 secretion achieved with dexamethasone is significantly altered by Pam3CSK4 pre-treatment 
(P<0.05). This is particularly notable at 0.01-1 µM dexamethasone, where the inhibitory impact 
of dexamethasone on cytokine secretion from A549 cells is significantly attenuated by 
Pam3CSK4 (Figure 6.1: P<0.05). 
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Figure 6.1 TLR2 ligand Pam3CSK4 induces corticosteroid insensitivity in A549 cells. A549 
cells were pre-treated for 30 min with either vehicle (0.0001-1 µM DMSO)  or Pam3CSK4 (1 
µg/ml), followed by vehicle or dexamethasone (0.0001-1 µM) for 30 min. After stimulation with 
TNFα (4 ng/ml) for 24 h, IL-6 was measured by ELISA. Statistical analysis was performed using 
two-way ANOVA then Bonferroni’s post-test (where * denotes a significant reduction of 
corticosteroid-mediated repression by Pam3CSK4 (P<0.05)). Data are mean+SEM values from 
n=9 independent experiments. 
 
6.3.2 Corticosteroid insensitivity induced by Pam3CSK4 is not due to altered 
translocation of GR into the nucleus 
We then wished to explore the molecular mechanism responsible for corticosteroid insensitivity 
exerted by the TLR2 ligand. Corticosteroids mediate their actions via interaction with the 
cytosolic GR that then undergoes translocation into the nucleus. As this is an essential step 
necessary for corticosteroid action, we examined whether the molecular basis of corticosteroid 
insensitivity established by Pam3CSK4 is due to a retardation of GR translocation. We address 
this in Figure 6.2, where the effect of Pam3CSK4 pre-treatment on GR translocation induced by 
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dexamethasone (0.0001-1 µM) was assessed under two experimental conditions: i.e. in the 
absence (Figure 6.2A) or presence of stimulation with TNFα (Figure 6.2B). Cytoplasmic and 
nuclear protein extracts were prepared and nuclear entry of GR determined by Western blotting, 
compared with α-tubulin and lamin A/C as loading controls for the cytosolic and nuclear 
fractions, respectively. As shown in Figure 6.2A, GR resides in the cytosol and is undetectable in 
the nucleus under unstimulated conditions. After treatment with dexamethasone however, GR 
undergoes translocation in a concentration-dependent manner. Notably, dexamethasone-induced 
GR translocation is unaffected by Pam3CSK4 (Figure 6.2A). These results were independent of 
stimulation with TNF; as confirmatory experiments (performed in Figure 6.2B) show a similar 
pattern of GR translocation in cells that have been treated with TNF. Taken together these 
experiments demonstrate that corticosteroid insensitivity induced by Pam3CSK4 is not due to 
altered translocation of GR into the nucleus. 
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Figure 6.2 Corticosteroid insensitivity induced by Pam3CSK4 is not due to altered 
translocation of GR into the nucleus. A549 cells were pre-treated for 30 min with either 
vehicle or Pam3CSK4 (1 µg/ml), followed by vehicle (0.0001-1 µM DMSO) or dexamethasone 
(0.0001-1 µM) for 30 min. GR  translocation was examined in the (A) absence or (B) or presence 
of stimulation with TNFα (4 ng/ml) for 1 h. Cytoplasmic and nuclear protein extracts were 
prepared and nuclear entry of GR (86 kDa) determined by Western blotting, compared with α-
tubulin (55 kDa) and lamin A/C (45, 50 kDa) as loading controls for the cytosolic and nuclear 
fractions, respectively. Data are representative blots from n=3 independent experiments. 
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6.3.3 Pam3CSK4 does not affect corticosteroid-induced upregulation of anti-
inflammatory MKP-1 
Thus far we have shown that Pam3CSK4 reduces the anti-inflammatory efficacy of 
corticosteroids on TNF-induced cytokine production without affecting GR translocation. We 
(Quante et al., 2008; Manetsch et al., 2012c; Che et al., 2014; Rahman et al., 2014) and others 
(Issa et al., 2007; King et al., 2009a) have shown that a major mechanism responsible for the 
anti-inflammatory actions of corticosteroids is via the upregulation of MAPK-deactivating 
phosphatase – MKP-1; thus, we investigated whether impaired MKP-1 upregulation was 
responsible for corticosteroid insensitivity induced by bacterial ligand Pam3CSK4. This is 
explored in Figure 6.3, where MKP-1 upregulation in whole cell lysates of A549 cells was 
compared by Western blotting (Figure 6.3A) and analysed by densitometry (Figure 6.3B). We 
demonstrate that TNF induces significant upregulation of MKP-1 protein (3.2±0.5-fold 
compared to vehicle-treated cells (designated as 1) (P<0.05)); in alignment with previous studies 
in A549 cells (King et al., 2009a). MKP-1 is corticosteroid-inducible (King et al., 2009a) and 
accordingly, TNF-induced MKP-1 in A549 cells pre-treated with dexamethasone is 
significantly enhanced at 0.01-1 µM (Figure 6.3B: P<0.05). However, when we examine the 
influence of Pam3CSK4 pre-treatment on MKP-1 upregulation there was no significant effect; as 
demonstrated by Western blotting (Figure 6.3A) and confirmed by densitometry analysis (Figure 
6.3B). Thus, our hypothesis that the bacterial ligand Pam3CSK4 attenuated upregulation of 
MKP-1 protein was not supported. 
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Figure 6.3 Pam3CSK4 does not affect corticosteroid-induced upregulation of anti-
inflammatory MKP-1. A549 cells were pre-treated for 30 min with either vehicle or 
Pam3CSK4 (1 µg/ml), followed by vehicle (0.0001-1 µM DMSO) or dexamethasone (0.0001-1 
µM) for 30 min. Cells were treated without and with TNFα (4 ng/ml) for 1 h and the impact on 
MKP-1 (40 kDa) upregulation compared by Western blotting (with α-tubulin as the loading 
control). (A) Results are representative Western blots and (B) densitometry analysis of MKP-1 
protein upregulation (normalized to α-tubulin and expressed as fold increase compared to 
vehicle-treated cells). Statistical analysis was performed using Student's unpaired t test or one-
way ANOVA then Fisher’s post-hoc multiple comparison test (where * denotes significant 
increase in MKP-1 protein upregulation induced by TNFα, and § denotes significant potentiation 
of TNFα-induced MKP-1 by dexamethasone (P<0.05); there was no effect of Pam3CSK4). Data 
are mean+SEM values from n=3 independent experiments. 
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6.3.4 Corticosteroid insensitivity may be due to Pam3CSK4-induced oxidization of MKP-
1  
However, MKP-1 protein is subject to redox regulation (Kamata et al., 2005; Hou et al., 2008) as 
the catalytic cysteine responsible for phosphatase action can be oxidized and thus reduce anti-
inflammatory function (Bonham and Vacratsis, 2009). Notably, Pam3CSK4 can increase 
oxidative stress in a TLR2-mediated manner and thus we were intrigued to examine whether 
MKP-1 expressed under these conditions may be oxidized.  
To do this, we utilized a technique referred to as PROP (purification of reversibly oxidized 
proteins) (Templeton et al., 2010; Victor et al., 2012). A549 cells were treated under conditions 
established above to induce corticosteroid insensitivity (dexamethasone (at 10 nM) + TNF 
without/with Pam3CSK4) in order to ask the question - is the MKP-1 produced in cells that have 
been pre-treated with Pam3CSK4 oxidized? In order to show that Pam3CSK4 increases MKP-1 
oxidation, experiments were performed in parallel, and then either prepared as whole cell lysates 
to measure native MKP-1, or subjected to the PROP technique to detect oxidized MKP-1. As 
shown in Figure 6.4A and in confirmation with our earlier data (Figure 6.3B), Pam3CSK4 had 
no significant effect on the dexamethasone + TNF-induced upregulation of MKP-1 detected in 
whole cell lysates (see native MKP-1 (WCL): Figure 6.4A). In contrast, there was a significant 
(P<.0.05) increase in oxidized MKP-1 detected by the PROP technique. In cells pre-treated with 
the widely-used positive control for oxidative stress – H202 (hydrogen per oxide) (Kamata et al., 
2005; Templeton et al., 2010; Victor et al., 2012) before TNF, we can confirm that the PROP 
technique detects increases in oxidized MKP-1. Taken together these results suggest that MKP-1 
oxidation induced by Pam3CSK4 may be a contributing factor in corticosteroid insensitivity. 
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Figure 6.4 Corticosteroid insensitivity may be due to Pam3CSK4-induced oxidization of 
MKP-1. (A) A549 cells were pre-treated for 30 min with either vehicle or Pam3CSK4 (1 µg/ml), 
followed by dexamethasone (0.01 µM) for 30 min then TNFα (4 ng/ml) for 1 h.  In order to show 
that Pam3CSK4 increases MKP-1 oxidation, experiments were performed in parallel, and then 
either prepared as whole cell lysates (WCL) to measure native MKP-1, or subjected to the PROP 
technique to detect oxidized MKP-1. (B) As a positive control for oxidative stress, A549 cells 
were pre-treated for 30 min without and with 100 µM H202 before stimulation with TNFα (4 
ng/ml) for 1 h. MKP-1 was detected by Western blotting and densitometry analysis performed 
(results expressed as fold increase compared to cells treated without (A) Pam3CSK4 or (B) 
H202). Statistical analysis was performed using one-way ANOVA then Fisher’s post-hoc 
multiple comparison test (where * denotes significant increase in MKP-1 upregulation, and § 
denotes significant increase in oxidized MKP-1 (P<0.05)). Data are mean+SEM values from 
n=3-4 independent experiments. 
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6.3.5 Alternative anti-inflammatory approaches to overcome corticosteroid insensitivity: 
known and novel PP2A activators 
By modeling bacterial exacerbation in vitro we have demonstrated that exposure to a bacterial 
ligand induces corticosteroid insensitivity. We revealed, in part, a contributing molecular 
mechanism (oxidation of MKP-1) and show that nuclear translocation of GR is unaffected. We 
now turn to exploring alternative anti-inflammatory approaches and hypothesize that PP2A 
activators, being non-steroidal, may prove to inhibit cytokine production when corticosteroid 
insensitivity exists. To address this we examine the impact of two compounds: FTY720 and 
theophylline. FTY720 is a well-established activator of PP2A (Perrotti and Neviani, 2013); while 
theophylline has only been recently reported by us (Patel et al., 2015)  to function as a novel 
activator of PP2A. We show that FTY720 (2.5 µM) in combination with dexamethasone (0.001-
1 µM) achieves significant repression of IL-6 with lower concentrations of corticosteroids 
(Figure 6.5A), and inhibits IL-6 secretion in cells where corticosteroid insensitivity has been 
established by exposure to the bacterial ligand Pam3CSK4 (Manetsch et al., 2012c; Alkhouri et 
al., 2014) (Figure 6.5B) (P<0.05). At a concentrtaion of 10 µM, theophylline is anti-
inflammatory and can repress TNF-induced IL-6 secretion (Figure 6.6A); in confirmation of 
our earlier publication (Patel et al., 2015). It also appeared to have an additive repressive effect 
together with corticosteroids, although this difference was not significant. However, theophylline 
can still significantly repress IL-6 secretion even when corticosteroid insensitivity exists (Figure 
6.6B: P<0.05). Thus, PP2A activators are a non-steroidal anti-inflammatory alternative and/or 
corticosteroid-sparing approach in respiratory inflammation where corticosteroid insensitivity 
exists. 
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Figure 6.5 FTY720 is corticosteroid-sparing and overcomes corticosteroid insensitivity. 
A549 were pre-treated for 6 h with vehicle (0.0001-1 µM DMSO) or FTY720 (2.5 μM), before 
30 min with (A) vehicle or (B) bacterial mimic Pam3CSK4 (1 μg/ml), then dexamethasone 
(0.0001-1 μM) for 30 min. After 24 h with TNFα (4 ng/ml), IL-6 was measured by ELISA. 
Statistical analysis was performed using two-way ANOVA then Bonferroni’s post-test (where * 
denotes a significant effect of FTY720 (P<0.05)). Data are mean+SEM values from n=3 
independent experiments. 
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Figure 6.6 Theophylline is anti-inflammatory and can overcome corticosteroid insensitivity. 
A549 were pre-treated for 30 min with (A) vehicle (0.0001-1 µM DMSO) or (B) bacterial mimic 
Pam3CSK4 (1 μg/ml), then dexamethasone (0.0001-1 μM) for 30 min, without or with 
theophylline (10 µM). After 24 h with TNFα (4 ng/ml), IL-6 was measured by ELISA. Statistical 
analysis was performed using two-way ANOVA then Bonferroni’s post-test (where * denotes a 
significant effect of theophylline (P<0.05)). Data are mean+SEM values from n=3 independent 
experiments.  
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6.4 Discussion 
Corticosteroid insensitivity is a major factor limiting treatment of chronic respiratory disease 
today. The relative responsiveness to corticosteroids can be influenced by a range of endogenous 
and exogenous factors, including respiratory infections. In this study we modelled bacterial 
infection in vitro and showed for the first time that ligation of the TLR2 receptor with a synthetic 
bacterial lipoprotein induces corticosteroid insensitivity. We then explored the cellular 
mechanisms responsible and demonstrate that, unlike rhinoviral-induced corticosteroid 
insensitivity, Pam3CSK4 did not perturb GR nuclear translocation. Notably, while the overall 
amount of native MKP-1 upregulation protein produced under these conditions was unaffected 
by Pam3CSK4 pre-treatment, a significant proportion of MKP-1 was oxidized and consequently 
may be rendered inactive. Finally, we explored alternative modalities to repress cytokine 
production and demonstrate the utility of PP2A activators as non-steroidal anti-inflammatory 
alternatives and/or corticosteroid-sparing approaches in respiratory inflammation where 
corticosteroid insensitivity exists. 
When a person with chronic lung disease (such as asthma and COPD) experiences an infection 
their lung function deteriorates and they require greater amounts of their anti-inflammatory 
medicines to treat their respiratory symptoms. This is because viral or bacterial infection changes 
the molecular pathways by which respiratory medicines act; making them less sensitive. These 
changes are due to interaction of viral and bacterial products with pattern recognition receptors, 
particularly TLRs expressed on airway cells (reviewed in (Saturni et al., 2015)). We have 
focused on mimicking bacterial infection in vitro with Pam3CSK4 and have previously shown 
that TLR2 ligation robustly increased TNF-induced secretion of cytokines implicated as 
playing a role in exacerbation (Manetsch et al., 2012c). Moreover, TLR2 activation causes 
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tachyphylaxis to bronchodilatory β2-agonists in vitro and ex vivo (Alkhouri et al., 2014). In the 
current study, we reveal an additional detrimental consequence of bacterial infection beyond 
amplification of inflammation and β2-adrenergic desensitization; namely, we show that 
Pam3CSK4 induces corticosteroid insensitivity.  
However, the molecular mechanisms responsible differ from those reported for corticosteroid 
insensitivity induced in A549 cells by rhinoviral infection (Papi et al., 2013).  Corticosteroids 
initiate their effects on gene expression by interacting with cytoplasmic GRs. Translocation of 
GR into the nucleus is a requisite step to allow GR to act as a ligand-dependent transcription 
factor. Once in the nucleus, ligand-activated GRs then repress inflammation by: (i) activation of 
glucocorticoid response elements and upregulation of anti-inflammatory genes, including MKP-
1, glucocorticoid-inducible leucine zipper 1; (ii) inhibitory interactions with proinflammatory 
DNA-binding transcription factors, such as NF-B; and (iii) effects on recruitment of 
transcriptional co-activators, co-repressors and the chromatin machinery (reviewed in (Ammit, 
2013)). Papi et al. (Papi et al., 2013) showed that rhinoviral infection reduced GR nuclear 
translocation, thus levels of MKP-1 upregulation was lower, Additionally, they demonstrated 
induction of MAPK signalling pathways (JNK in particular) and NF-B activation. In contrast, 
we show that GR translocation was unaffected by Pam3CSK4 and that the upregulation of MKP-
1 in whole cell lysates was unchanged. 
However, just examining the overall protein levels of MKP-1 may not reveal the entire story. It 
is increasingly recognized that the MAPK-deactivating ability of dual-specificity phosphatases 
(with MKP-1, aka DUSP1, being a founding member of this family) can be regulated post-
translationally by oxidation (Bonham and Vacratsis, 2009). The catalytic cysteine of MKP-1 can 
be modified by oxidation, thereby reducing its function as phosphatase. Redox regulation of 
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MKP-1 has been demonstrated in vitro (Kamata et al., 2005; Hou et al., 2008) and highlighted as 
a potential mechanism responsible for corticosteroid insensitivity in our recent in vivo study 
exposing MKP-1 wild-type and knock-out mice to ozone (Pinart et al., 2014). Notably, 
Pam3CSK4 can increase oxidative stress in a TLR2-mediated manner (Singh et al., 2015) and 
therefore we utilized the PROP technique to show that a proportion of MKP-1 expressed under 
these conditions is oxidized. Taken together, these results suggest that Pam3CSK4-mediated 
oxidation of MKP-1 may contribute to corticosteroid insensitivity. 
Finally, we explored alternative means of repressing cytokines when corticosteroid insensitivity 
exists. We focused on small molecules that are known and novel activators of the ubiquitous 
serine-threonine phosphatase –PP2A. PP2A dephosphorylates a number of kinases that drive 
inflammatory cell signaling, including MAPKs and NF-B (Shanley et al., 2001; Miskolci et al., 
2003; Junttila et al., 2008; Rahman et al., 2015). A number of small molecules can activate PP2A 
(Perrotti and Neviani, 2013). The best known of these is FTY720, and we recently showed that it 
activates TNF-induced PP2A enzymatic activity and represses cytokine production in A549 
cells (Rahman et al., 2015). In the current study we examine its efficacy when used as an adjunct 
therapy with corticosteroids in vitro and show that FTY720 can act additively in a corticosteroid-
sparing manner. Most importantly in the context of the bacterial exacerbation, FTY720 can 
significantly repress cytokine production when corticosteroid insensitivity exists. Lastly, we 
explored the potential effects of theophylline. Theophylline has beneficial effects in asthma and 
COPD and acts via a number of different molecular pathways (reviewed in (Barnes, 2013)). We 
recently reported a new anti-inflammatory function for theophylline; it increases TNF-induced 
PP2A enzymatic activity in A549 cells, as well as primary cultures of airway smooth muscle. 
Thus, we examined its impact on corticosteroid insensitivity and although the impact was not as 
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great as FTY720, theophylline was able overcome corticosteroid insensitivity. It is important to 
note however, that we believe that these repressive effects on cytokine function exerted by 
FTY720 and theophylline are anti-inflammatory effects acting via alternative, PP2A-dependent 
pathways, rather than restoration of corticosteroid sensitivity. 
Collectively, our study shows that, like rhinoviral infection modelled in vitro, bacterial ligands 
exert corticosteroid insensitivity. These models allow us to explore the molecular mechanisms 
responsible and highlight potential therapeutic strategies to combat inflammation in infectious 
exacerbation. We reveal that oxidation of anti-inflammatory MKP-1, rather than retardation of 
nuclear translation, occurs via TLR2-mediated pathways. Finally, we suggest that activating 
PP2A may prove to be efficacious, non-steroidal anti-inflammatory alternatives and/or 
corticosteroid-sparing approaches in the context of bacterial exacerbation. 
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Chapter 7 
Individual Cell type variation and different 
functional outcomes 
 
7.1 Introduction 
In Chapter 3 - Chapter 6, we clearly demonstrated the role of S1P mediated MAPKs in 
neutrophilic asthma, the anti-inflammatory role of basal PP2A, the link between PP2A and TTP 
and, most importantly, our studies reveal that PP2A activators have the potential to function as 
alternative anti-inflammatory strategies that are effective even when corticosteroid insensitivity 
exists. We performed most of our PP2A studies using A549 cells (partly using BEAS-2B). 
Therefore in this study we aim to perform some key experiments using BEAS-2B and ASM cells 
to further confirm our findings. However, due to individual cell type variability we fail to 
demonstrate a clear conclusion. 
Individual cell types are distinguished based on the morphology or the phenotype of cells within 
a species. Multicellular organisms consist of diverse and specialised cell types including 
structural cells, muscle cells and skin cells in humans. Although these cells are genetically the 
same, they are distinct both in appearance and functions.  
Cellular models (cell lines - a population of cells with same genetic makeup and derived from a 
single cell) were developed in the mid 20th century and gained robust acceptance in Molecular 
Biology research (Masters, 2002). To date, two types of cellular models are successfully 
employed in Biomedical research; immortal cell lines (cells that via intentionally induced 
mutation can undergo division indefinately while keeping their cellular features unchanged), and 
   Chapter 7 
169 
 
primary cell lines (derived directly from the parent tissue containing the same karyotype and 
chromosome number as those in the original tissue) (Hayflick). Both models have been 
extensively used in Molecular Biology research not only for their easy accessibility and but also 
as they can be employed in almost all types of experimental techniques.  
According to evolutionary principle it is believed that all organisms share some degree of 
relatedness and genetic resemblance due to common ancestry (Hendry et al., 2011). Therefore in 
vivo experimental models (animal models including mouse, rat and guinea pig) are considered as 
more authentic experimental models. However in vivo models are not suitable with certain 
experimental techniques such as siRNA or overexpression plasmid, whereas in vitro cellular 
models suit these techniques very well. Further, immortal cells undergo a significant mutation to 
become immortal and which may possibly alter their biology as well. This is why we use 
primary cell lines. 
Although there are options for selecting experimental models based on experimental need, 
individual variability is still the key issue we need to resolve. Here in this chapter we aim to 
address how individual cell type variability impacts on experimental outcomes using BEAS-2B 
and ASM cells. 
 
7.2 Materials and Methods 
7.2.1 Cell culture 
For detailed description, see Chapter 2.2.1 
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7.2.2 Chemicals 
FTY720 was purchased from Cayman Chemical Company (Ann Arbor, MI) and AAL(s) was 
synthesized (Don et al., 2007; Collison et al., 2013a; Hatchwell et al., 2014). TNF is from R&D 
Systems (Minneapolis, MN). Unless otherwise specified, all chemicals used in this study were 
purchased from Sigma-Aldrich (St. Louis, MO). 
 
7.2.3 PP2A activity assay 
For detailed description, see Chapter 2.2.8 
 
7.2.4 ELISAs 
Please see Chapter 5.2.5 
 
7.2.5 Real-time RT-PCR 
Please see Chapter 4.2.5 
 
7.2.6 siRNA transfection 
Please see Chapter 5.2.7 
 
7.2.7 Statistical analysis 
Statistical analysis was performed using either the Student's unpaired t test, one-way or two-way 
ANOVA followed by Bonferroni’s post-test. P values <0.05 were sufficient to reject the null 
hypothesis for all analyses. Data are mean±SEM of n≥3 independent replicates. 
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7.3 Results 
7.3.1 PP2A activators, FTY720 and AAL(S) increase TNFα-induced IL-6 mRNA 
expression and protein secretion in BEAS-2B cells. 
Respiratory epithelial cells are an important source of both IL-6 and IL-8 (Cromwell et al., 
1992), which are implicated in asthmatic inflammation. In our previous studies, we found that 
both IL-6 (Figure 5.3) and IL-8 (Figure 5.2) are significantly increased by the treatment of TNFα 
(4 ng/ml) in A549 cells and are significantly repressed by the pre-treatment of PP2A activators, 
FTY720 and AAL(S) (Figure 5.2, 5.3). To obtain further confirmation we wish to check TNFα-
induced expression of IL-6 and their suppression by PP2A activators using another respiratory 
epithelial cell line, BEAS-2B. Interestingly, in BEAS-2B cells we find that TNFα increased IL-6 
mRNA (Figure 7.1A, 7.1B) and protein (Figure 7.1B, 7.1D) expression; however, PP2A 
activators FTY720 and AAL(S) do not repress their expression. Instead expression further 
increased over TNFα. 
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Figure 7.1 PP2A activators, FTY720 and AAL(S), increase TNFα-induced IL-6 mRNA 
expression and protein secretion. BEAS-2B cells were pre-treated with (A, B) 2.5 µM FTY720 
or (C, D) 2.5 µM AAL(S) for 6 h, compared to vehicle-treated controls. Cells were treated with 
vehicle (1 µM DMSO) or TNFα (4 ng/ml) and then (A, C) IL-6  mRNA expression (results 
expressed as fold increase compared to vehicle-treated cells at 0 h) and (B, D) IL-6 protein 
secretion  measured  at the indicated times. Statistical analysis was performed using two-way 
ANOVA then Bonferroni's post-test (where * denotes a significant effect of TNF compared to 
vehicle-treated cells, and § denotes significant repression of TNFα-induced cytokine production 
by PP2A activators (P<0.05)). Data are mean+SEM values from n=4-5 independent experiments. 
 
7.3.2 PP2A activators, FTY720 and AAL(S), significantly repress TNFα-induced IL-8 
mRNA expression and protein secretion in BEAS-2B cells. 
We then intend to check IL-8 mRNA and protein expression in BEAS-2B cells with similar 
treatment conditions. Our data show that TNFα significantly increases IL-8 mRNA (Figure 7.2A, 
7.2C) and protein (Figure 7.2B, 7.2D) expression. Interestingly PP2A activators significantly 
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repressed (though the repression is very little) both mRNA at early time point (1 h and 2h) and 
protein expression at a later time point (4 h, 8 h and 24 h), which match with the data of A549 
cells (Figure 5.2). 
 
 
Figure 7.2 PP2A activators, FTY720 and AAL(S), significantly repress TNFα-induced IL-8 
mRNA expression and protein secretion. BEAS-2B cells were pre-treated with (A, B) 2.5 µM 
FTY720 or (C, D) 2.5 µM AAL(S) for 6 h, compared to vehicle (2.5 µM DMSO)-treated 
controls. Cells were treated with vehicle or TNFα (4 ng/ml) and then (A, C) IL-8  mRNA 
expression (results expressed as fold increase compared to vehicle-treated cells at 0 h) and (B, D) 
IL-8 protein secretion  measured  at the indicated times. Statistical analysis was performed using 
two-way ANOVA then Bonferroni's post-test (where * denotes a significant effect of TNF 
compared to vehicle-treated cells, and § denotes significant repression of TNFα-induced 
cytokine production by PP2A activators (P<0.05)). Data are mean+SEM values from n=4-5 
independent experiments. 
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7.3.3 PP2A activators FTY720 and AAL(S) do not affect TNFα-induced TTP mRNA but 
increased IL-6 and IL-8 mRNA and protein expression in ASM cells. 
In the BEAS-2B cell line, TNFα-induced IL-8 expression and its repression by PP2A activators 
consistent with A549 cells but not IL-6. We therefore aim to check IL-6 and IL-8 cytokines 
expression in ASM cells. Data in ASM cells is rather more complex than that of BEAS-2B 
(Figure 7.1, 7.2). In ASM cells, TNFα significantly increased IL-6 and IL-8 mRNA (Figure 
7.3B, 7.3D) and protein (Figure 7.3C, 7.3E) expression and PP2A activators further increased 
(though not significantly) both IL-6 and IL-8 expression. However, TTP mRNA (Figure 7.3A) 
expression was unaffected with the treatment with PP2A activators. 
   Chapter 7 
175 
 
 
Figure 7.3 PP2A activators, FTY720 and AAL(S), do not affect TNFα-induced TTP mRNA 
but increased IL-6 and IL-8 mRNA and protein expression in ASM cells. Primary ASM cells 
were pre-treated with 2.5 µM of FTY720 or AAL(S) for 6 h, compared to vehicle (2.5 µM 
DMSO)-treated controls. Cells were treated with vehicle or TNFα (4 ng/ml) and then TTP 
mRNA (A), and IL-6 and IL-8 mRNA (B, D) and protein (C, E) expression measured at the 
indicated times. Statistical analysis was performed using two-way ANOVA then Bonferroni's 
post-test (where * denotes a significant effect of TNF compared to vehicle-treated cells, and § 
denotes significant repression of TNFα-induced cytokine production by PP2A activators 
(P<0.05)). Data are mean+SEM values from n=4-5 independent experiments. 
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7.3.4. Specific knockdown of TTP with siRNA decreases TNFα-induced IL-6 and IL-8 
mRNA expression and protein secretion in BEAS-2B cells.  
Figure 7.1 and 7.2 both clearly demonstrate that PP2A activators (FTY720 and AAL(S)) have 
variable effects depending on the cell type. To confirm that this variability is not limited to 
certain experimental protocols, we decided to check the effect of TTP siRNA in the presence or 
absence of PP2A activators using BEAS-2B cells. Data in A549 (Figure 5.4) show that specific 
knock down of TTP with siRNA significantly increased TNFα-induced IL-6 and IL-8 mRNA 
and protein expression over TNFα. Also, in chapter 5, we demonstrated that activating PP2A can 
enhance the anti-inflammatory function of TTP in A549 cells. To the confirm efficacy of TTP 
siRNA we first of all checked TTP mRNA expression (Figure 7.4A). The data clearly 
demonstrates that TTP siRNA is working well in our experimental conditions. We then checked 
IL-6 and IL-8 mRNA (Figure 7.4B, 7.4D) and protein (7.4C, 7.4E). The results show that TNFα 
increased both cytokines mRNA and protein expression. However, in the absence of TTP, 
cytokines level was considerably reduced, which demonstrates the very unusual but 
inflammatory function of TTP. We also checked the effect of PP2A activators, FTY720 and 
AAL(S) in the absence of TTP. As shown in Figure 7.4F and 7.4H, TNFα-induced IL-6 mRNA 
and protein expression were further increased by FTY720 but AAL(S) significantly decreased 
IL-6 mRNA but did not affect IL-6 protein secretion; although in our previous experiments 
(Figure 5.4) we did find further increase of these cytokines expression. Data also show that 
PP2A activators reduced TNFα-induced IL-8 mRNA (7.4G; significantly) and protein (7.4I; 
statistically not significant) expression and more interestingly the absence of TTP further 
reduced IL-6 and IL-8 mRNA and proteins. These results further demonstrate cell type 
variability and it appears that in BEAS-2B cells TTP does not show anti-inflammatory functions. 
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Figure 7.4 Specific knockdown of TTP with siRNA decreases TNFα-induced IL-6 and IL-8 
mRNA expression and protein secretion. BEAS-2B cells were either left untransfected or 
transfected with scrambled control (scr) or siRNA against TTP, then treated with vehicle or 
TNF (4 ng/ml) before: (A) knockdown of TTP mRNA expression confirmed at 1 h by RT-PCR 
(results expressed as fold increase compared to untransfected vehicle-treated controls); and IL-6 
and IL-8 mRNA (B, D) and protein (C, E) secretion measured at 1 h and 24 h, respectively. 
Effect of AAL(S) and FTY720 on IL-6 and IL-8 mRNA (F, H) and protein (G, I) were measured 
at 1 h and 24 h, respectably in presence or absence of TTP siRNA. Statistical analysis was 
performed using Student's unpaired t test (where * denotes a significant effect of TNF 
compared to untransfected vehicle-treated controls, and § denotes a significant effect of siRNA 
against TTP compared to untransfected controls treated with TNF (P<0.05)). Data are 
mean+SEM values from n=3 independent experiments.  
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7.3.5 Steroid inhibited TNFα-induced IL-6 and IL-8 secretion was not affected by 
FTY720 and AAL(S) 
Our studies confirm that normal BEAS-2B and primary ASM cellular models do not corroborate 
the role of PP2A in asthmatic inflammation due to cell type variability. We then aimed to check 
whether these cellular models are suitable in the context of corticosteroid insensitivity. Firstly we 
checked the role of PP2A activators in the presence of corticosteroid (particularly 
Dexamethasone) in the BEAS-2B cell line. As shown in Figure 7.5A, AAL(S) further inhibited 
IL-6 protein secretion but not FTY720. Moreover, PP2A activators fail to demonstrate any effect 
on IL-8 protein secretion in the presence of Dexamethasone (Figure 7.5B). 
 
   Chapter 7 
180 
 
 
 
Figure 7.5 Steroid inhibited TNFα-induced IL-6 and IL-8 secretion was not affected by 
FTY720 and AAL(S). BEAS-2B cells were pre-treated with 2.5 µM FTY720 or 2.5 µM 
AAL(S) for 6 h, compared to vehicle (0.0001-1 µM DMSO)-treated controls or Dexamethasone 
(0.0001, 0.001, 0.01, 0.1 or 1 µM) for 30 min. Cell supernatants were harvested after 24 h of 
TNFα (4 ng/ml) stimulation. IL-6 (A) and IL-8 (B) protein secretion were measured by ELISA. 
Statistical analysis was performed using two-way ANOVA then Bonferroni's post-test. Data are 
mean±SEM values from n=3 independent experiments. 
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7.3.6 Steroid inhibited TNFα-induced IL-6 and IL-8 secretion was not repressed by 
pam3CSK4 or reversed by PP2A activators 
In A549 cells we clearly demonstrate that mimicking bacterial infection (Pam3CSK4) 
significantly repressed Dexamethasone inhibited IL-6 protein secretion (Figure 6.1). To further 
confirm this result, we perfomed similar experiment using BEAS-2B cells. As shown in Figure 
7.6A and 7.6B, Pam3CSK4 failed to demonstrate its effect in BEAS-2B cells and both IL-6 
(Figure 7.6A) and IL-8 (Figure 7.6B) protein secretion are unaffected by PP2A activators. These 
data clearly show that BEAS-2B cells are not suitable models to check corticosteroid 
insensitivity.  
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Figure 7.6 Steroid inhibited TNFα-induced IL-6 and IL-8 secretion were not repressed by 
pam3CSK4 or reversed by PP2A activators. BEAS2B cells were pre-treated with Pam3CSK4 
(1 µg/ml) for 1 h or Dexamethasone (0.0001, 0.001, 0.01, 0.1 or 1 µM) for 30 min or 2.5 µM 
FTY720 or 2.5 µM AAL(S) for 6 h. Cell supernatants were harvested after 24 h of TNFα (4 
ng/ml) stimulation. IL-6 (A) and IL-8 (B) protein secretion were measured by ELISA. Statistical 
analysis was performed using two-way ANOVA then Bonferroni's post-test (where * denotes a 
significant effect compared to TNFα-treated cells and § denotes a significant effect compared to 
Dexamethasone+TNFα-treated cells (P<0.05)). Data are mean±SEM values from n=3 
independent experiments. 
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7.3.7 Steroid inhibited TNFα-induced IL-6 and IL-8 secretion was not affected by 
pam3CSK4 
Our data regarding BEAS-2B cells clearly demonstrate that Pam3CSK4 does not effect 
Dexamethasone inhibited IL-6 and IL-8 protein secretion. We then planned to check the effect of 
Pan3CSK4 in ASM cells. Interestingly, we obtained consistent results in ASM cells such as 
BEAS-2B. Both IL-6 (Figure 7.7A) and IL-8 (Figure 7.7B) are unaffected with the treatment of 
Pam3CSK4. Overall the results in normal BEAS-2B and primary ASM cells are consistent. 
These results ultimately led us to check PP2A enzymatic activity level with the treatment of 
PP2A activators. As shown in Figure 7.7C, PP2A activators do have any effect on PP2A 
enzymatic activity. 
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Figure 7.7 Steroid inhibited TNFα-induced IL-6 and IL-8 secretion was not affected by 
pam3CSK4. ASM cells were pre-treated with Pam3CSK4 (1 µg/ml) for 1 h or Dexamethasone 
(0.0001, 0.001, 0.01, 0.1 or 1 µM) for 30 min. Cell supernatants were harvested after 24 h of 
TNFα (4 ng/ml) stimulation. IL-6 (A) and IL-8 (B) protein secretion were measured by ELISA. 
PP2A activity (C) was measured at 1 h after TNFα stimulation followed by 6 h pre-treatment 
with 2.5 µM of FTY720 and AAL(S) or 1 h with Pam3CSK4 (1 µg/ml). Statistical analysis was 
performed using two-way ANOVA then Bonferroni's post-test (where * denotes a significant 
effect compared to TNFα-treated cells and § denotes a significant effect compared to 
Dexamethasone+TNFα-treated cells (P<0.05)). Data are mean±SEM values from n=3 
independent experiments. 
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7.4 Discussion 
Individual variability is one of the key issues in selecting experimental models. Despite 
similarities between cellular models, it is not unusual that very different functional outcomes can 
occur. Evidence supports that certain drugs (especially anti-cancer drugs) may be effective in 
some patients but not as effective in other patients (Schilsky, 2010). This individual variability 
ultimately leads to the concept personalized medication, which has recently emerged as an 
effective therapeutic approach to treat cancer. 
In this project, we successfully demonstrate that endogenous PP2A effectively combats 
asthmatic inflammation and PP2A activators are potent even under corticosteroid insensitive 
conditions using a widely used cellular model (A549). A549 is an immortalized cellular model 
derived from lung carcinoma tissue. To obtain further confirmation of our findings we wished to 
employ another widely used respiratory epithelial cells, BEAS-2B (immortalized but isolated 
from normal human bronchial epithelium) and primary ASM cells to further corroborate the role 
of PP2A in asthmatic inflammation. 
PP2A activators (FTY720 and AAL(S)) significantly repress TNFα-induced IL-6 and IL-8 
mRNA and protein expression in A549 cells, whereas in BEAS-2B cells PP2A activators fail to 
repress (rather increased over TNFα) IL-6 mRNA and protein, though expression of IL-8 is 
repressed a little. Results using BEAS-2B corroborate the concept that treatment with IL-6 can 
repress PP2A enzymatic activity in Rat-1 fibroblast and human hepatoma Hep3B cells (Choi et 
al., 1998; de la Torre et al., 2005). It is reported that IL-6 binds with specific receptors on the cell 
surface and causes inactivation of PP2A via phosphorylation of tyrosine on its catalytic subunit, 
which in turn prolongs the activation of protein kinases (Chen et al., 1992; Wera and Hemmings, 
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1995). However, in ASM cells both IL-6 and IL-8 mRNA and protein expression are further 
increased over TNFα with the treatment of PP2A activators. 
A growing body of evidence supports TTP as an mRNA binding protein targeting cytokines 
mRNA, which are implicated in asthmatic inflammation (Lai et al., 2006; Tudor et al., 2009). In 
A549 cells we show that blocking TTP using OA and siRNA against TTP significantly increased 
TNFα-induced cytokines expression over TNFα alone. Notably, our studies reveal that while 
blocking TTP using siRNA, PP2A activators lose their potential to suppress cytokines 
expression, which demonstrates that PP2A works via enhanching TTP anti-inflammatory 
function. However studies in BEAS-2B show opposite functional outcomes than that of A549 
cells.  
We modeled A549 to study Pam3CSK4-induced corticosteroid insensitivity and showed that the 
PP2A activator, FTY720, can bypass steroid insensitive conditions in the context of IL-6 protein 
expression. However, Pam3CSK4 does not cause steroid insensitivity in BEAS-2B and ASM 
cells and ultimately the PP2A activator failed to demonstrate its potential. More interestingly, 
PP2A activators fail to augment PP2A enzymatic activity in ASM cells. Results obtained using 
BEAS-2B and ASM cells suggest that PP2A activators may not be equally effective in all cell 
types. In addition, TTP fails to target cytokines mRNA both in BEAS-2B and ASM cells. This 
may be the reason for the ineffectiveness of the PP2A activator. 
PP2A is highly regulated at multiple levels and associated with MAPKs and TTP as shown in 
Figure 1.8. We and others have reported that MKP-1 is regulated by MAPKs (especially p38 
MAPK) (Franklin and Kraft, 1997; Manetsch et al., 2012b). A wide range of inflammatory 
stimuli are responsible for p38 MAPK phosphorylation and hence activation (Prabhala et al., 
2015). Upon activation p38 triggers MKP-1 expression, which in turn downregulates p38 
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phosphorylation via negative feedback mechanisms (Manetsch et al., 2012b). TTP is also 
predominantly regulated by p38 activation. By regulating MAPKs, both PP2A and MKP-1 shift 
the TTP balance towards the unphosphorylated – active – from. Although the link between 
MKP-1 and PP2A is not yet clear, based on our studies in this project we deduce that they might 
be interlinked.  
Further, PP2A is the key controller of MAPKs and at the same it is itself a target of several 
endogenous inhibitory proteins (Goldberg, 1999) including SET, CIP2A, α4, SV40 ST and 
PyMT (Figure 1.6). These complex regulatory mechanisms and the inter relationship between 
PP2A, TTP, MKP-1 and MAPKs may be the reason behind the individual variability. Extensive 
studies are required to explore the underlying molecular mechanisms, which may eventually lead 
to better understanding of individual variability.  
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Chapter 8 
General discussion and conclusion 
 
Overview: Asthma is a widespread noncommunicable chronic health problem that affects 
millions of people around the globe. The prevalence of asthma has increased very significantly in 
recent decades and most alarmingly it is still an increasing trend. Inflammation is the major 
driving force of asthma pathogenesis, which is associated with the structural remodelling of the 
airway wall. Long-term exposure to pro-inflammatory mediators, including cytokines, results in 
remodelling or thickening of the airway. Development of remodelled airways is correlated with 
deterioration of lung function. Reducing inflammation thus remains a key goal in asthma therapy 
to ameliorate long term decline in patient health. The corticosteroids are the major class of anti-
inflammatories currently used in the treatment of asthma. However, despite their efficacy as 
powerful anti-inflammatories, the array of side-effects following chronic corticosteroid use 
causes significant unwanted effects. Besides, many asthmatic inflammatory conditions (e.g. viral 
or bacterial infection, exacerbation) are not responsive to them. Corticosteroid insensitivity can 
range from relatively mild insensitivity to steroid resistance, as seen in severe asthma (Ammit, 
2013; Chung, 2013). Therefore the challenge for asthma treatment today is to identify alternative 
anti-inflammatory strategies with reduced side-effects and greater effectiveness in steroid 
resistant conditions. 
Substantial research on asthmatic inflammation over the last couple of years has increased our 
understanding of the mechanisms of airway inflammation and has ultimately led to a number of 
possible therapeutic targets. Notably, some alternative strategies such as sputum guided 
treatment and fractional concentration of FeNO have been evaluated, mainly in severe or 
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difficult-to-treat asthma, for adjusting asthma treatment. However sputum guided treatment is 
only beneficial when the patients required secondary care (Haldar et al., 2008) and FeNO has not 
generally been found to be effective (Petsky et al., 2012). In this project we therefore aimed to 
explore the potential of an endogenous protein phosphatase, PP2A, which offers great promise in 
the context of asthmatic inflammation. 
 
Our approaches: The role of inflammation in asthma pathogenesis and airway remodelling is 
well studied. In searching for an alternative anti-inflammatory strategy, firstly we aimed to 
explore the role of the bioactive sphingolipid S1P in the context of neutrophilic asthma, which is 
relatively unexplored to date. A growing body of evidence supports the role of S1P in asthmatic 
inflammation and airway remodelling (Lai et al., 2011; Che et al., 2012). In our previous study 
we reported elevated levels of S1P in the broncho-alveolar lavage fluid of allergic asthmatics 
(Ammit et al., 2001). Mast cells are considered the major sources of S1P in allergic asthma (Jolly 
et al., 2002; Olivera and Rivera, 2011) and interestingly in asthmatic patients mast cells are 
micro-localized in ASM cells, airway mucous glands and bronchial epithelium (Oskeritzian et 
al., 2007). S1P potently induces secretion of IL-6 from ASM (Ammit et al., 2001; Che et al., 
2013) and IL-8 from alveolar epithelial cells (Milara et al., 2009). This suggests that the 
bioactive sphingolipid S1P can orchestrate cytokine production in airway inflammation. In line 
with these studies, our present study shows that stimulation of primary ASM cells with S1P 
results in IL-8 gene expression and protein secretion (Figure 3.1A, 3.2A). Recently we 
demonstrated that corticosteroid-induced MKP-1 attenuated S1P-induced IL-6 secretion by 
dephosphorylating p38 MAPK and also the ERK-mediated activation of MSK1 and histone H3 
phosphorylation (Che et al., 2014). Besides, we propose that S1P-induced IL-8 may be 
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controlled in a similar MSK1-dependent manner. In this study we reveal that S1P-induced IL-8 
secretion is p38 MAPK- and ERK-dependent (Figure 3.6) and that these key phosphoproteins act 
on the downstream effector MSK1 to control secretion of the neutrophil chemoattractant 
cytokine IL-8 (Figure 3.7). To demonstrate the functional relevance of our in vitro data we 
perform neutrophil chemotaxis assays and show that S1P-induced effects can be significantly 
attenuated by pre-treatment with dexamethasone, pharmacological inhibition of p38 MAPK- or 
ERK-mediated pathways, or by knocking down MSK-1 with siRNA (Figure 3.7). These studies 
partly reveal the molecular mechanisms of S1P in the development of IL-8-driven neutrophilia in 
airway inflammation and suggest further studies into the causal role played by S1P in the 
neutrophilic asthma. 
Findings of our first approach: 
1. The inflammatory mediator, S1P, upregulates IL-8 secretion from primary ASM 
cells and contributes to the development of airway inflammation. 
2. S1P-induced IL-8 secretion is p38 MAPK and ERK-dependent. 
3. MSK1 controls the secretion of the neutrophil chemoattractant cytokine IL-8. 
4. The corticosteroid dexamethasone significantly represses S1P-induced IL-8 
expression. 
PP2A is a master controller of multiple inflammatory signalling pathways. PP2A 
dephosphorylates a number of kinases that drive inflammatory cell signalling (Shanley et al., 
2001; Junttila et al., 2008). Notably, PP2A can dephosphorylate members of the MAPK 
superfamily, including p38 MAPK (Junttila et al., 2008). The role of PP2A as a tumour 
suppressor is well studied and thus PP2A activator has emerged as a novel therapy for treating 
cancer. Excitingly, the knowledge gained from understanding of PP2A in cancer has propelled 
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research into its role and function in respiratory disease and more recently it has emerged as a 
druggable target in asthmatic inflammation; although the underlying molecular mechanisms 
remain relatively unexplored. In order to unveil the molecular mechanisms of PP2A in asthmatic 
inflammation we aimed to explore the role of basal PP2A in cancer patient derived respiratory 
epithelial cells (A549) and some confirmatory experiments were performed using normal 
respiratory epithelial BEAS-2B cells. Mounting evidence supports the role of PP2A as a negative 
regulator on MAPKs and in line with these studies we find that inhibition of basal PP2A by OA 
upregulates p38 MAPK, ERK and JNK phosphorylation in A549 cells (Figure 4.2). To 
demonstrate the role of basal PP2A in respiratory epithelial cells we employ multiple approaches 
including modulation of PP2A phosphatase activity by using a PP2A inhibitor, OA (Figure 4.1); 
two PP2A activators, FTY720 (Figure 4.7A) and AAL(S) (Figure 4.8A); an expression plasmid 
to overexpress the catalytic subunit of PP2A (PP2A-C) (Figure 4.9A & B); and siRNA to 
knockdown PP2A-C (Figure 4.11A & B). We and others previously reported that IL-6 and IL-8 
are the two major cytokines upregulated via MAPK-mediated pathways. Studies performed in 
this project confirm the role of basal PP2A in restraining cytokines (especially IL-6 and IL-8) 
expression and demonstrate the link in asthmatic inflammation. Most importantly, in support 
with previous reports (Brook et al., 2006; Clement et al., 2011), in this study we have found that 
PP2A inhibition has a significant impact on the critical anti-inflammatory protein, TTP, which 
demonstrates the potential of endogenous phosphatases as novel anti-inflammatory strategies in 
asthmatic inflammation. 
Findings of our second approach: 
1. PP2A dephosphorylates MAPKs that regulate inflammatory cell signalling.  
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2. Inhibition of basal PP2A activity releases restraint on MAPKs and increases MAPKs-
mediated gene expression, such as cytokines IL-6 and IL-8. 
3. TTP mRNA expression ensues but resultant protein is rendered inactive by MAPKs. 
4. Basal protein phosphatase 2A activity restrains cytokine expression and thereby regulates 
TTP functions. 
TTP is a mRNA destabilizing protein that targets numerous cytokines (Brooks and Blackshear, 
2013), including those which are implicated in asthmatic inflammation. TTP is controlled by 
phosphorylation and has a dynamic equilibrium between unphosphorylated and phosphorylated 
forms. Unphosphorylated forms of TTP are active and are capable of targeting cytokines mRNA. 
However, the activated form is unstable and undergoes proteosomal degradation, whereas 
phosphorylated TTP is stable but inactive and unable to target cytokines mRNA for decay. It is 
reported that P38 MAPK targets two important serines (Ser52 and Ser178) of TTP (Brook et al., 
2006), causes phosphorylation of TTP and most importantly PP2A targets the same serines and 
shifts the balance toward the unphosphorylated active form. In our previous study we showed 
that under unstimulated conditions inhibition of PP2A switch off TTP (Rahman et al., 2015); but 
whether PP2A activators can switch TTP on and repress cytokine production under inflammatory 
conditions mimicked in vitro is currently unknown. As a continuation of our previous study here 
we find that during TNFα-induced inflammatory conditions PP2A activators can enhance PP2A 
enzymatic activity (Figure 5.1), which effectively shifts the equilibrium from 
phosphorylated/inactive towards unphosphorylated/active TTP. It is reported that blocking PP2A 
robustly increases IL-8 expression in A549 cells via post-transcriptional mRNA stabilization 
(Cornell et al., 2009); TTP was implicated but not directly examined. Besides, PP2A 
dephosphorylates a number of kinases that drive inflammatory pathways (Shanley et al., 2001; 
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Miskolci et al., 2003; Junttila et al., 2008). Whether TTP was involved remained an open 
question. In support of these studies here we show that PP2A is the phosphatase responsible for 
TTP dephosphorylation (Figure 5.6); hence boosting PP2A activity offers a promising 
therapeutic avenue in asthmatic inflammation. 
Findings of our third approach: 
1. PP2A is responsible for dephosphorylating (and hence activating) TTP. 
2. Small molecule PP2A activators, FTY720 and AAL(S) can enhance TTP’s anti-
inflammatory function to inhibit cytokine production. 
3. PP2A activators ensure the potential to act as alternative anti-inflammatory strategies to 
reduce airway inflammation in respiratory disease. 
More recently defective PP2A is linked with corticosteroid insensitivity in severe asthma 
(Kobayashi et al., 2011). In addition, it is reported that reduced PP2A activity induces 
corticosteroid resistance and this can be reversed by the long-acting β2-agonist formoterol 
(Kobayashi et al., 2012). These studies clearly demonstrate the role of PP2A in corticosteroid 
insensitivity; whether enhancing PP2A activity can overcome this condition remains unclear. To 
explore this we modelled bacterial infection in vitro to show for the first time that ligation of the 
TLR2 receptor with Pam3CSK4 induces corticosteroid insensitivity (Figure 6.1). Notably, unlike 
rhinoviral-induced corticosteroid insensitivity (Papi et al., 2013), Pam3CSK4 does not affect GC 
nuclear translocation or the overall amount of native MKP-1. However, in support of Singh et al 
(Singh et al., 2015) we find a significant proportion of MKP-1 is oxidized and consequently may 
be rendered corticosteroid inactive. Most importantly, we explore in our study that PP2A 
activators known (FTY720) and novel (theophylline, recently we reported as PP2A activator 
(Patel et al., 2015)) can significantly repress cytokine production when corticosteroid 
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insensitivity exists (Figure 6.5 & Figure 6.6); although we believe that these repressive effects on 
cytokine function exerted by FTY720 and theophylline are anti-inflammatory effects acting via 
alternative, PP2A-dependent pathways, rather than restoration of corticosteroid sensitivity. 
Hence we propose that activating PP2A may prove to be efficacious, non-steroidal anti-
inflammatory alternatives and/or corticosteroid-sparing approaches in the context of bacterial 
infection. 
Findings of our fourth approach: 
1. TLR2 ligation with a synthetic bacterial lipoprotein (Pam3CSK4) induces corticosteroid 
insensitivity. 
2. Unlike rhinoviral-induced corticosteroid insensitivity, Pam3CSK4 does not perturb GR 
nuclear translocation. 
3. The overall amount of native MKP-1 upregulation protein is unaffected by Pam3CSK4, 
but a significant proportion of MKP-1 was oxidized and consequently may be rendered 
corticosteroid inactive. 
4. PP2A activators function as non-steroidal anti-inflammatory alternatives and/or 
corticosteroid-sparing approaches in respiratory inflammation where corticosteroid 
insensitivity exists. 
In order to obtain further confirmation of our above findings we performed some key 
experiments using normal BEAS-2B and primary ASM cells. However, due to individual cell 
type variability, we failed to demonstrate further confirmation but explored new possibilities to 
uncover the reasons for this result. 
Conclusion: In this project we further confirm the role of inflammatory mediators such as S1P, 
TNFα and Pam3CSK4 in cytokines expression and a novel role of one important corticosteroid, 
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dexamethasone, in neutrophilic asthma using primary ASM cells. We successfully demonstrate 
that basal PP2A restrains cytokines, especially IL-6 and IL-8 expression via MAPKs mediated 
signalling pathways. Our study also reveals that blocking PP2A activity causes TTP 
phosphorylation and hence inactivation. Further, our study confirms that PP2A is directly linked 
with TTP anti-inflammatory functions and PP2A activators can work effectively during 
Pam3CSK4-induced corticosteroid insensitive condition. Therefore we propose that enhancing 
PP2A activity can serve as an alternative anti-inflammatory strategy to combat asthmatic 
inflammation.  
 
Future directions: Here in this thesis we mainly focus on the exploration of alternative anti-
inflammatory strategies to combat asthmatic inflammation in a safer and more effective way. 
Though our studies successfully reveal that PP2A activators can act as alternative anti-
inflammatory agents, further understanding of the molecular mechanism of PP2A regulation in 
respiratory inflammation is required. Based on the findings of this project and previous reports it 
could be speculated, however, that PP2A activators may repress inflammation under inflamed 
(mimicked here with TNF), rather than non-inflamed conditions. Most importantly, the 
underlying molecular mechanism involved in corticosteroid insensitivity is as yet unclear and 
warrants extensive study. In addition, individual cell type variability is an important issue to 
explore. In this project we demonstrate the role of PP2A in asthmatic inflammation and 
corticosteroid insensitivity using mainly respiratory epithelial cells (mostly A549 cancer cells 
and some confirmatory experiments in normal BEAS-2B cells), using an in vivo model. 
TTP/PP2A knock-in and/or TTP/PP2A knock-out mouse models are especially needed for 
greater understanding. 
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Moreover, some specific questions are needed to be addressed, such as: 
a) How endogenous PP2A is regulated? 
b) How TNFα increases PP2A enzymatic activity? 
c) How Pam3CSK4 induces corticosteroid insensitivity? 
d) How PP2A activators bypass Pam3CSK-4-induced steroid insensitivity? 
e) Why cell type variability affects functional outcomes?  
We do believe addressing these questions will certainly increase our understanding, which will 
ultimately lead to the creation of a novel therapeutic avenue (alternative anti-inflammatory 
strategy) to combat asthma safely and effectively.  
Several conditions, including infectious exacerbation, severe asthma and COPD induce 
corticosteroid insensitivity. Among them COPD has emerged as a major public health concern 
worldwide and a leading cause of morbidity and mortality. Notably, the burden of COPD is 
predicted to increase due to continued exposure to COPD risk factors including tobacco smoke, 
outdoor air pollution and indoor noxious particles and gases from cooking and heating. The 
prevalence, morbidity and mortality of COPD are increasing in many westernised countries and 
cigarette smoking is the main cause. In our thesis we mainly focuse on Pam3CSK4-induced 
corticosteroid insensitivity and demonstrate the potential of PP2A activators as alternative anti-
inflammatory strategies in this condition. Hence the role of PP2A activators as alternative anti-
inflammatory strategy in the context of COPD will be a logical extention of our study for better 
understanding and to check whether PP2A activators are able to bypass the COPD mediated 
corticosteroid insensitivity. To achieve this target the following approaches can be addressed 
using both in vitro and in vivo models: 
1. Confirm whether active TTP is capable to reduce inflammation in COPD.  
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2.  Investigate the molecular mechanisms of PP2A regulation and pharmacological 
modulation in the context of COPD mediated corticosteroid insensitivity.  
3. Investigate the role of PP2A activators as alternative anti-inflammatory strategy to bypass 
corticosteroids insensitivity in COPD. 
Our studies in this project successfully demonstrate that PP2A activators offer great promise as 
alternative anti-inflammatory strategies and druggable targets. To date a number of small 
molecules are reported to activate PP2A enzymatic activity (Perrotti and Neviani, 2013). Among 
these small molecules the sphingosine analog, FTY720 is well-studied. FTY720 is a non-specific 
PP2A activator and hence it has other targets. Most notably in the context of respiratory disease, 
FTY720 can induce S1P signalling. To overcome S1P agonism a chiral analog of FTY720, 
AAL(S), has recently been developed. AAL(S) is as equally potent as FTY720 in activating 
PP2A complexes in vitro and significantly represses airways disease in mouse models in vivo 
(Collison et al., 2013b). Although AAL(S) is an improved analog of FTY720, there is scope to 
improve it furher for greater efficacy. Thus, development of new and improved PP2A activators, 
examination of their mechanisms of action and demonstration that they repress cytokines in 
COPD in vitro and in vivo via enhanching TTP activity may offer better therapeutic avenues of 
alternative anti-inflammatory strategies to combat asthmatic inflammation in the future. 
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